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Abstract 
 
The number of people being diagnosed with cancer is increasing year on year and it can 
therefore be assumed that the number of people living with late effects of the cancer 
treatment is also increasing. Using a descriptive and exploratory qualitative approach, 
this study considers the experiences of those people with late gastrointestinal effects of 
cancer treatment. Using this knowledge recommendations will be made to improve 
future awareness and support for this group of people.  
 
Cancer treatment can cause problems which may be evident during or after the 
treatment is completed, even many years later. Those that occur four to six months after 
treatment are referred to as late effects, or consequences of treatment. Radiotherapy 
for pelvic cancer can affect organs within the pelvis, including the gastrointestinal (GI) 
tract. Therefore, although the cancer treatment may be successful, the person may then 
be living with late GI effects that can have a significant impact upon their life. These 
symptoms are collectively known as pelvic radiation disease (PRD).  
 
Using a qualitative approach, nine participants were involved in interviews, five of whom 
also had their spouse present. Framework analysis (FA) was used to analyse the 
interview transcripts. Through the process of familiarisation with the literature the 
issues that people with PRD were experiencing began to emerge and thus formed the 
basis of the framework. When applied to the interview transcripts, the framework 
developed further to highlight three main areas of concern: feelings of stigma, 
experiences of contact with healthcare services and the need of, but occasional lack of, 
support from family and friends.  
 
This study shows that there is a significant physical, psychological and social impact upon 
quality of life (QoL) for people with PRD. It is therefore anticipated that the knowledge 
gained from this study will contribute to improving the care that people with PRD 
receive, by increasing awareness of PRD, and the affect upon patients, amongst 
healthcare professionals (HCPs). In addition, this study developed recommendations to 
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encourage the identification of people with PRD, through the use of existing guidelines 
and assessment tools.  
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Chapter 1: Introduction 
 
The number of people being diagnosed with cancer is increasing year on year. With 
19,088 new cancer diagnoses in Wales in 2015, this was a 10% increase from the 
previous ten years (Welsh Cancer Intelligence and Surveillance Unit 2017a). Cancer 
survival in Wales also continues to grow, with an average increase of approximately 3% 
for both one and five year survival (Welsh Cancer Intelligence and Surveillance Unit 
2017b). Of these new diagnoses, the two disease origins with most new cases were 
prostate and bowel and both frequently require pelvic radiotherapy as part of their 
treatment.  
 
Radiotherapy causes cell death, which although necessary to treat the cancer, results in 
collateral damage to healthy tissue within the radiotherapy beam area. As well as the 
initial tissue damage, there is progressive ischaemia and stem cell loss, which can result 
in long term loss of function of the affected tissue (Denham and Hauer-Jensen 2002).  
 
Gastrointestinal (GI) symptoms are the most commonly reported side effect following 
treatment for prostate cancer (Bacon et al 2002), gynaecological cancer (Dunberger et 
al 2010) and colorectal cancer (Downing et al 2015). The range of GI symptoms identified 
include diarrhoea, abdominal pain and rectal bleeding, although due to the role and 
function of the GI tract, different pathological changes caused by the radiotherapy can 
display differing symptoms, thus making a simple diagnosis of the medical conditions, 
very difficult. (Andreyev 2007). The term used to describe this group of symptoms is 
Pelvic Radiation Disease (PRD)  
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The literature review within this thesis, demonstrates that quality of life (QoL) in people 
with PRD is often negatively affected. Many of the studies which looked at potential 
effects of cancer treatment, also measure QoL to some extent. The World Health 
Organisation (WHO) (1997) recommends that any study examining a care intervention 
should also include an assessment of QoL. They went on to develop two assessment 
tools, WHOQOL-100 and WHOQOL-BREF which are unique in that they include 
assessment of the patient’s own perception, which can then be used by HCPs to guide 
care interventions (WHO 2018). As demonstrated in the Literature of Quality of Life 
Tool’s review table (Appendix 1), none of the studies identified, used these 
recommended QoL assessment tools. This is not to say that the tools that were used are 
any less adequate, and this will be further discussed in sections 3, 4 and 5 of the 
literature review which looks at studies of PRD amongst prostate, gynaecology and 
colorectal cancer patients.  
 
The lack of studies involving patient perception and understanding of the patient’s 
experience of PRD was noted throughout the papers looking at the various pelvic 
cancers. There was a high level of recognition of physical symptoms, but little in way of 
how these symptoms impacted on the patients’ lives, even though the term QoL was 
prevalent throughout. This suggests a gap between what QoL means to researchers, 
HCPs, patients and their families, and subsequently how this is assessed and translated 
into meaning.  
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In the United Kingdom (UK) there are very few sites offering specialised care for people 
with PRD, with just one GI service in Wales currently doing so. Whereas these few 
specialist services have recognised the need to identify people experiencing 
consequences of pelvic radiotherapy, such as Ludlow et al (2017), there is still an 
underlying lack of awareness amongst healthcare professionals (HCPs) (Henson et al 
2011, 2012). This results in patients initially not being made aware of the potential of 
such problems once their treatment finishes and then, if they do present with bowel 
symptoms, it is unlikely that the necessary appropriate investigations and treatment will 
follow.  
 
If, as discussed, awareness of PRD is poor amongst HCPs who manage people with and 
after cancer, this would suggest that there are a significant number of people living with 
PRD and its inherent difficulties. The actual number is unknown, but Gami et al (2003) 
and Denton et al (2000) argue that the incidence figures reported in some studies, such 
as over 50% of patients developing chronic GI symptoms (Andreyev 2005), is 
underestimated in clinical trials. Davidson and Faithful (2006) suggest that a possible 
reason for this perceived lack of incidence data is due to the difficulty in defining bowel 
symptoms and the subjectivity between patients and HCPs over what is a problem and 
to what extent they become bothersome enough to mention.   
 
The literature review demonstrates that people who have symptoms of PRD often 
experience a reduction in QoL, although it will be shown that frequently the actual 
symptoms are what are measured and recorded, rather that the effect of the symptoms 
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on the person’s life.  Therefore, the aim of this study is to gain an insight into the 
participants’ experiences of living with PRD. To achieve this, the objectives are: 
  
• To explore the current literature surrounding PRD and to identify gaps in 
knowledge  
   
• To provide an insight into the experiences of living with PRD. This will include the 
physical, psychological and social impact, examining what this means for the 
person and their friends and families  
 
• To develop recommendations aimed at identifying people with PRD through the 
use of existing guidelines and assessment tools.  
 
Thesis structure 
 
The search strategy for the literature review (Chapter 2) will be discussed, including 
search terms, which databases were used and how the quality of the papers was 
assessed. The resulting literature will then be presented and critiqued, offering an 
analysis of the contribution to the impact of PRD on peoples’ lives. The literature review 
will be clearly laid out to categorise the papers into the identified themes, and this will 
be defined in the literature review overview.  
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The Research Paradigm, Chapter (3), will discuss how a qualitative approach was 
identified to be the most appropriate methodology for examining the experiences of 
people with PRD. This will include the author’s personal views on the production of 
knowledge and how this led to the structure of the study. In the Method, Chapter (4), 
the structure of the research study itself will be presented, including participant 
selection, the reasons for the choice of method of information gathering, i.e. through 
interviews, and how the method of analysis, framework analysis (FA), was identified as 
a beneficial way to analyse the transcripts obtained from the interviews.  The findings 
will then be presented, (Chapter 5,) using the three main themes developed from the 
FA: stigma, healthcare and support.  The Discussion, Chapter (6), will then link the 
findings to current theory and identify how they impact upon peoples’ experiences of 
PRD. 
 
The Conclusions, Chapter (7), will consider the limitations of the study, the contribution 
to knowledge offered and recommendations for further study to be carried out. A 
personal reflection will conclude the thesis, with a discussion of the impact the 
Professional Doctorate journey has had on a personal level, and the changes it has 
already afforded.   
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Chapter 2: Literature review 
 
Chapter overview 
 
The aim of the literature review is to undertake a thorough enquiry into the current 
evidence surrounding PRD and people’s experiences of it. The review will be presented 
under headings to clarify what is already known and where there are gaps in the 
literature. The literature search strategy will be discussed, including search terms and 
databases used, followed by how the quality of the papers was evaluated. The literature 
will then be discussed in the following order: 
 
1. The development of the recognition of Pelvic Radiation Disease as a 
consequence of cancer treatment  
• PRD- diagnosis frequently made following investigations into 
symptoms of PRD  
• PRD- defining the problem 
• PRD- addressing the problem, through the ORBIT study 
• PRD- improving recognition of those who may have PRD 
 
2. PRD following treatment for prostate cancer 
3. PRD following treatment for gynaecological cancer 
4. PRD following treatment for colorectal cancer 
5. Quality of life scores- a help or hindrance? 
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6. Current awareness of PRD by healthcare professionals 
7. The effect of faecal incontinence  
8. Conclusions and gaps in the knowledge 
 
Following each of the subject sections there will be a summary discussion where the 
literature will be synthesised and observations made.  
 
Literature Search 
 
The main body of the literature review, as seen in sections 1-4 and 6, was undertaken 
at the very beginning of the development of the research process, prior to formalising 
the study protocol. This used the broad search terms associated with PRD. Later on in 
the study development and after the first few interviews had taken place, the Patient, 
Exposure and Outcome (PEO) format, as described below, was utilised to ensure a 
thorough search was performed, using the wider range of search terms. This additional 
review data was necessary after identifying comments and themes that had arisen 
during the early stages of the interviews, and so subsequent literature searches were 
made to examine papers concerning QoL and the effects of faecal incontinence, as seen 
in sections 5 and 7. The additional review findings were then considered and added to 
the final literature search and review process. 
 
To ensure appropriate literature was found, the aims of the research question were 
considered in a PEO format- Patient, Exposure and Outcome, as described by Bettany-
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Saltikov (2012). Table 1 shows how the PEO format was used to ensure that all the 
elements of the questions were included in the literature search.  
 
Simplified research question: what is the experience of people, their friends and families 
of living with PRD?  
 
Table 1 - PEO to develop literature search  
 
P Population and their problems  People who have PRD and their relevant 
family members and friends 
E Exposure  PRD after pelvic radiotherapy, 
gastrointestinal symptoms, faecal 
incontinence 
O Outcomes or themes  Experiences, quality of life, stigma, 
taboo, shame dignity 
 
 
With guidance from the librarians, search terms were then developed from the PEO 
framework and included pelvic radiation disease, gastrointestinal 
symptoms/disease/disorder, quality of life, faecal/fecal incontinence, patient 
experience, stigma, taboo, shame and dignity. Boolean operators AND, OR and NOT 
were used, as were * and / symbols to widen potential key word detection. Due to the 
relatively recent awareness of the consequences of cancer treatment, date boundaries 
were not set.  
 
Following advice from the librarians it was initially decided to limit the search to just 
OVID-Medline and Cinhal, but then PyscINFO was included to check for papers regarding 
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psychological issues. Table 2 below shows which databases were searched, the terms 
used for each of the databases, how many potential papers were initially found and 
checked, how many were discarded and how many then went on for further in-depth 
reading and consideration for inclusion once duplicates had been identified and 
removed. An alert service was also set up for Ovid Medline with the terms “pelvic 
radiation disease” and “consequences of cancer treatment” to access newer 
publications as they were released.  
 
Whereas table 2 demonstrates in more detail the individual results from each search 
term, the quasi PRISMA diagram below summarises the process of the literature review. 
This is divided into the 2 main groups of search terms used, as well as the individual 
database results.  
 
 
1. Terms associated with PRD/GI Symptoms 
 
2. Terms associated with QoL/FI/experience/stigma 
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Diagram 1 Literature search quasi PRISMA Diagram 
 
 
 
 
 
 
 
 
 
 
 
Records identified through Data base searches 
1. PRD/GI Symptoms: Ovid Medline (N= 62), CINAHL (N= 42) 
(PsycINFO not searched for these themes)
2. QoL/FI/experience/stigma: Ovid Medline (N= 207), CINAHL ( N= 70)
PsycINFO (N= 61)
All screened against
PEO
Full text articles reviewed and examined for review
PRD/GI: Ovid Medline (N= 35), (CINHAL N= 10)
QoL/FI/experience/stigma: ovid Medline (N= 43), CINAHL (N= 24), PsychINFO (N= 
42) 
Discarded papers: 
 
PRD/GI: Ovid Medline (N= 27), CINAHL (N= 32) 
 
Qol/FI/exp/stigma: Ovid Medline (N= 164), 
 CINAHL (N= 46), PsycINFO N= 19) 
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Table 2 - Database Search 
 
Ovid Medline Search 
 
Search Search term Found Checked Discarded Reviewed 
1 pelvic radiotherap* 1258    
2 gastrointestinal symptom* 9289    
3 Gastrointestinal disease* 40945    
4 Gastrointestinal disorder* 5700    
5 Gastrointestinal diseases/ 36858    
6 2 OR 3 OR 4 OR 5 51978    
7 1 AND 6  62 62 27 35 
8 “quality of life”  247095    
9 “Quality of life”/ 161200    
10 8 OR 9 247095    
11 faecal incontinen* 10125    
12 Fecal incontinence/ 9112    
13 fecal incontinen* 10125    
14 11 OR 12 OR 13 10511    
15 10 AND 14 1752    
16 patient experience  2985    
17 Experience 501945    
18 social stigma/ 5261    
19 stigma* 25249    
20 taboo/ 779    
21 taboo* 2170    
22 Shame/ 2047    
23 Shame 4158    
24 Dignity 5277    
25 16 OR 17 OR 18 OR 19 OR 20 
OR 21 OR 22 OR 23 OR 24 
533707    
26 15 AND 25 207 207 164 43 
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PyscINFO 
 
Search Search term Found Checked Discarded Reviewed 
1 “quality of life”  69491    
2 “quality of life”/ 37432    
3 1 OR 2 69491    
4 faecal incontinen* 59    
5 fecal incontinence/ 616    
6 Fecal incontinen* 706    
7 4 OR 5 OR 6 735    
8 3 AND 7 51 51 14 37 
9 patient experience 1054    
10 Experience 367948    
11 Stigma/ 10776    
12 stigma*mp 28246    
13 Taboos/ 520    
14 taboo* 3225    
15 Shame/ 3764    
16 shame*mp 12073    
17 Dignity.mp 4670    
18 Dignity/ 555    
19 9 OR 10 OR 11 OR 12 OR 13 
OR 14 OR 15 OR 16 OR 17 OR 
18 
405583    
20 8 AND 19 10 10 5 5 
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CINAHL 
 
Search Search term Found Checked Discarded Reviewed  
1 pelvic radiotherap* 488    
2 gastrointestinal symptom* 3025    
3 gastrointestinal disease * 8771    
4 (MH“gastrointestinal 
diseases”) 
6144    
5 gastrointestinal disorder* 1921    
6 2 OR 3 OR 4 OR 5 12051    
7 1 and 6  42 42 32 10 
8 “quality of life” 139041    
9 (MH “quality of life”) 86619    
10 8 OR 9 139041    
11 faecal incontinen* 2968    
12 fecal incontinen* 2968    
13 11 OR 12 2968    
14 10 AND 13 512    
15 patient experience  29381    
16 experience  252832    
17 (MH “stigma”) 11588    
18 Stigma* 18848    
19 Taboo* 946    
20 Shame 3197    
21 (MH "Shame") 1580    
22 Dignity 5274    
23 (MH "Human Dignity") 2621    
24 15 OR 16 OR 17 OR 18 OR 19 
OR 20 OR 21 OR 22 OR 23 
285,979    
25 14 AND 24 70 70 46 24 
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Selecting relevant papers  
 
As the database search outcome shows, the number of papers identified was significant, 
although these were reduced to a more manageable number through the combining of 
search terms. Articles found from the final combined searches were then assessed for 
suitability for inclusion in the literature review. This was undertaken using elements of 
the original PEO format, as described by Bettany-Saltikov (2012). There is also a section 
in the table on quality and for comments. Whereas there are strict guidelines for 
assessing quality in quantitative literature, with randomised controlled studies being of 
the highest standard, the criteria for qualitative is somewhat different. For qualitative 
studies “authenticity and trustworthiness” Bettany-Saltikov (2012, p. 91) are considered 
valuable. Caldwell et al (2011) provides further examples of differences when assessing 
what to consider for quality in qualitative papers, which includes: 
 
• Has the philosophical background and study design been identified, with rational 
for choice of design evident? 
• Are the major concepts identified? 
• Is the participant selection process described, along with the sampling method? 
• Is the method of data analysis credible and confirmable? 
• Are the results transferable? 
 
Caldwell et al (2011) p. 4 
 
Some articles were more opinion presentations; although not research-led, they 
enabled a wider understanding of experiences of living with, or supporting those that 
live with, PRD. Although not fully transferable, many of the elements suggested by 
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Caldwell et al (2014) were used to assess the appropriateness for inclusion of these non-
study, or opinion articles, many of which were found useful within this study.  Reasons 
for discarding papers included those involving paediatrics, surgical and non-surgical 
treatments of FI including biofeedback and tibial nerve stimulation, as well as FI related 
to genetic conditions. 
 
Table 3 below uses two papers, one quantitative and one opinion-led, as examples to 
show how these aspects were applied to the papers identified on the search. 
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Table 3 - Example of PEO application to literature 
 
Paper: Algorithm-based management.. 
ORBIT.. RCT Andreyev et al (2013) 
Which 
Inclusion 
criteria met? 
Include? High 
quality? 
Comments 
P: People who have PRD and their relevant family 
members and friends 
People with bowel 
symptoms are 
cancer treatment 
(no family 
opinions) 
Yes RCT, no 
qualitative 
elements 
E: PRD after pelvic radiotherapy, gastrointestinal 
symptoms, faecal incontinence 
GI symptoms 
descriptions, clear 
overview 
  
O: Experiences, quality of life, stigma, taboo, 
shame dignity 
Effects on QoL    
 
 
Paper: GI consequences of cancer 
treatment… a bad gut feeling Muls 
(2014) 
Which 
Inclusion 
criteria met? 
Include? High quality? 
Comments   
P: People who have PRD and their relevant 
family members and friends 
Clear description 
of who might be 
affected 
Yes  Trustworthiness 
of author, lots 
of experience in 
area 
 
E: PRD after pelvic radiotherapy, 
gastrointestinal symptoms, faecal incontinence 
Examples of GI 
symptoms, 
importance of 
systematic 
assessment   
 Examples, clear 
discussion 
O: Experiences, quality of life, stigma, taboo, 
shame dignity 
Social/psychosocial 
impact, QoL 
 Examples, clear 
discussion 
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For papers that were considered likely to be appropriate, the abstracts were read and 
assessed using the PEO and quality criteria. Those selected as suitable, (as described 
above, and once duplicates were identified), were then downloaded, printed and 
thematically analysed using coloured marker pens, a useful step to highlight those areas 
identified in the PEO, and any further areas considered useful, such as interventions to 
improve assessment and/or QoL. It is noted that electronic methods for saving and 
reviewing papers are available, but it was found to be helpful to have physical printouts 
available to aid study comparisons and cross-referencing.  
 
The articles were then placed in groups according to the topics they covered and where 
there was cross-covering, notes were written on the front page to keep track.  For 
example, Andreyev et al’s (2013) paper presenting the ORBIT trial discussed an overview 
of PRD, the symptoms it causes as well as the effect on QoL. The paper then went on to 
discuss the trial and its conclusion that a specialist nurse is effective in assessing and 
managing people with PRD. Therefore, on the front page of that article, the following 
notes were made: RCT, PRD symptoms, QoL, and PRD management. This was helpful to 
keep track of appropriate papers when writing the review.   
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Literature review 
 
Pelvic Radiation Disease- the development of the recognition of PRD as a consequence 
of cancer treatment  
 
This section will examine the literature surrounding the initial recognition that 
radiotherapy cancer treatment can cause long term health problems and will include 
studies that have tried to address this problem. 
 
Radiotherapy has been used to treat cancer for over one hundred years and uses high 
dose x-rays to damage cells by stopping their growth and multiplication (Gianfaldoni 
2017). Although an effective cancer treatment for tumours involving the urological, 
gynaecological and colorectal anatomy (Gami et al 2003), there is growing 
acknowledgement that the collateral damage to surrounding healthy tissue can result 
in chronic health problems for many years after treatment has finished (Andreyev et al 
2012). 
 
Although this literature review will demonstrate that there is a growing number of 
studies looking at the symptoms of PRD and what impact they may have on QoL, there 
are very few that consider how this affects the patients’ daily lives, a point that was 
recognised over eleven years ago by Gillespie et al (2007), yet has changed little to date.  
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Diagnosis frequently made following investigations into symptoms of PRD 
The document “The Practical Management of the Gastrointestinal Symptoms of Pelvic 
Radiation Disease” (Andreyev 2014), provides a systematic process for investigating 
each of the GI symptoms commonly experienced. A step-wise initial management plan 
for each of the symptoms is also described but the aim of the document is to facilitate, 
where one exists, a firm diagnosis of specific physiological conditions in order that they 
may be successfully treated. 
 
Appendix 2 presents the literature discussing each of the more frequently encountered 
conditions, how they are diagnosed and the current recommended treatments for 
them.  It is important to note the potential symptoms a person may present with, which 
may lead to the subsequent diagnosis, as well as an appreciation of the treatment 
options where available.   
 
Pelvic Radiation Disease- defining the problem 
In one of the first articles describing the symptoms suggesting PRD, Andreyev (2005) 
calculated that about 12,000 people in the United Kingdom (UK) had received pelvic 
radiotherapy. Considering the aforementioned rise of cancer diagnoses year on year, 
then this figure is now likely to be much higher. He goes on to describe how up to 80% 
of these patients are likely to experience acute bowel problems during or shortly after 
treatment and that although many of these will settle within 3 months, studies have 
shown that up to 78% of patients may develop chronic GI symptoms significant enough 
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to affect their QoL (Potosky et al 2000 and Kollmorgen et al 1994). In the closing 
paragraph of his article, Andreyev (2005) states that 
 
“What we have still failed to address systematically is how best to care for the 
patient who is cured of their cancer but living with the physical consequences”. 
Andreyev (2005 p. 1053) 
 
The GI symptoms that develop following pelvic radiotherapy have become known as 
Pelvic Radiation Disease. Although a collection of symptoms, rather than a specific 
disease, Andreyev, who developed the term, was heard to present at the British Society 
of Gastroenterology 2005 conference that he felt the term ‘disease’, rather than 
‘syndrome’ was more likely to gain the professional interest he felt was deserved, such 
as that held by inflammatory bowel disease (IBD). He followed up his concern that other 
diseases such as IBD were given far more attention in one of his early papers, shortly 
after his initial presentation (Andreyev 2005). He believed that perhaps due to this 
perceived lack of awareness, and/or interest, people experiencing such late GI effects 
may not receive the treatment they require.  
 
The main charitable organisation linked with IBD, The National Association for Colitis 
and Crohn’s Disease (now known as Crohn’s and Colitis UK), also recognised the growing 
disparity between what was known about IBD compared to PRD. They therefore 
commissioned a study to look at the issues surrounding living with bowel problems 
following radiotherapy (Wilson 2006). This study was one of only a few found in the 
literature search that provided participants with a chance to tell their story and to talk 
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about their individual experiences. For this study, nine people with a median average 
age of 54 were interviewed either by telephone or by giving a written response.  This 
qualitative work provided patients’ stories about their experiences and identified a 
significant impact upon their lives. The study concluded that there was a lack of voice 
from people living with PRD, and that experiences from other chronic diseases, such as 
IBD, could be used to support people living with PRD. Considering that this study was 
undertaken over twelve years, this literature review highlights that there has been little 
further study into people’s experiences of living with PRD, as opposed to a number of 
studies looking at the symptoms.  
 
Following Andreyev’s growing awareness of the increasing number of patients with GI 
symptoms following radiotherapy, being referred to the clinic, he and the team at The 
Royal Marsden Hospital in London, have undertaken a number of studies to develop the 
knowledge base surrounding PRD. This work culminated in the document “The Practical 
Management of the Gastrointestinal Symptoms of Pelvic Radiation Disease” (Andreyev 
et al 2014). With the publication of this document, Andreyev addressed his perceived 
lack of a systematic assessment and treatment plan. It is also noted that many of the 
articles examined in the following literature, list him as one of the co-authors. Therefore, 
a potential suggestion of an over-use of his work in this thesis is unavoidable without 
ignoring much of the current knowledge surrounding PRD.  
 
In a further paper examining the symptoms experienced by people with PRD, Andreyev 
(2007a) discusses how the toxicity of the treatment appears only indirectly linked with 
dose and volume and describes a complex mix of many factors, both patient and 
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treatment related. In a second paper, later that year, Andreyev (2007b) details such 
factors which include genetic variations, smoking and pre-existing medical conditions. 
The first paper (Andreyev 2007a) highlights the importance of the HCP having a full 
history of any presenting bowel problems the patient has, such as pre-existing problems 
before the radiotherapy treatment began. A clear understanding of what the presenting 
problem actually is, is also vital, as people may have different understanding of different 
terms- for example, diarrhoea may mean a loose stool once a day to one person whereas 
to another the term may actually describe the passage of watery stool 10-15 times per 
day; clearly the two scenarios are very different and require clarification.  
 
It is interesting to note in the papers over the years, the growing recognition of the need 
for a systematic approach to assessing a patient’s symptoms. Andreyev (2007b) 
quantifies that a third of patients may experience QoL affecting bowel changes after 
pelvic radiotherapy. The paper lists 38 different symptoms that patients describe 
although Andreyev does not explain if these were elicited during any studies or simply 
mentioned during clinical consultations. In a later research paper (Andreyev et al 2013), 
which is described in more detail below, he supported the development of the 
Guideline, using two further studies (Gami et al 2003 and Olopade et al 2005) to refine 
the list of symptoms to a more manageable 23. He then describes how the timing of the 
development of the symptoms can vary enormously, from soon after the radiotherapy 
has been completed, to many years later. He goes on to highlight that patients mostly 
did not report symptoms but that equally, HCPs did not enquire about them, often 
resulting in a delay in symptom assessment and subsequent treatment. Further on in 
this thesis, it will be discussed how a lack of awareness is an important reason for the 
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failure to identify people with PRD (Henson et al 2011, 2012), which then results in 
ongoing GI symptoms, with the physical, psychological and social impact that this 
entails. 
 
Pelvic Radiation Disease- addressing the problem, through the ORBIT study  
As discussed, PRD has a significant impact on the person experiencing it. To assess and 
demonstrate if a suitably trained HCP could appropriately use an algorithm to assess and 
treat patients with PRD, the ORBIT (Optimising Radiotherapy Bowel Injury Therapy) 
study, described by Andreyev (2013) was developed. This important study would form 
the basis for the theory behind the later guidelines (Andreyev et al 2014), to manage 
care for people with PRD. Over a four-year period, 218 patients were identified, who 
were still experiencing GI symptoms at least six months after completion of pelvic 
radiotherapy. The study steering group also included patient representatives. Involving 
patients in the study development and data discussion not only acknowledges the 
importance of their opinions but also improved reliability and validity of the findings.  
 
Using computer generated randomisation, which included stratifying for the tumour 
sites, participants were allocated to one of three groups. One group received a self-help 
booklet, which was then current practice. Another was managed by a Consultant 
Gastroenterologist using the algorithm. The third was managed by a specially trained 
nurse, also using the algorithm. The primary end-point of the study was improvement 
in the patient’s GI symptoms, which was assessed using the IBDQ-B tool at baseline, six 
months and one year. The study showed that using the algorithm, irrespective of 
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whether by the Consultant Gastroenterologist or a trained nurse, resulted in a clinical 
improvement in the patient’s GI symptoms, compared against using the self-help 
booklet alone, which was found to be less effective. With the final assessments being 
undertaken at one year, the study was also able to demonstrate that the improvements 
continued if the algorithm had been used. This is an important point and is relevant to 
current practice as it suggests that the benefits are longer lasting only when 
management is undertaken by a specialist team. It is important to note that this study, 
as per the majority of studies in this review, concentrates on symptoms of PRD, and little 
to no exploration of the person’s experiences of living with the symptoms.  
 
The ORBIT study showed that correct use of the algorithm is likely to involve costly 
investigations such as endoscopy, scans and breath tests. The purpose of the algorithm 
is to request only investigations identified as necessary, and to do this early on in the 
assessment process. In this way, the symptoms’ causes can be identified and treated 
promptly, avoiding the long term clinical care of managing chronic bowel symptoms, 
with multiple hospital visits that was, up to then, the norm. Clearly however, these 
investigations will have financial implications and unfortunately an economic evaluation 
of the ORBIT study did not show that it was cost effective despite the evidence that it 
was extremely beneficial for the patients themselves (Jordan et al 2017). It was 
calculated that although algorithmic care demonstrated an improvement in IBDQ-B 
scores, this comes at a cost of approximately £1,000.  The evaluation concludes that 
using generic health related QoL instruments may not capture the full patient benefit 
and that when the cost of treating the original cancer can be up to £15,000, then the 
25 
 
additional cost to manage the consequences of that treatment should be considered 
acceptable.  
 
Pelvic Radiation Disease- improving recognition of those who may have PRD 
Identifying those people who may be experiencing PRD is the first step to ensuring they 
receive the appropriate treatment. The need to acknowledge that recognition of those 
experiencing consequences of any cancer treatment is also important for future cancer 
care delivery plans. Not only will this inform clinicians of the size of the problem, but it 
will also enable future patients to be more aware of the potential of consequences of 
their cancer treatment.  
 
Following a recognition that treatment centres were using different assessment tools, a 
working party was set up to develop a tool aimed at standardising symptom reporting, 
thus reducing variability in study data collection and outcome (Pavy et al 1995). 
Involving two large trial co-ordination groups (European Organization for Research and 
Treatment of Cancer (EORTC) and the Radiations Therapy Oncology Group (RTOG)), the 
sub-group developed a new scoring system which included data regarding the grades of 
toxicity and patient perception of the severity of their symptoms. What would become 
known as the LENT-SOMA (Late Effects of Normal Tissue and Subjective, Objective, 
Management and Analytic) assessment scale was so developed. These tools were 
designed to be simple to apply whilst providing accurate and comparable data (Rubin et 
al 1995).  
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There is disagreement however, whether the LENT-SOMA is practical to use in clinical 
practice.  Routledge et al (2003) evaluated the tool in eighty-nine patients post 
radiotherapy for cervical cancer. Not only did they believe it to correctly represent the 
clinical data but also claimed to find it “feasible to use … in a busy cancer centre” (p. 
509). Within their paper however, they noted that postal questionnaires were also used, 
due to the reluctance of patients to return to the hospital to complete the assessment 
tool. This would indicate that it was not always possible for the questionnaires to be 
fully completed during the clinic appointment and may therefore not be particularly 
simple to complete as per the original aim of the development group.  Taylor et al 
(2016a) also identified that other current symptom-based scoring systems also had 
issues surrounding ease of use. They identified that the Gastrointestinal Rating Scale 
(GSRS) was too long at fifteen questions and the IBD-Q was even longer with thirty-two 
questions. Another assessment tool, the Vaizey incontinence questionnaire, focused on 
only faecal incontinence and would therefore not provide detailed information on other 
symptoms. Therefore, Taylor et al (2016a) believed that for use in a clinical situation, in 
the case where patients had received pelvic radiotherapy, a simpler assessment tool was 
required; entitled ALERT-B (Assessment of Late Effects of RadioTherapy- Bowel), the tool 
was developed in four phases: 
 
Phase one: A consensus meeting was held that included those involved in the original 
Guidance: The Practical Management of the Gastrointestinal Symptoms of Pelvic 
Radiation Disease (Andreyev et al 2014), along with a patient representative who had 
been treated for PRD.  Phase two: Twelve patients underwent cognitive interviewing 
which assessed participants’ understanding of the screening tool questions, and 
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whether their judgment regarding their responses was appropriate. Both inductive and 
deductive analyses were used to assess the interview transcripts.  Phase three: A final 
consensus meeting was held to develop the tool in readiness for use in clinical practice. 
Phase four: A psychometric validation of ALERT-B was undertaken against GSRS, which 
had been used in the EAGLE study (Taylor et la 2016b).  
 
The completed ALERT-B tool consists of the following three questions, where a positive 
“yes” answer will encourage discussion between the patient and their HCP and a referral 
to specialised gastroenterology services where appropriate. 
 
1. Do you have difficulty in controlling your bowels (having a poo) such as: 
i. Having to get up at night to poo? 
ii. Having accidents such as soiling or a sensation of wetness? 
 
2. Have you noticed any blood from your bottom recently? 
 
3. Do you have any bowel or tummy problems that affect your mood, social life, 
relationships or any other aspect of your daily life? 
 
This tool is now being used to screen patients who have received pelvic radiotherapy at 
the local cancer hospital. Patients with positive results, where further assessment is 
considered necessary, are then seen by the GI/PRD CNS.   
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This section has discussed how the recognition and subsequent naming of PRD was only 
acknowledged in the last two decades despite radiotherapy being used for the past one 
hundred years (Gianfaldoni 2017) and that the late effects of radiotherapy are a growing 
problem. Development of a simple to use assessment tool, ALERT-B, has enabled large 
cohorts of patients to be quickly assessed for PRD, with identification of those requiring 
further follow-up clearly recognisable. It is noted however, that for more detailed 
symptom data collection, as required by the Cancer Therapy Evaluation Programme 
(Common Terminology Criteria for Adverse Events (CTAE) (National Cancer Institute 
2017) then the longer assessment tools may be necessary, but for patients with PRD 
recognition, the ALERT-B is a valuable tool than can be used to trigger a GI referral where 
appropriate. Again, it is important to note that each of these studies and data collection 
tools have concentrated on the participants physical symptoms, and very little attention, 
if any, has been paid to the effect that the physical symptoms may be having upon the 
patient’s life.  
 
The following sections will look at the issues of PRD in the three main pelvic cancer 
groups: prostate, gynaecological and colorectal cancer. The literature identified through 
the search was generally split into one of these three categories.  
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Pelvic Radiation Disease following treatment for prostate cancer 
In 2015, the most recent cancer statistics available, prostate cancer was the most 
common cancer in men in Wales (Welsh Cancer Intelligence and Survival Unit 2017b). 
Radiotherapy is a common treatment for prostate cancer and late effects following this 
treatment are noted to be significant (Gami et al 2003). Up to now much of the 
knowledge of PRD has come from Dr Andreyev and the team at the Royal Marsden 
Cancer Hospital. However, there are many other reports from both the UK and across 
the world, highlighting that awareness and interest in this topic is growing. Problems 
following radiotherapy for prostate cancer are perhaps one of the largest areas where 
research into both the causes and treatment for late effects is noted. This section of the 
literature review will examine the available papers looking at what is known about PRD 
in men following treatment for prostate cancer. This will include how PRD is identified, 
what symptoms occur and whether impact on QoL or patient experience was 
considered, and if any work is being undertaken to manage the problem.  
 
TrueNTH is a worldwide initiative partially funded by the charitable event, Movember, 
where men are sponsored to grow a moustache throughout the month of November 
and the money is donated to fund research into prostate cancer. The main aim of 
TrueNTH is to improve survival rates for men with prostate cancer. As well as supporting 
research into treatment for prostate cancer and so improving survivorship rates, they 
also aim to improve the quality of that survivorship. One of the UK based projects of 
TrueNTH has been developed specifically to investigate the late effects of radiation 
treatment of men with prostate cancer and part of this is the EAGLE study- Evaluating 
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and Addressing the Gastrointestinal Late Effects of radical treatment for prostate cancer 
(Taylor et al 2016b). The aims of this study were to raise awareness of PRD and the 
treatment available for PRD following prostate cancer. To do this they used the 
assessment tool developed by Andreyev et al (2014) and monitored the participants’ 
progress and healthcare utilisation over a one year period.  
 
The study involved consented participants being screened at their follow-up oncology 
appointments. Screening was performed using GSRS and also the DESIGNER tool, which 
subsequently evolved into the ALERT-B tool, through which this tool was then validated. 
Those who were screened as positive for bowel symptoms were then referred to one of 
the three specialist PRD centres for further assessment. At the PRD clinic, patients were 
further assessed using the Guidance: The Practical Management of the Gastrointestinal 
Symptoms of Pelvic Radiation Disease (Andreyev et al 2014). The guidance follows an 
algorithmic approach whereby each individual symptom identified results in a number 
of investigations being suggested. For example, abdominal bloating/cramps would 
suggest the following investigations are appropriate: a full blood screen, abdominal x-
ray, dietary and drug history, oesophageal gastroscopy or breath test to look for small 
intestinal bacterial overgrowth or carbohydrate intolerance. If all return normal, then a 
USS, CT or MRI may be indicated. As with all symptoms, positive findings were then to 
be treated and followed up for further assessment. As part of the EAGLE study, 
participants, their families and the HCP were regularly interviewed to discuss process 
acceptability and to discuss and identify issues. The financial evaluations also included 
costs such as those to the participants, such as incontinence protection, travel costs for 
hospital appointments and lost working hours and also the costs to the NHS of the HCP 
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and investigational costs. Although the full outcome of this study is still awaited, three 
specialist PRD services have been developed as a direct result, which continue to provide 
care for those with PRD following treatment for a range of pelvic cancers. 
 
Crook et al (1996) developed and used their own self-administered questionnaire to 
investigate the effect on bowel, bladder and sexual function following radiotherapy 
treatment for prostate cancer. Their 20-point questionnaire was developed using 
previously used questionnaires by Fowler et al (1993) and Jønler et al (1996). Fowler et 
al (1993) stated that their questionnaire was evaluated for participant comprehension 
but it was not formally validated. Jønler’s et al (1996) study said that they utilised a 
previously validated questionnaire, although upon further reading this was the one used 
by Fowler et al (1993) that was merely evaluated for understanding and was not formally 
validated. This highlights the need to examine the tools used for studies, particularly if 
the validity of the questionnaires used is a vital part of a review. In a study by Crook et 
al (1996), 92 patients responded to an invitation to take part, and of these 11% reported 
a “severe change” in their bowel function. They noted that patients reported an 
improvement over time in rectal bleeding, with 17% experiencing this in years 1-3 but a 
reduction to just 4% in years 4 and onwards. This is a useful study if considering when 
PRD symptoms are likely to be most prevalent, however, although the questionnaires 
enquired about effects on bowel, bladder and sexual function, the study did not look at 
what effect these function problems may have on the men’s lives, such as did it stop 
them going out, has it affected their mood and so on. The experience of what it is like 
to live with these functional difficulties is not examined although this would have 
provided valuable data on men’s experiences of living with PRD. 
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A similar study based in Texas, United States of America, also looked at the late effects 
on radiotherapy in men with prostate cancer. Nguyen et al (1998) utilised patient 
administered questionnaires and found a higher than expected level of symptoms 
reported. 101 patients from an existing randomised trial using differing doses of 
radiotherapy were asked to complete questionnaires enquiring about bladder and 
bowel function. They also developed their questionnaires from the ones used by Crook 
et al (1996), Fowler et al (1993) and Jønler et al (1996), again highlighting how un-
validated questionnaires can be utilised numerous times, which may then affect the 
quality of evidence the paper produces. The participants would have completed their 
radiotherapy at least 2 years prior to the study. 29% reported that urinary incontinence 
was a current problem and 21% noted at least a moderate change of bowel function. As 
these patients were already part of a radiation dose randomised trial, it was possible to 
note which dose each of the patients had received and to consider if this affected the 
severity of their symptoms. Interestingly, those patients who had received the higher 
treatment doses actually reported slightly less late effects although no comment on 
statistical significance is mentioned. This observation is perhaps unexpected yet concurs 
with Andreyev et al (2007a, 2007b and 2012) who notes that the radiation dose alone is 
insufficient to define expectation of late effects and that others factors such as genetic 
factors and co-morbidities may also have a role. It is anticipated that newer radiotherapy 
techniques will minimise normal tissue exposure to radiotherapy and so reduce late 
effects (Macmillan 2016) although Andreyev et al (2012) believes that more targeted 
treatment will only alter the timing and severity of effects in the GI tract. Again, 
Nguyen’s et al (1998) study focussed on symptoms; what was their experience and to 
what extent of severity. There is no mention of the impact of these symptoms on the 
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men’s lives, even though in their conclusion they comment on lifestyle impact and use 
urinary leakage as an example. This study lacks information on the impact of something 
like urinary leakage such as did it stop them going out and further work in the area is 
necessary and will be addressed by the study presented in this thesis.    
 
Cameron et al (2012) also explored men’s experience of symptoms following 
radiotherapy for prostate cancer although used a much earlier time scale of just 1 month 
following completion of radiotherapy. Using a prospective descriptive survey, 73 men 
from the Canadian Cancer Centre were recruited to study both their symptoms and their 
perceived health state prior to and following radiotherapy. Symptoms were assessed 
using a modified Expanded Prostate Cancer Index Composite (EPIC) tool, that was 
designed and validated by Chang et al (2011) to specifically measure urinary, bowel, 
sexual and hormonal function and to encompass health related QoL issues in men 
receiving prostate cancer treatment. Statistical analysis was used to compare the scores, 
which demonstrated that each of the functions deteriorated during the first month after 
treatment although did not necessarily bother the patients. This may be because 
patients are often told to expect some changes during their treatment and so find them 
easier to tolerate. Specifically, bowel symptoms did not appear to cause enough distress 
to impact upon the men’s perceived health state, but it is important to note the short 
time scale, and this is likely to be non-representative over a longer period of time. 
Although the assessment tool used measured QoL, the short time period again results 
in difficulty in applying the data to men over a longer period of survivorship. There are 
many things which could alter the men’s perception of their QoL being measured so 
close to completion of cancer treatment, such as relief that their cancer was found and 
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that the treatment is over and this is likely to impact of their general idea of well-being 
and contentedness with their lives, at that exact time period. The authors conclude that 
men need to be informed about the likelihood of symptoms post-radiotherapy, although 
accept that their findings should not be used to inform longer-term time frames or 
different types of treatments due to the limited time frame of their study.  
 
In an attempt to further address the issue of identifying when and which patients are 
more likely to develop late symptoms, Pinkawa et al (2010) undertook a longitudinal 
study of 298 patients in a German cancer hospital who were receiving radiotherapy for 
prostate cancer. Also using the EPIC assessment tool, they identified that those who 
received >70gy of radiotherapy were more likely than those receiving lower doses to 
develop acute toxicity symptoms and that this group were more likely to go on to 
develop chronic late effects. Although QoL was measured as part of the EPIC tool, there 
were no examples given as to how this was demonstrated in the men’s’ lives such as 
what effect any symptoms might have upon them.  They believed this was due to acute 
damage to the intestinal mucosa and that this non-healing response is more likely to be 
a predictor of subsequent long-term problems. These findings are in contrast to Nguyen 
et al (1998) who did not find an obvious link with increased symptoms and higher 
radiation dose and are also in conflict with Andreyev et al (2007a, 2007b and 2012) who 
identified that the radiotherapy dose did not directly correlate with severity of 
symptoms. Also noted within the study was a mention that steroids and/or Mesalazines 
may have a treatment role, although Andreyev (2005) had highlighted five years 
previously that due to the biological process causing PRD, such treatments would be 
ineffective. This disparity of findings merely identifies that knowledge in this area 
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requires further study and that for now all patients receiving pelvic radiotherapy should 
be considered at risk of developing late GI effects.  
 
Andreyev et al (2012) address the issue of time frames, which has been demonstrated 
in the literature above, identifying that acute, sub-acute and chronic symptom 
presentations, are very different. Acute symptom presentation may result from 
infection, neutropenic enterocolitis, haemorrhage, perforation, ischaemia/infarction, 
thrombosis and bowel obstruction. These are medical/surgical emergencies and require 
prompt assessment by appropriate and experienced HCPs. He identifies that often, the 
more chronic the symptoms, the more difficult they are to detect, possibly because 
patients do not report them and HCPs may not enquire of them, possibly due to lack of 
awareness. This paper does not define time scales for chronic/long-term/late-effects 
but does comment that when patients attend cancer follow-up clinics, they should be 
assessed for such problems. In his earlier paper however, Andreyev (2007) does cite 
Olopade et al’s (2005) data suggesting that up to 90% of patients receiving pelvic 
radiotherapy, develop permanent changes in their bowel function. Olopade et al’s 
(2005) data is produced using 2 previously validated and commonly used questionnaires 
in looking at bowel and incontinence problems in people with inflammatory bowel 
disease (IBD) and faecal incontinence (FI). The IBD Questionnaire (IBDQ) and Vaizey 
incontinence score are both simple and quick to use tools that assess not only the 
symptoms but also the effect these have on the patients’ QoL (Guyatt et al 1989 and 
Vaizey et al 1999). Results using both of these tools were then compared against the 
Late Effects on Normal Tissue (LENT)- Subjective, Objective, Management and Analytic 
(SOMA) questionnaire (Pavy et al 1995) to see if they were comparable in assessing the 
36 
 
effects of pelvic radiotherapy on GI symptoms. Their study concluded that all 3 
questionnaires were useful in determining GI symptoms following pelvic radiotherapy 
and that the IBDQ and Vaizey tools were perhaps more sensitive in identifying patients 
who may benefit from specialist gastroenterology input.  
 
Macmillan (2014a) has developed a booklet which provides information and advice for 
men who have developed late GI effects following pelvic radiotherapy for prostate 
cancer. In it, they describe the differing types of symptoms that men may experience 
and suggest that they talk to their HCPs about any concerns they may have. The booklet 
mentions that once the man has discussed his problems with the cancer specialist, they 
will be offered assessment and advice (p.11). However, Henson et al (2011) identified 
that oncologists struggle to appropriately manage these patients or to refer them to a 
specialist gastroenterology service. Indeed, of the 190 oncologists who responded, 91 
said that they refer less than 10% of their patients for specialist gastroenterologist 
support. Studies including Olopade et al (2005), Potosky et al (2000) and Kollmorgen et 
al (1994) show that up to 90% of patients may experience late GI effects following pelvic 
radiotherapy, these referral figures are likely to be inadequate.  
 
Each of the studies examined has demonstrated a consideration of the effects of pelvic 
radiotherapy on men’s lives, through symptom assessment and QoL scores. The 
TrueNTH organisation and subsequent study recognises that PRD has a significant 
impact on the participants, their families and the NHS. Although the full report is 
currently awaited, the study has already shown that it has met part of its aim in 
improving access for men with PRD post prostate cancer treatment with the 
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development of the new clinics as its legacy. Studies by Crook et al (1996) and Nguyen 
et al (1998) solely concentrated on the physical symptoms of PRD. Although it is 
important to be aware of the symptoms men present with, the study did not contribute 
to the knowledge of what it means for the participant to live with these symptoms. If 
there is no discussion of the impact upon lives then it is unclear how important these 
symptoms may be to the men.  The study by Cameron et al (2012) went further in 
evaluating the impact of symptoms upon the men’s lives, although used a timescale of 
one month following treatment, which does not meet the generally accepted criteria of 
late effects of treatment. They acknowledged this time-scale discrepancy in their 
discussion, noting that it may not be applicable to those with longer-term symptoms. 
Their conclusion was however, similar to most of the papers’ findings; people should be 
informed of the possibility of late effects of the treatment before commencing, and 
HCPs should be aware of the possible effect on patients at follow-up. Pinkawa et al 
(2010) looked at a longer time frame than the Cameron et al study (2012) although their 
suggestion of using steroid or mesalazine treatment, that had previously been described 
as unsuitable, calls into question the authors’ knowledge and prior research. QoL was 
measured within the EPIC tool they used, although again, no mention was made of how 
this then correlated with the impact upon the men’s lives.   
 
Andreyev et al (2012) summarised that the lack of knowledge of the significant impact 
of PRD upon people’s lives was contributing to a perceived lack of care. Patients are 
unlikely to report symptoms if HCPs do not raise the subject and HCPs are unlikely to 
enquire about problems if they themselves are unaware.  Andreyev recommends that it 
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should become standard practice to raise the subject with patients at their follow-up 
clinics and suggests that assessment tools are utilised.    
 
Although some of the papers discussed do examine QoL, even those that mention it, do 
not go on to discuss the effect upon the lives of the men in their studies. The literature 
surrounding men with PRD following prostate cancer, notes that late GI effects are not 
uncommon after treatment but also reveals a significant gap in the knowledge about 
the experience of what it is like to live with PRD, the effect that symptoms of PRD has 
on their lives and how the person sees their future whilst living with these issues.  
 
PRD following treatment for gynaecological cancer 
Female cancers in Wales have the second highest cancer rate in the UK, and the 7th 
highest in the 22 European Countries (Welsh Cancer Intelligence and Surveillance Unit 
2017a). Of these female cancers, after breast cancer, uterine then ovarian cancers have 
the highest incidence. Due to female pelvic anatomy, radiotherapy to treat cancers of 
the ovaries, uterus, cervix or vagina, is highly likely to affect surrounding tissues, which 
includes the small and large bowel and which will inevitably receive doses of 
radiotherapy (Andreyev 2007). This section of the literature review will examine the 
papers that report on studies of women with PRD. As well as a critical analysis of the 
papers, this review aims to look at the recognition of PRD as an issue, the suggestions 
for either avoiding or improving PRD and which studies consider QoL or take patient 
experience into account.      
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Danielsson et al (1990) noted that following pelvic radiotherapy for gynaecological 
cancers, diarrhoea was a common problem in women attending their oncology clinics. 
In their prospective study of 173 women attending follow-up for cervical and ovarian 
cancer in a Swedish hospital, they utilised a questionnaire to assess the patients’ bowel 
habits and gastrointestinal symptoms, although did not say if this was a pre-validated 
tool or one they had developed themselves. They identified 20 people who had chronic 
or intermittent diarrhoea that was significant enough to affect their daily lives. The only 
question enquiring about any effect on their lives was one that asked if they were 
content, or discontent with their bowel habit. Within the cohort, and identifying with 
Andreyev (2007) and Olopade et al (2005) that a large proportion of patients will have 
chronic GI symptoms, the mean number of years since completing radiotherapy 
treatment was 11 (4-29). It was noted that it was difficult to analyse whether there was 
any notable similarities between cancer types/treatments due to the improvements in 
surgical techniques and radiological treatments over such an extended period of time. 
The main finding from this study was that a large proportion of women had significant 
diarrhoeal symptoms post pelvic radiotherapy.  
 
Following identification of the group of women with symptoms, they then went on to 
have further investigations to see if there was a treatable cause to their diarrhoea. These 
investigations included a SeHCAT scan (selenahomocholic acid-taurine test) to measure 
bile-acid malabsorption (BAM), breath testing and also small bowel biopsies for small 
intestinal bacterial overgrowth (SIBO), faecal testing to measure fat content, lactose 
testing and a range of blood tests. These tests revealed important findings, 
demonstrating that many of these women had treatable causes of their chronic 
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diarrhoea. Of the 20 women, 13 had a reduced SeHCAT with 7 of these significant 
enough to have marked BAM. Of the 20 women, 9 showed evidence of SIBO, 7 had low 
level of vitamin B12 and 10 had high levels of fat in their diet, which may be 
contributable to pancreatic insufficiency.  
 
Further follow-up of the women in this study with abnormal results showed that the 
majority responded to treatment and demonstrated an improvement in the diarrhoeal 
symptoms.  The authors go on to recommend that healthcare professionals caring for 
women with diarrhoeal symptoms at any time following pelvic radiotherapy should have 
a high suspicion of treatable causes such as BAM and SIBO. So, although this was a useful 
study to highlight potential physical causes contributing to PRD, they treat the 
participants purely as a disease statistic, rather than considering the lives behind the 
symptoms.  
 
A separate qualitative, mixed methods, Swedish study of 616 women (78% of the initial 
cohort) who received pelvic radiotherapy for gynaecological cancer, also identified that 
many of them had chronic GI symptoms, although this study only involved women who 
were 2-10 years post treatment (Dunberger et al 2010). Using a study-specific symptom 
and QoL questionnaire, which was validated through a robust interview and pilot testing 
process, the types and rates of GI symptoms were recorded. The data was collected in 
two ways, firstly with a questionnaire and then a semi-structured interview for those 
who further consented. The questionnaire consisted of 351 questions, including 
demographics, cancer type and treatment and then followed by psychological issues 
such as anxiety, depression, QoL and social functioning. The study reported little of the 
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psychological findings and none of the experiences that may have been heard in the 
interviews; it instead tended to concentrate on the physical symptoms. They did 
however note an ambition of theirs regarding the women’s experiences: 
 
“to help improve communication between professional health care providers 
and patients when cancer survivors seek help and treatment options for faecal 
incontinence, a socially disabling and embarrassing condition” 
Dunberger et al (2010) p. 614 
 
 
With a similarity to studies by Andreyev (2007a and 2013), the Dunbergers et al (2010) 
study elicited 32 different GI symptoms. Although followed by a disclaimer that 
generalisation should not be made from their study, they go on to describe how 25% of 
the women experienced ‘emptying of all stools into clothing without forewarning.’ 
Results from the study were compared to those from Olopade et al (2005), which looked 
at women who had treatment for cervical cancer, as well as other pelvic cancers. It was 
noted that the figures for symptoms such as incontinence with both solid and liquid 
stools, as well as gas, were much higher in that group but Dunberger et al (2010) felt 
that comparison was inappropriate due to newer methods of assessing such symptoms 
that were utilised in their study. It was also noted that the length of time from end of 
treatment to study were quite different, with a mean of 27 months in Olopade et al 
(2005) compared to 86 months in Dunberger et al (2010) and that this time difference 
may play a part in both the symptoms themselves and the women’s perception of them.  
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 The Dutch based Post-Operative Radiation Therapy in Endometrial Cancer (PORTEC) 
trial compared impact on QoL scores following either external beam radiotherapy 
(EBRT) or vaginal brachytherapy (VBT), which is internal radiotherapy. This randomised 
multicentre trial found marked differences in patient-reported QoL at 2 years post 
treatment (Nout et al 2009). The assessment tool was the European Organization for 
Research and Treatment of Cancer C30 Questionnaire (EORTC-C30), which the paper 
reports, was developed for repeated QoL assessment during clinical trials and has been 
found to be valid in different cancer care situations. Function and global QoL was 
measured from 0-100, with high scores representing a better level of functioning, 
whereas with the symptom assessment, also from 0-100, a higher score pointed to more 
symptoms and decreased QoL. No clarification is given if the scoring system was 
explained to participants beforehand, merely that they were “handed out”. This may 
have impacted upon participant completion if no clarification or confirmation of 
understanding was made.  
 
In a major difference to Danielsson et al (1990) study, where different treatments/doses 
were used, in this study, every patient had undergone initial surgery and then the 
radiation dose for every patient receiving EBRT was the same and for patients receiving 
VBT, 90% had high-dose treatment and 10% low-dose. The primary endpoint of the 
study was comparing disease recurrence rates between the two treatment modalities 
and the second endpoint was to assess the impact of the different modalities on QoL. 
At baseline, just prior to commencement of radiotherapy, both groups scored low for 
global health and functioning, with a slight improvement at 6 months. Symptoms of 
diarrhoea and faecal leakage were significantly higher in the EBRT group compared to 
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the VBT group, which coincided with the increased feeling that the EBRT group needed 
to be near a toilet with subsequent impact upon social functioning. These differences 
were seen throughout the 6-24 month follow-up period. Although the study used a 
validated QoL tool, there was little mention in the findings about the actual impact upon 
the women, except for comments regarding social functioning and sexual activity. It 
would be difficult to translate these findings into a meaningful understanding of their 
experiences, and what it was like to live with PRD. The study team concluded their paper 
with the recommendation that if, as they expected, disease control was as effective with 
VBT as EBRT then due to the improved QoL with VBT it should perhaps be regarded as 
the preferred treatment.   
 
In contrast to the findings in the above study, that GI symptoms were more common in 
patients treated with radiotherapy, Bye et al (2016) found that in their cohort of 79 
women, post treatment for cervical and endometrial cancer, only 5% reported side 
effects. They do however report that in general, the whole group of women had a higher 
stool frequency than the general population, and that actually, 7% had resorted to anti-
diarrhoeal medication, so it could be argued that this alone is classed as a late effect. It 
was noted however that those women who did report substantial diarrhoea, scored 
their social functioning as low.   
 
A second paper from the PORTEC-2 trial (Nout et al 2010), describes further follow-up 
of the original study group participants and concludes that at 65 months, the group who 
received EBRT continued to experience GI symptoms, compared to the VBT groups, 
whose HRQL were similar to an age-matched general population group. This does not 
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necessarily mean that the VBT group are without QoL affecting symptoms, however, 
with sexual function, including vaginal dryness, stricturing and painful intercourse being 
more problematic than in the EBRT group. This later paper does not comment on the 
original paper’s (Nout et al 2009) primary endpoint of measuring cancer recurrence, 
although a further literature search uncovered a separate study report (Nout 2010) 
which describes VBT as being as an effective a treatment as EBRT, but with fewer longer 
term side effects, particularly GI, and therefore should be considered as the first line 
treatment of choice.  
 
Abayomi et al (2005) recognised that the figures given at the time by the National Cancer 
Institute (2005 web page is now unavailable and cannot therefore be confirmed) for late 
GI effects of radiotherapy following cervical cancer were likely to be underestimated 
and that many of these women were experiencing a significant reduction in their QoL. 
This was one of few papers that considered patient experience of PRD. Their qualitative 
study interviewed 10 women using an interviewer-guided approach. Each interview 
lasted between 30-120 minutes and used open-ended questions to cover experiences 
of their diagnosis and treatment, including any problems they encountered during and 
after their treatment, impact of their symptoms on everyday life, any attempts they 
made to control symptoms, and if they received or sought professional advice for their 
symptoms. Their use of a qualitative approach would have enabled the women to share 
their experiences in their own words, rather than be guided by a fixed questionnaire 
framework. All the women had initially had surgery followed by radiotherapy and they 
described how all but one had symptoms either during or after treatment, although they 
do not specify how many were later side effects, other than describing ‘most women’ 
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as having problems. Symptoms experienced by the women included diarrhoea, faecal 
incontinence, abdominal pain, bloating and either weight loss or weight gain. This study 
also looked at reasons why the women may not have discussed their symptoms with 
their HCPs. Embarrassment was a major factor, with a reluctance to talk about bowel 
problems, something that is ‘very personal and private’ (p. 360). There was also a sense 
of just having to get on with things now the cancer treatment was finished. This study 
concluded that HCPs need to be more aware of such symptoms following pelvic 
radiotherapy and that they must be more proactive in offering treatment. Led by a 
dietetic team, the study also highlighted the importance of dietetic input as part of the 
multi-disciplinary team and identified that it was important to undertake further study 
to establish the size and impact of post-radiotherapy problems. This study provides a 
valuable insight into the life of women with PRD post cervical-cancer treatment. They 
conclude that they wished to undertake a further study, with one aim being to consider 
the consequences of the problems they found, which is discussed below.   
 
Following on from the above study, three members of the original study group went on 
to develop a second study looking at the numbers of women who experience GI 
symptoms following radiotherapy plus brachytherapy or brachytherapy alone for 
cervical or endometrial cancer and to identify if radiation dose or stage of cancer is more 
likely to increase the risk of developing such problems (Abayomi et al 2009). Using an 
adaptation of the validated Kings Health Questionnaire to assess women with urinary 
incontinence, 85 women who were at least 3 months post-radiotherapy, completed the 
9-domain questionnaire, enquiring about general health perception, impact of 
incontinence, role, physical function, social function, personal relationships, emotions, 
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sleep/energy and severity/coping mechanisms. Results demonstrated that just under 
half (47%) described some form of GI symptoms and interestingly this did not have any 
statistical relationship when comparing if radiotherapy dose, delivery method, cancer 
stage or time since treatment ended, had an impact upon symptom type and/or 
severity. This concurs with previous papers by Andreyev et al 2007a, 2007b and 2012) 
who recognises that there are many varied factors that may impact upon development 
of late GI effects of pelvic radiotherapy. Although this study did not collect data through 
interviews, thus missing out on hearing the women’s voices, they conclude that it is 
important that HCPs are aware of the potential for symptoms following pelvic 
radiotherapy and that due to the difficulty in predicting who is more likely to experience 
problems, all patients should be screened to identify those who are affected.  
 
Holmes (2010) concludes her study with a similar recommendation. Following a growing 
awareness that women who had received radiotherapy for gynaecological cancer were 
experiencing GI symptoms, she used a questionnaire developed by Andreyev’s team at 
the Royal Marsden Hospital, specifically to identify radiation-induced bowel injury 
symptoms. This was the one gynaecological study identified that involved patients in 
reviewing the suitability of the questionnaire, as recommended by Alrubaiy et al (2014). 
The questionnaire also enquired about bladder symptoms although these were 
addressed separately. 109 women were identified through the local cancer network, 
who had been diagnosed with a gynaecological cancer between 2006 and 2008 and who 
had completed their radiotherapy at least 12 months prior. Of the 109 questionnaires 
sent, 77 were returned. Of these, 44 had received treatment for endometrial cancer, 29 
for cervical cancer and 4 for vulval cancer. Of the 77 who responded, 61 reported a 
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change in their bowel habit. 31 respondents experienced constipation, 47 had 
diarrhoea, 33 had increased frequency, 20 had rectal bleeding, 39 had mucous or slimy 
faeces, 26 had faecal incontinence and 42 had abdominal pain/discomfort. Following 
completion of the questionnaires, the paper reports that several women contacted the 
department to enquire about the potential for further investigation and/or treatment 
for their symptoms. This implies that these issues had not been previously discussed or 
offered, yet clearly there was a need. Through the use of a comment section on the 
questionnaire from respondents, the study also demonstrated a need for increased 
awareness of the potential for GI symptoms following pelvic radiotherapy and that 
patients should be asked directly about the prevalence of their symptoms, rather than 
waiting for the women to mention it themselves. This was following several comments 
about the embarrassing nature of the symptoms, which was similar to those identified 
by Abayomi et al (2009).  
 
Each of these studies looking at late GI effects of pelvic radiotherapy in gynaecology 
cancers, have all identified that approximately 50% of women will experience bowel 
problems after treatment. The studies have noted that awareness amongst HCPs needs 
to be increased and that women should be asked about potential symptoms, rather than 
waiting for them to mention it themselves. A common theme in these studies, as with 
the papers looking at PRD following prostate cancer treatment, is that they tended to 
concentrate on symptom identification, rather than what effect these symptoms were 
having on the women’s lives. In the Danielsson et al study (1990) they merely enquired 
if the participant was ‘content or discontent’ with their bowel habit. This does not 
consider differences in the participants understanding of being ‘content’ with their 
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bowels or of any allowance to ascertain what level of being ‘discontent’ they may have, 
or indeed what impact this has, if any, on their lives. Dunberger et al (2010) went further 
in enquiring about QoL issues and was one of the very few studies identified in the entire 
literature review to give the participants an opportunity to express their experiences 
using a semi-structured interview. The paper did not however, describe any of the 
participants’ experiences, and again concentrated on symptom reporting such as 
diarrhoea and abdominal pain.   
 
Without a greater understanding of the impact of PRD on women’s lives, it may be 
difficult to provide holistic care, taking into account their experiences, or what other 
women have experienced. Although the studies reviewed demonstrate that PRD is not 
infrequently identified in women after gynaecological cancer treatment, very few 
discussed the experiences of the women who had these symptoms.  This could therefore 
limit not only the understanding of the difficulties people with PRD experiences, but also 
the treatment offered to improve their QoL.   
 
Macmillan (2014b) is leading the way in encouraging awareness amongst both patients 
and HCPs of late effects of pelvic radiotherapy. This document, written for HCPs, 
identifies that it is good practice for patients to be made aware of the potential of late 
effects prior to their treatment. They believe this to be vital for informed consent to be 
given, to ensure that the patient is fully aware of the potential consequences of their 
treatment. This will also make the patient aware that should they develop these 
symptoms post treatment, support and advice will be available to them.  
 
49 
 
PRD following treatment for colorectal cancer  
Colorectal cancer is the 4th most common cancer in Wales, after prostate, female breast 
and lung cancers (Welsh Cancer Intelligence and Surveillance Unit 2017a). Unlike the 
other pelvic cancers, the radiotherapy is directly targeted at bowel tissue, and therefore 
radiation affecting colonic tissues is unavoidable. This section of the review will analyse 
literature where studies specific to late effects of treatment for colorectal cancer were 
undertaken. The papers will be critically analysed to identify contributions of knowledge 
around people’s experiences of PRD following colorectal cancer as well as the 
prevalence and nature of PRD in this patient group.  
 
A large, England-wide study by Downing et al (2015) identified 34,467 suitable patients 
from the National Cancer Registration Service who were 12-36 months post diagnosis 
for colorectal cancer. No mention was made of the average time post completion of 
treatment. Their aim was to look at QoL issues in people living with and beyond 
treatment for colorectal cancer. A piloted questionnaire made up of several elements, 
including generic health related QoL assessments, colorectal cancer specific outcomes, 
social difficulties, experience of care and cancer treatment, disease status and long-term 
conditions was offered. Of the 21,802 who participated 3,632 had received radiotherapy 
as part of their treatment. The participants who had colon cancer treated with surgery, 
chemotherapy and radiotherapy were 326 (2.4%) and 91 (0.7%) were treated with 
surgery and radiotherapy. For recto-sigmoid cancer, 181 (12%) had received surgery, 
chemotherapy and radiotherapy, and 46 (3%) had surgery and radiotherapy.  2,437 
(36%) patients with rectal cancer, received surgery, chemotherapy and radiotherapy 
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and 696 (10%) had surgery and radiotherapy. The findings showed that patients with 
rectal cancer were more likely than all other cancer types to report problems, with 
pain/discomfort being the most common. Further analysis was not designed to examine 
if the combination of treatment (surgery alone, surgery and chemotherapy, surgery, 
chemotherapy and radiotherapy or surgery and radiotherapy) had any effect on the 
symptoms described. The study showed that after treatment, 17.5% of patients with 
colon cancer reported having ‘no control over their bowels’ (p. 621), compared to 15.4% 
of patients with recto-sigmoid cancer and 13% with rectal cancer. In addition to these 
figures, a further 17% of patients reported having moderate bowel problems, with little 
or some control. Other symptoms described by patients were poor urinary and sexual 
function. The paper mentions that it presents only the reporting of symptoms (p.623) 
and so although they offer details of the prevalence of PRD, there is no discussion on 
how this impacts upon the patients’ lives. The study data are in keeping with previously 
discussed studies (including Holmes 2010, Abayomi et al 2005 and Olopade et al 2005). 
It is impossible to extrapolate whether radiotherapy was a major contributor to their 
long-term symptoms, or what this means to the patient experience. Despite this, the 
authors highlight the Andreyev et al (2013) algorithm for patients who have received 
radiotherapy as part of their treatment, and recommend that cancer services must 
consider such services in their cancer care pathways. 
 
A Canadian trial discussed the balance between using short-course, pre-operative 
radiotherapy for rectal cancers, compared to no pre-operative radiotherapy and the 
potential impact radiotherapy may have on the patients’ QoL post-treatment (Stephens 
et al 2010). After noting that the QoL questionnaire used, EORTEC QLC-CR-38, generated 
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so much data, they developed two hypotheses with which to stratify their findings on 
primary QoL aims: 
What are the longer term (2-year) effects of the treatment on: 
• Sexual function? 
• Bowel function? 
What is the effect of treatment on physical function and general health? 
 
Stephens et al (2010) p. 4234 
 
The use of the QoL questionnaire provided data for symptoms, and although it is a 
validated QoL tool, symptom data alone does not provide information on what impact 
these symptoms have on peoples’ QoL, specifically how it is affected, what the 
symptoms prevent them from doing, or modifications that need to made in order to 
function at a level considered acceptable to the patient.  The findings showed that 
although there was evidence that pre-operative radiotherapy treatment reduced the 
risk of localised recurrence, there was also a significant statistical reduction in sexual 
function and increased bowel problems. They noted that many patients who have 
treatment for rectal cancer will have either a permanent or temporary stoma so figures 
for those experiencing bowel symptoms are likely to be under represented. 
‘Unintentional release of stool’ (p.4236) was significantly worse in the group who had 
received pre-operative radiotherapy when assessed at 2 years. The study concludes with 
a recommendation that patients who are likely to require pre-operative radiotherapy 
are counselled as to the possibility of having late effects, although they anticipate that 
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the number of patients requiring such treatments will reduce over coming years due to 
improved surgical techniques.  
 
Jansen et al (2010) undertook a systematic review looking at QoL issues amongst 
colorectal cancer survivors of a time span greater than 5 years. Utilising a robust search 
approach, 10 studies were identified for review. A clear limitation of the review, which 
was acknowledged by the authors, was the lack of ‘gold standard’ (p. 2886) for QoL 
assessment, resulting in differing methods across the original studies. (See below for 
further discussion concerning this). Methods included face-to-face interviews (n=4), 
telephone interview (n-1) and postal surveys (n=5). Although the review authors 
summarise that radiotherapy can affect specific areas of QoL up to many years later, 
they presented that radiotherapy was not related to reduced QoL in rectal cancer 
survivors. They go on however to note that one study (Pollack et al 2006) looking at pre-
operative radiotherapy versus no pre-operative radiotherapy, found that those who had 
received treatment recorded higher levels of diarrhoea. The findings of the low impact 
that diarrhoea had on QoL may be explained by the theory of a reframing/response shift, 
as described by Bernhard et al (1999).  This is seen when cancer survivors may develop 
a new understanding of their QoL, partly due to relief of successful cancer treatment. 
Potentially therefore, this could explain the perceived discrepancy between reasonably 
good QoL scores but marked GI and other symptoms, where the patients develop a 
perceived new normality in their lives. The lack of ‘gold standard’ mentioned in this 
paper confirms the contention of what QoL means, and that it may mean different things 
to different people, including patients and clinicians. This highlights the lack of 
consideration given to exploring peoples’ experiences of living with PRD, how this 
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impacts upon their lives, and if the QoL is affected. The study within this thesis will 
attempt to address this shortfall.  
 
A systematic review of the literature by Panjari et al (2012) looking at sexual function, 
urinary and faecal incontinence and wellbeing in women after treatment for rectal 
cancer found that 50% of women experienced unexpected loss of flatulence (Peeters et 
al 2005). They described this as Anterior Resection Syndrome (ARS) (Hassan and Cima 
2007), which is ‘increased number of daily bowel movements, erratic defecatory 
patterns, urgency, tenesmus, obstructed defaecation and minor faecal leakage’ Collie 
(2013, p.1). There is often confusion and cross-over in clinical practice between the 
symptoms of PRD and ARS, but it would seem appropriate, considering the evidence 
seen in the literature review, to recognise the strong possibility of PRD causing bowel 
symptoms where pelvic radiotherapy treatment has been used.  The conclusion of the 
review was that there was need for further study in to ‘the long-term effect on these 
parameters’ (incontinence, sexual function and QoL) p. 2756. This declaration highlights 
that studies are often purely symptom focused. In contrast to papers such as this, the 
qualitative work in this thesis will look at participants’ experiences of PRD, rather than 
parameters.  
 
A later systematic review of the literature on QoL issues relating to radio-chemotherapy 
for anal cancer was under taken by Sodergren et al (2015). They identified that the use 
of chemotherapy alongside radiotherapy has been increasing, particularly following 
studies describing excellent response rates in 1974, despite previous thoughts that 
surgery was the only treatment option. One key finding from the review was that very 
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few (4%) of the studies included had used any formal QoL assessment although they 
suggest this may be due to there not being a specific assessment tool for QoL issues with 
anal cancer, a similar finding to the lack of ‘gold standard’ identified by Jansen et al 
(2010). The studies that did assess QoL did so via tools such as the LENT-SOMA and 
criteria outlined by the National Cancer Institute Common Terminology Criteria for 
Adverse Events (CTAE). The Christie NHS Foundation Trust (2016) describes how the 
LENT-SOMA was initially developed in 1995 by the European Organisation for Research 
and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (ROTG), 
in an attempt to develop an international scoring system to measure late effects of 
cancer treatment. This work was further developed by the CTAE using aspects of the 
LENT-SOMA to assess both early and late effects of treatment. Currently used across the 
UK, the questionnaires have been extensively validated for various cancer specific sites, 
including prostate and bladder, although not currently for colorectal cancer.  
 
A further observation made by Sodergren et al (2015) regarding low quality level of QoL 
detail was one paper that compared QoL following surgery or radio-chemotherapy 
where QoL data was extracted from medical records, rather than asking the patients. 
This may affect the reliability of the data, as it could depend on what the clinician asked, 
unless the patient voluntarily offered details of QoL issues. Indeed, the authors describe 
this as giving ‘a very incomplete assessment’ p. 3620. It was also discussed that none of 
the studies in the review had utilised a qualitative approach and the authors described 
this as limiting the evidence of the impact of symptoms on QoL issues. This would 
suggest acknowledgement that using QoL data collection tools alone may miss out on 
identifying QoL elements that could be discovered using qualitative methods.  
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Overall, the Sodergren et al (2015) review ascertained that most patients QoL post 
treatment, of whatever source, had levels comparable to that of the general population. 
One reason for this was thought to be the high cure level of the disease, although it may 
also be due to Bernhard et al’s (1999) theory of a reframing/response shift as discussed 
earlier. It was noted however that in a number of studies, bowel and sexual function 
were shown to be a significant concern and which subsequently reduced QoL scores. No 
mention was made of time scales post-treatment to ascertain how close to treatment 
these problems occurred, or potentially settled. The review concludes with a 
recommendation that QoL issues are considered in cancer trials and that potential 
treatment impact upon patients’ QoL be discussed prior to treatment to enhance 
informed choice and consent. After noting the authors’ comment on incomplete data 
emerging from some of the quantitative studies, this suggests that qualitative methods 
would provide further knowledge about the impact of PRD, and this is an objective of 
the research within this thesis.  
 
A 4-year prospective German study of breast cancer and rectal cancer patients by Engel 
et al (2003) compared QoL issues between the two groups. They used two validated 
cancer care questionnaires and described differing long-term effects than demonstrated 
in previously discussed studies. The questionnaires used were the EORTEC QLQ-30, that 
use 5 functional scales (physical, emotional, cognitive, social and role functioning), 
global QoL measure and symptom assessment and the CR-38 which was specifically 
designed for rectal cancer patient questions including body image, sexual 
function/enjoyment, future perspective, GI & urinary problems. The GI symptoms were 
classed as constipation, diarrhoea or defecation problems, with 24 other non-GI related 
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variables. Much of this study looking at rectal cancer patients concentrated on the 
details of differing types of surgery with or without stoma formation, although it was 
noted that patients who had received radiotherapy had statistically worse QoL in 16 of 
the variables within the year following treatment, of which 3 were those mentioned 
above. It was then demonstrated that following that first year, QoL began to improve in 
the radiotherapy only group, whereas it continued to stay poor in the stoma and low 
and high anterior resection groups. As the individual variables were not discussed 
separately, it may not be particularly clear or helpful when investigating late GI effects 
by stating that the radiotherapy group patients improved their QoL in the following 
years. Although certain aspects of life may improve in their study, it does not appear to 
show a significant improvement in, for example, diarrhoeal symptoms. Table 3 in their 
paper (p. 207) shows that the diarrhoea mean scores, on which their statement of 
improvement was based, were developed from just 48 responding patients, down from 
the original 169 participants. Although an interesting study, the reduction in participant 
numbers and the lack of clarity of individual variable explanations do not provide 
enough data to assume that GI effects of radiotherapy will improve after year one.  
 
Another point of particular interest, is that the Engel et al (2003) notes that ‘younger 
patients appear to be more psychologically affected by their cancer experience’ (p. 220), 
even though this study was designed to look at QoL rather than experience. This again 
highlights the confusion between what constitutes QoL, how best to understand it and 
whether it can be measured statistically, rather than qualitatively.  Engel et al (2003) 
concludes, as do the majority of the other studies, that patients should be adequately 
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informed, pre-treatment, about the potential for later problems with each individual 
treatment method and that QoL issues should be included in studies.  
 
Sunesen et al (2015) also looked at problems experienced by people who had undergone 
treatment for anal cancer, recruiting 84 patients who had received surgery and/or 
radiotherapy alone or alongside chemotherapy.  The median range from participating in 
the study from end of treatment was 33 months (5-92 months), providing some longer-
term data than other studies had included so far. The authors identified that commonly 
used QoL assessment tools may not adequately capture long term symptoms and 
distress from treatment related problems, a point which had also been highlighted in 
the work of Sodergren et al (2015). The research team developed their own, anal-cancer 
specific, questionnaire. This was constructed through utilising appropriate elements 
from existing tools, such as the LENT-SOMA and a group of experts, although no patients 
appear to have been involved in the development, which may have provided useful 
additions and/or alterations. Distressing GI symptoms featured heavily in participant 
responses. 54% of patients reported incontinence of liquid stool on at least one occasion 
per month; this caused ‘great distress’ to 76% of the participants. 56% reported faecal 
urgency occurring at least once a day, causing ‘moderate to great distress’ to 85% in that 
group. Other problems expressed included urinary and sexual dysfunction. The authors 
go on to consider some studies which looked at whether total radiation dose increased 
the likelihood of developing long-term problems although the findings were unclear. 
The authors are vigorous in describing limitations of their study; they did not measure 
baseline date pre-treatment and suggest this would be valuable to measure change. 
They also recognise that their investigation was at just one time point and note that 
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follow-up episodes would provide further useful data on changing symptoms over time. 
Finally, they comment that radiotherapy techniques are changing, improving and often 
vary in different counties and so individual findings may be difficult to replicate and find 
in other populations. They again, also conclude, as with the majority of other studies, 
that patient information is a vital part of the treatment pathway. Although the authors 
did include some measurement of distress of symptoms, using ‘none’, ‘little’, ‘moderate’ 
or ‘great’ as parameters, there was no discussion of the experiences or impact this had 
on the patients’ lives. This highlights the difficulty in obtaining data regarding 
experiences from qualitative studies, and leaves a significant gap in knowledge.   
 
A similar study by Das et al (2010) also showed that patients who had received 
radiotherapy as part of their anal cancer treatment generally had higher QoL scores 
compared to patients who had received surgery for colorectal cancer. They did not, 
however, compare them with a healthy population group, so it seems difficult to present 
the scores as acceptable. The study team used 2 different assessment scales. The 
Functional Assessment of Cancer Therapy- Colorectal (FACT-C) enquired about 4 QoL 
domains- physical, social/family life, emotional and functional and had an extra 
colorectal section. The second assessment tool, the Medical Outcomes Study (MOS) is a 
sexual problems scale that uses a scoring system whereby the higher the score, the 
worse sexual function. Higher participant age and pre-existing comorbidity, particularly 
of depression or anxiety, contributed to worsening of QoL scores. All patients were at 
least 2 years post treatment, with a median of 5 years (3-13 years). Although the paper 
concentrated on reporting sexual dysfunction, they also note that 31% reported 
problems with diarrhoea and 23% described problems with bowel control. The authors 
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conclude that although ‘a significant percentage of patients had difficulty with 
diarrhoea, bowel control and different aspects of sexual function’ (p.828), they still 
describe that overall QoL scores are acceptable. These two findings appear to contradict 
each other and demonstrate that QoL means different things to different people.  
They also note that although newer radiotherapy technologies, such as intensity-
modulated radiotherapy (IMRT), will reduce the amount of background radiation to 
organs others than those intended to be the focus, with anal cancer, there will likely 
always be an issue of radiation damage to the anal sphincter resulting in diarrhoeal and 
control problems.  
 
A paper looking at a challenging situation, where, for various reasons patients being 
treated for rectal cancer received unconventional doses of radiation, provided a useful 
insight into late complications of pelvic radiotherapy. Jung et al (2001) analysed data 
from the event, noting that many of the patients affected took legal action due to what 
was seen as unacceptable consequences of the care they received. The authors defined 
late effects as “symptoms which appear or persist 3 months after the first radiotherapy 
session or later” (p 234). As with previous studies, the LENT-SOMA and EORTC 
questionnaires were used to assess the participants’ symptoms. Although an 
extraordinarily complicated paper to extract results from, it presents a major finding 
that was not apparent in any other paper to date namely that the time from treatment 
completion to development of late effects, may not necessarily decrease. The authors 
calculated that the “probability for the manifestation of late sequelae remains 
unchanged for many years” (p. 244). If correct, this has significant implications for both 
patients and the provision of health services given the increasing number of cancer 
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survivors, as this study implies that they may develop symptoms at any time following 
treatment. Andreyev (2007) and Olopade et al (2005) also noted that symptoms were 
reported up to 29 years post treatment. Interestingly, Jung et al’s (2001) study also 
concludes that there may be a ‘random process’ by which some people develop late 
effects while others do not. This concurs with Andreyev et al (2007a, 2007b and 2012), 
yet contradicts others who believe higher radiation dose to be the causative agent (Nout 
et al 2010, Nout et al 2009 and Danielsson et al 1990). 
 
A Norwegian based cross-sectional study involving 128 anal cancer survivors, with a 
median time since diagnosis of 66 months and who were treated with chemo-
radiotherapy provided QoL information via a questionnaire (Bentzen et al 2013). A 
matched healthy population group were used, drawn from the National Populations 
Register, to provide an example of what could be considered a healthy control, thus 
highlighting any changes in QoL levels. This provides a direct comparison group, which 
was highlighted to be lacking in the Das et al (2010) study. Bentzen et al (2013) also 
presented that an absence of anal cancer specific health related QoL assessment tools 
directed them to use the EORTEC core questionnaire. The QLQ-C30 version of the 29 
item questionnaire was felt to be relevant to the anal cancer patient group, including 
questions about bowel function and abdominal pain (Whistance et al 2009). As well as 
using the questionnaires, the participants also took part in structured telephone 
interviews where pre-defined yes/no questions were used. It would seem a missed 
opportunity that the telephone interviews did not have a qualitative element; indeed if 
the questions had answers that were simply yes/no there seems little benefit of using a 
telephone call to do this rather than add it to the questionnaire. Potentially rich 
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qualitative QoL data could have been obtained. However, the quantitative data 
concurred with the study’s hypothesis that patients treated with radiotherapy (usually 
chemo-radiotherapy) often experienced late side effects. Indeed, the anal cancer 
survivor group showed a deterioration in all aspects of the QoL assessment tool, with 
the largest score difference between the healthy group for GI symptoms being stool 
frequency, flatulence and faecal incontinence. As with the previously discussed studies, 
sexual function difficulties were also a major concern. The authors noted that it was 
unclear if the deterioration in the anal cancer survivors group was due to the disease 
and its impact itself and/or the treatment they received. Potentially, qualitative data 
may have helped clarify this matter a little further, noting when the problems began and 
if the symptoms progressed over time and what impact this had on the patient. The 
authors recommend that treatments should be specifically optimised to help reduce late 
effects although they note that anal cancer radiotherapy will always involve radiation of 
the anal sphincter and thus some level of tissue damage and impact on function is 
probably unavoidable.  
 
Knowles et al (2013) recognises that the improvements in survival rates from rectal 
cancer is likely to see an increase in the number of people living with late and long term 
effects of the treatment. 381 participants responded to the offer to take part, 138 of 
whom had received treatment for rectal cancer and 243 having received treatment for 
colon cancer. Median time from surgery was 53 months (38-68 months) but a time scale 
from radiotherapy was not provided for the whole group, although a median time of 52 
months post radiotherapy was given for the rectal cancer group. Similar questionnaires 
were used as the previous studies discussed, although later versions of the EORTC were 
62 
 
utilised which involved similar elements. Of the rectal cancer group, 50 patients (36.2%) 
received pre-operative radiotherapy. Within this group, comparison of QoL was made 
with the group who did not receive radiotherapy. The treated group had significantly 
increased problems with defecation that then subsequently reduced their overall QoL. 
There was no mention of the experiences of defecation amongst these participants or 
how this actually impacted upon their lives. The authors go on to identify that new 
models of care that recognise the potential for late effects of cancer treatment are 
needed, yet acknowledge that at this time there are few specialist services able to 
support those with GI late effects (Henson et al 2011).  
 
Each of the studies examined in prostate, gynaecological and colorectal cancer groups 
appear to recognise the importance of QoL after cancer treatment. There was a distinct 
spotlight on reporting of symptoms however, rather than the effect of the symptoms, 
on the participants’ lives. This was acknowledged by Downing et al (2015). There seemed 
to be a general acknowledgement that clinicians must be aware of what symptoms may 
result from the treatment, in order to minimise problems in the future and increase 
patient awareness of the potential problems. There was an overwhelming reliance on 
QoL questionnaires, which will produce quantitative results, unless allowance was made 
for free-text. Jansen et al (2010) agreed that adequate data on QoL issues was difficult 
to extrapolate, despite its importance, partly due to a lack of “gold standard” of 
definition of QoL (p. 2280).  This makes it difficult to understand why researchers have 
concentrated on quantitative methods to measure something that does not have an 
easily definable concept.  
63 
 
What is clearly lacking by using these methods then is an understanding of what QoL 
scores mean to patients. What, for example, is the effect of persistent diarrhoea, what 
does it stop them doing and how does it make them feel. In their systematic review, 
Sodergren et al (2015) agree that the lack of specific QoL assessment tools for certain 
cancers, including anal cancer, may reduce the benefit of using general QoL tools in 
studies looking at impact upon participants’ lives. Sunesen et al (2015) conclude that 
patient information about the effect of symptoms on their lives forms an essential part 
of the treatment pathway, yet again allows their participants a limited vocabulary to 
describe their symptom distress, such as ‘little’ or ‘great’. This highlights the lack of 
participant voice amongst the current literature. A further example of this is where 
Bentzen et al (2013), used mixed methods to examine participants’ QoL after pelvic 
radiotherapy. As well as using a questionnaire they use telephone interviews. Rather 
than using this as an opportunity to gain rich insight into the participants’ experiences, 
they limited it to “Yes/No” answers.   
 
The study within this thesis is designed to listen to the participants’ stories and to 
improve understanding of patients’ experiences rather than concentrate on purely what 
physical symptoms they are experiencing.  
 
Quality of life scores: a help or hindrance? 
In the first few sections of this literature review, where studies were examined that 
looked at PRD in people with prostate, gynaecological and colorectal cancers, it was 
repeatedly seen that there was ambiguity between what the QoL questionnaires were 
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designed to show. On the whole, they appeared to be data collection tools just for the 
symptoms, rather than focus on how the symptoms resulted in experiences which in 
turn impacted on peoples QoL. This section will look at definitions of quality of life, what 
scoring systems are intended to show, and subsequently what they are not designed to 
recognise.  
 
The World Health Organisation (WHO) (1997) defines quality of life as: 
 
“ an individual’s perception of their position in life in the context of the culture 
and value systems in which they live and in relation to their goals, expectations, 
standards and concerns. It is a broad ranging concept affected in a complex 
way by the person's physical health, psychological state, level of independence, 
social relationships, personal beliefs and their relationship to salient features of 
their environment ”. 
WHO (1997, p.1)  
Within the WHO document, the authors recommend that any assessment of health 
state and effectiveness of healthcare should involve an assessment of QoL. They 
developed two QoL assessment tools, WHOQOL-100 and WHOQOL-BREF, after 
engagement with fifteen worldwide centres involving patients and HCPs managing a 
range of diseases. They believe that the main value of the tools is that they are based 
on the patient’s perception, which may then alter the HCPs understanding of how the 
disease is impacting upon the individual. When considering the effect of PRD on 
patients’ and their partners’ lives, such a tool would provide an insight into how 
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different symptoms may affect people differently. For example, some people may be 
able to cope with chronic diarrhoea better than others. Although the physical symptoms 
are the same for each, one may find it more distressing than another. The authors 
suggest that the tool may be useful to use alongside other disease measuring tools and 
that it may be beneficial to use a period of time to assess change in disease and QoL 
status.  
Cella (1994) agrees that QoL measurement is an essential part of providing quality health 
care. He comments, “no goal can be more important” (P. 186) than ensuring that 
patients are experiencing wellbeing. Although the paper relates to palliative care, much 
of what he says is as relevant for anyone living with a chronic disease. He believes that 
healthcare interventions should be directed to improving QoL and treating the 
symptoms that are causing most distress and disruption. The article goes on to discuss 
the various QoL measurement tools available and suggests that there is often 
disagreement about which provides a more holistic view. He goes on to refer to a review 
(Cella 1991) that concluded the essential involvement in any tool of four main areas: 
physical, functional, emotional and social. Adams et al (2014) agrees about the 
importance of identifying the psychological impact of PRD on people’s lives, and 
therefore added the Hospital Anxiety and Depression Scale (HADS) to their other QoL 
assessment tools. Developed by Zigmond and Snaith (1938), it was designed to be a 
quick and simple to use scoring system to identify where anxiety may be leading to 
depression or where it already co-exists. The use of this tool identified higher levels of 
depression associated with lower QoL levels, indicating that the symptoms were indeed 
impacting not only on people’s physical well-being, but on their psychological wellbeing 
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also. No mention was made of any free-text or interviews to ascertain what aspects the 
participants thought contributed most to their negative experiences.  
Felce and Perry (1995) recognise that varying concepts of what defines QoL may explain 
why there are so many different measurement tools. They cite Liu (1976, p.52) who 
wrote that there were “as many definitions of QoL as there were people”. Following a 
review of the available literature at the time, Felce and Perry (1995) concluded that 
there were 5 main QoL themes: physical, material, social and emotional wellbeing and 
development and activity. The last element, activity, may be because this work was 
developed in a mental health area and potentially is not as important in areas of chronic 
disease such as PRD. They conclude that the agreement of QoL assessment across all 
groups of people is important for data interpretation, yet they agree that this is unlikely 
and so differing tools should be used with caution in different disease/social groups.  
The EORTC Quality of Life Group, tasked with developing validated QoL questionnaires 
for cancer studies and clinical practice, also noted that an over-reliance on 
toxicity/symptom scales may have reduced awareness of the social and psychological 
impact of PRD, as these issues are not included in many assessment tools (Halkett et al 
2018).  The group have recently produced EORTEC QLQ-PRT20, a QoL assessment tool 
that is specific to people with radiation proctitis, and which they describe as being “quick 
and easy to complete, acceptable to patients, has good content validity and high 
reliability” (p. 8). The tool encompasses five domains, one of which is emotional 
function/lifestyle. They propose that the tool is used alongside their previous QoL tool- 
EORTC QLQ-C30 for a fuller assessment of both symptoms and the effects of those 
symptoms on QoL. The authors note that further studies are required to not only 
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establish the incidence of PRD but also the effect the disease has on patients’ QoL. This 
thesis will go some way into addressing this call for further information on the impact 
of PRD on people’s lives.   
As previously discussed, gaining a greater understanding of what the patient is 
experiencing will help to direct treatments and resources to where the patient requires 
it most. The studies reviewed so far have generally adopted a quantitative approach. An 
alternative method of further exploring understanding is that of the ‘lived experience’. 
In her work with people with chronic disease, Gullickson (1993) describes the benefits 
of using interpretive methodologies to better understand the human position. Utilizing 
a Heideggerian phenomenological approach, unstructured interviews were used to gain 
a deeper awareness of the human issues behind the lived experienced of chronic 
disease. It was clear from the interpretation of the interview text that each patient 
brought with them past experiences and past knowledge that would affect not only how 
they now perceived their disease but also how they might manage it in the future.   
Walker et al (1999) used a narrative phenomenological approach to gain a deeper 
understanding of people experiences of living with chronic back pain.  From analysing 
patients’ stories they found a theme throughout; patients felt they were “in the system”, 
the system/process of chronic disease; they felt things were done to them, happened to 
them, and that this made them feel powerless. These types of findings, explanations of 
why patients may feel as they do, are extremely valuable in helping HCPs understand 
the patient’s situation and their experience. This knowledge would be unlikely to be 
discovered through QoL tools. Qualitative methods offer so much more information 
than “yes/no” questionnaires and can provide insight into expressed behaviour, such as 
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why patients with chronic back pain may express negativity (Walker et al 1999).  
Kleinman (1988) summarises the benefits of hearing the patient story, of narrative, 
directly from the patient, rather than relying on the HCP’s opinion of the problem. He 
says:  
“Disease is the problem from the practitioner’s perspective”  
Kleinman (1998, p. 5) 
 
This poignant statement highlights that in the case of PRD, the aim of this thesis is to 
hear about the issues from the participants’ perspective, not what HCPs think it is, or 
what “yes/no” answers will tell us.    
 
Finally, a further tool to assess patients’ experiences, and one that is becoming 
increasingly popular, is that of patient reported outcome measurements (PROMs). NHS 
England (2016) describes PROMs as tools that measure a patient’s health status or QoL 
pre and post- surgery and that are then used to assess the quality of care received. 
Originally limited to evaluating surgical outcomes, the use of PROMs is becoming more 
widespread. Muls (2014) presented how the use of a PROM, using a modified GSRS, 
allowed focus on GI symptoms that were affecting the patients’ daily activities. This 
appears to benefit both symptom identification, for purposes of medical management, 
and also highlighting what the patient feels is important for them. Alrubaiy et al (2014) 
describe the current availability of over 100 PROMs directly related to gastrointestinal 
diseases and how they can improve health assessment as patient experiences and 
perceptions are included in the assessment. With a plethora of PROMs available, 
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Alrubaiy et al (2014) recommend 5 components be considered to ensure the 
appropriate PROM is used/developed:  
 
• Item selection- gained via assessment of old PROMs, patient and HCP 
involvement (patient involvement found to be the most valuable) 
• Validity- actually measures what it is meant to 
• Reliability- demonstrate consistent measures  
• Responsiveness- able to change as required to the patient’s condition 
• Interpretability- being easily interpreted to clinical meaningful values 
 
This section has demonstrated conflicting ideas on how best to gather data about what 
the participant is experiencing. There seems to be some ambiguity over what QoL is 
measuring. Many of the tools described, concentrate simply on symptoms and how 
many people experience them. Qualitative methods and PROMS would suggest that QoL 
is more about how patients experience the symptoms and what impact they have on 
their lives. The use of PROMS is a growing area, yet is not fully embedded at this point 
in time in the care of people with PRD. This thesis will address the lack of qualitative 
data about peoples’ experiences of living with PRD, and will aim to provide a rich analysis 
of what this means to them and their loved ones.   
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Current awareness of PRD by healthcare professionals 
With any chronic disease, the HCPs ability to recognise the problem is the first step in 
the patient receiving appropriate treatment. For more complex diseases, it may be 
necessary for specialised services to become involved. In this section of the review, the 
literature surrounding a HCPs awareness and knowledge of appropriate investigations 
and treatment of PRD will be examined.  
 
A disparity between the awareness of PRD and IBD, despite a similar number of new 
diagnoses in both patient groups, has been highlighted by Andreyev (2005).  In this 
paper, he raises the conflict between gastroenterologists, who say they are rarely 
referred this group of patients, and oncology radiologists who say that even if they do 
refer, often very little is achieved. Henson et al (2011) set out to scope the awareness 
amongst the 314 clinical oncologists that treated pelvic cancers within the UK and 
undertook a nationwide study. Using a questionnaire developed by a specialist working 
party, enquiries included whether any screening methods to identify patients with PRD 
were used, their estimation of patient numbers with PRD, how they manage PRD, if and 
how they refer for specialist input and their opinion of the current and potential future 
services available.  124 of those radiologists who responded said that they would 
attempt to treat PRD symptomatically, such as with anti-diarrhoeals. 91 oncologists 
refer this group of patients for specialised assessment, although 111 stated that they 
did not have access to a specialised service with a special interest in bowel radiation 
toxicity. Henson et al (2011) concluded that the services at that time were inadequate 
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and that it was hoped that the anticipated guidelines (Andreyev et al 2014) would go 
some way to addressing this shortfall in service provision.  
 
A follow-up study to scope the awareness of PRD and service availability amongst 
gastroenterologists was undertaken the following year by Henson et al (2012). Using a 
questionnaire designed by the same specialist working party, they enquired about the 
practice of all gastroenterologists who were on the current list of membership for the 
British Society of Gastroenterology (BSG). 866 gastroenterologists were approached yet 
only 165 (20%) responded. Admittedly, purely speculatively, this poor response rate 
may identify the lack of awareness/involvement of a large proportion of the speciality. 
Another statistic which highlights the lack of experience in this group is that just 5 
gastroenterologists reported being referred more than 20 PRD patients in a year. Of all 
the referrals, sources included oncologists, urologists, gynaecologists, colorectal 
surgeons, and GPs, who had the highest referral rate. Henson et al (2012) concludes that 
PRD assessment and management services are sparse and that there needs to be 
improved communication between oncology and gastroenterology services.  
 
Richardson et al (2011) believed that patients who had finished their cancer treatment 
were neglected, particularly if they were experiencing problems as a consequence of 
their treatment. They felt that any service improvement needed to be evidence-based, 
yet there was very little research focused on this aspect of cancer care. They undertook 
a literature review of research carried out between 1990-2009, to identify where future 
research could be directed. Of their top 5 topics suggested was ‘methods to identify and 
manage the consequences of cancer and treatment’ (p. 589). Andreyev et al (2016) ‘The 
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Practical Management of the Gastrointestinal Symptoms of Pelvic Radiation Disease’ 
went a long way to providing the answer. 
 
Doyle (2008), a Nurse Consultant at the Royal Marsden Hospital, recognised that the 
term ‘cancer survivorship’ was a growing phenomenon. Her concept analysis concluded 
that with the ever-growing population of people surviving cancer, this presented the 
opportunity to promote healthy lifestyle advice and support, if consequences of their 
treatment were identified. She believed that nurses were ideally placed to take the lead 
in this. In contrast, only 7 years after Doyle’s recommendation, Sanoff et al (2015) 
provided a bleak view of the lack of information and support provided to survivors of 
rectal cancer. Using a social media survey, with 11 fixed-responses and 1 open-ended 
question, they achieved 116 replies. The main themes identified were that the patients 
were given very little information about potential consequences of their treatment both 
before and after the treatment and that this needed to be improved.  
Muls et al (2016) highlight however that a PRD service is neither a cheap nor easy service 
to provide. Their service has the capacity for 12,000 outpatient slots and receives 
approximately 400 new referrals each year. The authors note that NHS England do not 
have a cost-tariff to fund such services, even though they calculate an average cost of 
£1,563 per patient, including assessment and treatment, although they identify that the 
typical cost of the initial cancer treatment that the patients receive in the service was 
between £2,000 and £45,000.  The authors summarise that it is essential that services 
treating consequences of cancer treatment, in this case GI consequences, must be 
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adequately funded and supported if the needs of this growing patient population are to 
be met.   
The National Cancer Survivorship Initiative (2013) set up the ‘Living with and beyond 
cancer’ initiative, which includes the aim of enabling further work to ensure effective 
management of the consequences of treatment (p.111). As a result of their co-
operation, Macmillan have produced a number of documents that offer information 
about PRD for both patients, families and HCPs (Macmillan 2014a, 2014b, 2014c, 2015 
and 2016) 
This section of the literature review highlights that although there is a growing 
awareness of the consequences of cancer treatment, including PRD, there is still 
inadequate awareness amongst HCPs. This is likely to affect timely identification of 
people with PRD and difficulty in obtaining local treatment. Organisations such as the 
NCSI and Macmillan are working to provide education for both patients and HCPs, which 
in turn should improve care available for people with PRD.  
The effect of Faecal incontinence 
Diarrhoea and difficulty in controlling the passage of stool following pelvic radiotherapy 
is frequently reported yet the full incidence is unknown, in part due to inadequate 
measures in prospective studies of GI symptoms (Putta and Andreyev 2005). Such bowel 
symptoms are commonly reported in the QoL sections of previously discussed studies 
and it appeared to be a significant area of distress for patients. This section of the 
literature review will focus on the papers surrounding faecal incontinence (FI). The areas 
will include QoL issues and measurement of such, specifically in relation to FI and not 
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PRD exclusively, hence this separate section. The review will continue to look at the 
prevalence of stigma and depression related to FI and the impact on carers and partners.  
 
Faecal incontinence (FI) is a description of a sign, or a symptom of a bowel problem, 
rather than a diagnosis (National Institute of Clinical Excellence 2007). Olsson and 
Berterö (2014) highlight a difference of opinion as to what actually constitutes FI, 
particularly whether the expulsion of flatulence should be included or not. This lack of a 
strict definition however, causes difficulties in interpreting data in studies (Maeda et al 
2011). Another reason for lack of clarity in the prevalence of FI after radiotherapy is that 
patients often do not tell their oncologists about these symptoms, often because they 
feel there are more important things to discuss within the short clinic appointment time 
available (Putta and Andreyev 2005). 
 
Quality of life 
Of the 37 articles selected to review in further detail, everyone one of them referred to 
the effect of FI on QoL in some way. With regards to FI following treatment for cancer 
the knowledge of impact on QoL is limited (Knowles et al 2015). QoL is an important 
outcome that should be considered alongside cancer recurrence and survival rates 
(Murata et al (2008). Cotterill et al (2008), who summarised the issues, suggest that 
typical clinical QoL assessments were inadequate and unable to fully identify and 
appreciate the impact FI was having on people’s lives.  They referred to an international 
consultation on incontinence which identified that the clinician-administered tools 
typically used, were not specific enough to assess the impact of FI on QoL and there 
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were no validated tools to do this (Donovan et al in Abrams et al 2005). Cotterill et al 
(2008) thus set out to look at QoL issues from the viewpoint of those affected, and to 
see if any existing tools were suitable for assessing impact. Through a series of sub-
studies, the authors asked both clinicians and those experiencing FI, what 
questions/terms they felt were should be included. They then compared these with 
existing assessment tools and commented that ‘none of the available instruments 
contains all of the important issues for patients’ (p. 86).  
 
Wilson (2007) also noted that existing FI assessment tools did not involve patients with 
FI in the tool development, people she terms as “insiders” (p. 204). Using a grounded 
theory approach, she interviewed 22 people. Of these, 21 commented that the 
unpredictability of FI resulted in “subsequent life restriction” (p. 84).  She then identified 
five themes from the analysis, which encapsulated the experience of living with FI: 
 
1. Impact of FI on self 
2. Response to FI, including adaptation/maladaptation 
3. Interaction with partners/close relatives/friends/public 
4. Positive/negative life direction 
5. Interaction with health professionals  
(Wilson 2007 p. 204) 
 
These 5 themes noted that many patients moved through a ‘dynamic continuum’, from 
overwhelming negativity about the impact of their FI, to becoming ‘stoic’ and ‘resigned’ 
and then on to greater acceptance. Further follow-up studies at 5 and 10 years (Wilson 
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2013 and 2015) showed that those participants who had remained in the study follow-
up, had often developed adaptation strategies, either through practical techniques or 
acceptance of the limitations that FI placed upon them, and that those who reached this 
point often reported an improvement in QoL. Cotteril(2011) comments on this study, 
believing that HCPs should enable people with FI, to move along this pathway towards 
acceptance and to help them gain ‘mastery of symptoms’ (p.53), resulting in an 
improvement in their QoL.  
 
However, not all people with FI will necessarily move along this journey to a satisfactory 
level of acceptance. In their study of 11 men, Peden-McAlpine et al (2012) found that 
‘resignation’ was the main response to living with the effects of FI. Most felt that it was 
an inevitable part of aging, and therefore almost normal. They did not develop the 
coping strategies that the authors had found in other studies that had included women 
but did comment that perhaps ‘resignation is a coping strategy that protects against 
lower quality of life’ (p.303). In their systematic review of the literature, looking at FI in 
men post radiotherapy for prostate cancer, Maeda et al (2011) also found differences in 
the coping behaviour of men and women. They identified that women were perhaps 
more used to the wearing of sanitary towels for menstruation purposes, and so felt more 
comfortable with their use for protection against FI episodes, than men. This was also 
commented on during an earlier paper by Maeda et al (2008). The review also noted 
that the effect of FI on QoL had received little attention in research studies.  
 
Olsson and Berterö (2014) used an interpretive phenomenological approach to identify 
and describe the effect FI has on everyday life. Their Swedish study involved 5 women 
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and the interviews began with ‘tell me how it is to live with FI’.  The 4 themes identified 
were: 
 
1. Self-affirmation 
2. Guilt and shame 
3. Limitations in life 
4. Personal approach 
Olsson and Berterö (2014) p.145-146 
 
These are similar to the themes identified by Wilson (2007), although Olsson and 
Berterö (2014) felt that ‘self-affirmation’ and ‘personal approach’ were not previously 
identified themes. Changes to how lives were now led were common. Participants told 
how they avoided going out, often making up excuses to miss events. Their homes 
became their ‘safe place’, where they could avoid social interaction and did not need to 
worry about their bodily functions. Knowledge of toilet location was important, an 
awareness called ‘toilet mapping’ (Ness 2012). The participants in this study were keen 
to tell their stories; they felt it would help to address the problem, to help others in 
similar situations and to encourage others to seek help. Expressions of guilt and shame 
were common in this study, and attempts to hide and disguise the problem were the 
norm. Chelvanayagam and Norton (2000) found similar feelings of devastation in their 
focus group of women with FI. They found the women often became tearful when they 
described how every aspect of their lives was affected by FI, but said they had found it 
helpful to talk to others about what they were experiencing. A diminishing ability to 
continue everyday activities was demonstrated by Lamb et al (2011), Murata et al (2008) 
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and Horrocks et al (2004) who recognised that the restrictions were likely to be long 
term.  
 
Stigma of faecal incontinence 
Several authors wrote of how FI returns one to the bodily control of a small child, and 
of the associated shame and embarrassment associated with this (Alderman 1989, Bliss 
et al 2010 and Norton 2004). Lea (1999) describes the contradiction of excretion in 
modern society; on one hand a pleasurable and desirable event, even promoting total 
excretion clearance through procedures such colonic irrigation as a health and beauty 
treatment, yet on the other hand as something that needs to be hidden away and kept 
totally private. Elias (1978) cited by Lea (1999) pointed to the changes in the way society 
felt about bowel opening, describing how in the 16th century, books on manners and 
etiquette spoke freely of toileting, yet towards the end of the 18th century comments 
had all but disappeared. It would seem that what makes the difference between the act 
of excretion being normal and good, to shameful and troublesome is the matter of 
control (Lee 1999). Norton (2004) describes how we are taught from an early age that 
this lack of control is ‘naughty and unacceptable’ (p. 85).  
 
People living with FI often talk about the shame, disgust and stigma they experience 
(Ness 2012, Rasmussen and Ringberg 2009, Alderman 1989, Wilson 2013 and 
Chelvanayagam 2014). Stigma is a term used to refer to something that is ‘discrediting’ 
and therefore the humanity of a person with a stigma may be called into question 
(Goffman 1963, p13). People with FI may differ in the level of shame and feelings of 
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stigma. Reynolds et al (2014) undertook a study where 80 people from a waiting list of 
a pelvic floor clinic were asked about how they felt about their symptoms. Their 
sensitivity to disgust was measured using a validated questionnaire and it was noted 
that symptom severity did not necessarily correlate with reduced QoL and that a greater 
or lesser sense of disgust towards their symptoms was heavily involved. Likewise, Perry 
et al (2002) noted that not every person with FI saw it as a significant problem. In their 
study of 10,116 participants, 1.4% reported major FI but just 0.7% reported this as 
having an impact on their QoL. It may be that different coping mechanisms (Somerfield 
et al 2000, cited in Norton 2004) as well as differing levels of disgust (Reynolds et al 
2014) could explain this apparent contraindication.   
 
Depression 
Depression related to FI was also identified as an issue. One interesting letter to the 
Editor, (Bailey and Parés 2010) looked at the association between altered levels of 
neurotransmitters in patients with incontinence, noting that there was a high 
prevalence of depression in people with incontinence, both urinary and faecal. 
Biochemical changes in people with depression are thought to increase the possibility 
of urinary incontinence and the authors wonder whether there could be a similar 
mechanism with FI. They do note however, that the significant impact on QoL and the 
stigma attached to FI are the likely the main contributors to developing depression. They 
conclude that there is evidence to show that people with FI are likely to benefit from 
psychological support to deal with the impact it has. Parés et al (2011) studied 518 
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people from a general primary health centre and found the prevalence of FI to be 10.8%. 
Mental health issues were found in 51.8% of people with FI compared to 30.5% of those 
without FI. Their study recommends that all people with FI should be screened for 
mental health issues due to such a high detection rate in their study. The link between 
FI and depression was also identified by the Crowell et al (2007) study, where it was 
associated with impaired psychological functioning and decreasing, health-related, QoL. 
They also conclude that people with FI should be offered psychosocial assessment and 
intervention and that this may improve patients’ QoL.  
 
 
Impact on the carers/partners 
The effects of FI can also have a significant impact on the patients’ families/carers. 
Thomas (2008) believes we should ‘consider continence essential to QoL’, and 
recognises that the same goes for the carers’ QoL. Van der Veen et al (2011) conclude 
that the silence and secrecy that surrounds incontinence, contributes to the difficulty in 
carers seeking and accessing help and support.   
 
Information needs 
With regards to FI and other gastrointestinal symptoms experienced by people after 
radiotherapy, Boulton et al (2015) examined the provision of information about such 
symptoms to people with cancer, to see if it was helpful or not. They recognise that 
keeping the patient informed about their cancer and its treatment is an important 
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aspect of care, but wanted to know if the same applied to information about the late 
effects they might experience. 30 participants were provided with the Macmillan Cancer 
Support booklets- ‘Pelvic Radiotherapy in Men- possible late side effects’ and ‘Pelvic 
Radiotherapy in Women- possible late effects’. Responses to the benefit and timing of 
information were varied. Some people wanted to know about the possibility of late 
effects whereas some did not. Other participants wanted the information before or 
early on in treatment and others wanted it right at the end of treatment. It was evident 
that one approach did not suit all. The study concluded that it was best to tailor 
information given once a relationship had been established by the HCP.  
 
Many authors concluded that by increasing awareness of the issues surrounding FI, then 
not only might research into its treatment increase, but that the problems and 
associated stigma of the effects of FI could be addressed (Norton 2004, Bliss et al 2010, 
Ness 2012 and Alderman 1989).  
 
Conclusions and gaps in the knowledge 
This literature review has demonstrated a growing awareness of issues surrounding 
PRD, including the diagnosis frequently made following investigations and the treatment 
of different pelvic cancers which can cause PRD. Following treatment for the main pelvic 
cancers, prostate, gynaecological and colorectal, it has been shown that people may 
experience significant GI symptoms which can affect their QoL.  The use of QoL tools 
used in studies and clinical practice to evaluate the impact of PRD were discussed and 
whether these tools are appropriate for use if the HCP is to understand the effect on the 
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patient’s life, rather than just the symptoms PRD causes. Faecal incontinence is a 
common symptom of PRD and can result in significant problems for the patient, 
including feelings of stigma and depression. This section will summarise the gaps in the 
literature and where further study is required.  
 
Summary  
The recognition of cancer as a disease is many thousands of years old, and radiotherapy 
has been used to treat it for the past 100 years. Due to its effectiveness in destroying 
cancer cells, any healthy tissue that lies in the radiotherapy beam will also be affected 
to some extent. Pelvic anatomy makes it likely that bowel tissues will receive some part 
of the radiotherapy dose when pelvic cancers are being treated. Although acute toxicity 
effects of radiotherapy are well recognised, knowledge about the later effects on GI 
tissue is an area that is still growing.  
 
Advances in the recognition, assessment and treatment of PRD have been made in 
recent years.  This followed findings from the ORBIT study (Andreyev 2013) and 
subsequent publication of an algorithmic pathway, Guidance: The Practical 
Management of the Gastrointestinal Symptoms of Pelvic Radiation Disease (Andreyev et 
al 2014). Due to the perceived difficulty in using symptoms assessment scores in busy 
clinics, further work was undertaken to improve recognition of people with PRD through 
the development of a quick and easy to use tool- ALERT-B (Assessment of Late Effects 
of RadioTherapy- Bowel) (Taylor et al 2016a). By using both the ALERT-B tool and the 
guidance document, the required investigations may highlight several GI diagnoses 
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including radiation proctopathy/enteritis, bile acid malabsorption, small bowel bacterial 
overgrowth, carbohydrate malabsorption and pancreatic insufficiency.   
 
The three main pelvic cancers recognised to often result in PRD following radiotherapy 
treatment are prostate cancer, gynaecological cancers such as cervix and endometrial 
and colorectal cancers. These are amongst the most prevalent cancers in the Welsh 
population. The studies reviewed highlighted that QoL measurement was frequently 
undertaken, yet actual impact of PRD upon the participants’ lives was rarely considered. 
It was shown that the commonly used QoL tools concentrated on symptom 
identification, but that these tools did not allow for data gathering of the experience of 
living with the symptoms. If patient care is to be as holistic as possible, it is important 
that patient experience is included in the identification of PRD. This would then allow a 
greater understanding by HCPs of how PRD can cause significant problems for the 
patient and their families. Identification of symptoms is important, but so is an 
awareness that experiencing profuse diarrhoea and FI may mean the person no longer 
leaves home, potentially gives up work or perhaps becomes a social recluse, for 
example.  
 
Knowledge of PRD amongst HCPs was noted to be poor, even amongst those who care 
for people who are likely to be affected (Henson et al 2011 and 2012). However, the 
‘Living with and beyond cancer’ initiative led by The National Cancer Survivorship 
Initiative (2013) and supported by Macmillan, have made significant steps toward 
improving both patient and HCP awareness of PRD, through campaigns and production 
of several documents as part of their ‘Consequences of Cancer Treatment’ programme.  
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FI was noted throughout the literature to be one of the more distressing symptoms of 
PRD. Impact of FI upon QoL was noted in all the articles examined, and several authors 
identified the development of feelings of stigma and/or depression as a result. It was 
not only the study participants who suffered due to FI; this was also shown to affect 
families and friends, often with a breakdown in communication between the two 
parties.  
 
The literature looking at the provision of information about the potential late effects of 
cancer treatment was reviewed. This was a complex area as different people want 
varying amounts of information whilst considering their treatment options. For some, 
end-survival was all that mattered, but for others, it was important that they knew all 
potential outcomes. Norton (2004), Bliss et al (2010), Ness (2012) and Alderman (1989) 
all noted that the more information and discussion there was about FI and its impact, 
the greater the potential reduction in the associated stigma. 
 
The most significant gap in the literature available was a knowledge and understanding 
of peoples’ experience of living with PRD. There was much detail about what symptoms 
people may experience, how PRD can be identified and even treated, but very little 
about what it is like to live with, apart from Wilson’s (2006) study that did offer examples 
of peoples’ experiences of living with PRD. This lack of knowledge suggests that HCPs 
are not fully informed of what their patients are experiencing. It would suggest that if 
asked by their patient ‘am I the only one who can no longer leave the house?’ the HCP 
is unable to answer with any certainty. If people with PRD are to be cared for with a 
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fuller understanding of what types of difficulties they may be experiencing, then there 
needs to be further research in to peoples’ experiences of living with PRD.  
 
This thesis aims to address this gap in the knowledge currently available by enquiring 
specifically about the experiences of the participants, using a method and analysis that 
will allow the participants’ experience to be clearly heard and discussed.  
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Chapter 3: Research paradigm focus  
 
In this chapter, I will discuss the researcher’s ontological alignments and ideas that have 
shaped this thesis. Denzin and Lincoln (2008) define such personal positioning behind 
research direction as the ‘research paradigm’. This will guide the research and utilise my 
world view as ‘interpretive-bricoleur’ (p. 245), as opposed to following a set text-book 
process that cannot be deviated from.  Using Becker’s (1998), in Denzin and Lincoln 
(2008), description of a bricoleur as a maker of quilts, this draws a picture of the 
qualitative researcher using various thoughts, strategies and methods to finely weave 
the finished work, often resulting in unique pieces, blended together as appropriate and 
desired. It is important however to ensure that quality attributes of the study are visible, 
as suggested by Caldwell et al (2011).  
 
In the early days of the research process, it was invaluable to keep returning to the 
research question as well as to my own personal philosophical stance. This helped 
ensure that the research journey was appropriate to the question under consideration, 
that the methods utilised remained appropriate and that my passion as a nurse, who 
cares deeply about the people she cares for, would hopefully shine through the 
research.  
Research Paradigm 
To help with clarification of how to select the research method, an examination of 
one’s philosophical underpinnings was necessary to identify what were felt to be 
important philosophical aspects.  This would also help to ensure that the research was 
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in line with one’s own beliefs in how truth and knowledge is learned. In the very early 
days of the Professional Doctorate course, the work of Durant-Law (2005) guided this 
thought process through the rocky journey of developing a position on philosophical 
foundations. Utilising his work provided the opportunity to examine the 3 questions of 
‘what exists?’ (ontology), ‘how do I know?’ (epistemology) and what is valuable? 
(axiology)’ and this would together guide the chosen methodology.  
Ontological alignment 
To further ascertain how best to approach the research process development, there 
needed to be a consideration of ideas about truth and reality and how they exist, 
develop and can be identified. For some, the only way to uncover a truth is to study it 
using scientific methods, often testing it against set criteria through modernist 
quantitative methods (Lincoln et al 2011). Yet post-modern, constructivist, and 
interpretive approaches recognise that social reality relates to culture, and often to 
previous experience. From my extensive nursing experience, seeing how different 
people, perhaps from differing cultures or social class, treat similar events, such as pain 
or chronic disease, it is felt that what is truth, and how truth is viewed through 
experience, can differ widely. People may cope with similar events in different ways, 
including bowel problems after radiotherapy. It seems evident that even those who 
experience the same events, such as these bowel symptoms, may identify their 
experiences through different realities. For example, some may cope well with FI and 
learn to adapt to its impact whilst others struggle to cope. Therefore, a research method 
was required that enabled knowledge to be gained through listening to and interpreting 
peoples’ experiences of PRD.     
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Epistemological and axiological alignment 
Epistemology enquires how truth and reality can be known and asks us as individuals 
“how do I know the world” (Denzin and Lincoln 2008, p. 245). It is necessary to consider 
this when selecting one’s research method as it will influence which method will provide 
the answers to how you feel the knowledge can be uncovered. As Christians (2008) 
noted, to increase understanding of human lives there is imperative need for change 
from previously blanket quantitative methods of research to methods which can explore 
humanity and the differences we all as individuals express. When linked to my own 
ontology, that reality is often different for different people, then this again points 
further towards a qualitative approach of enquiry and one that asks different 
participants for their individualised view on their reality.  
 
It was helpful to again return to the research question. This was vital in order to ground 
oneself in the task of identifying, initially personally for one’s professional growth and 
then more importantly to others, what it is like for people who experience PRD. No 
amount of figures or statistics would get to the lived experience of what it is like for 
them. Yes, numerical data could explore the number of times the person had episodes 
of FI but it was perceived to be vitally important to grasp from the very beginning that 
this was not what was important to pass on to others experiencing PRD. What was 
important was to tell others about what it is like to experience something like FI, how 
that made them feel and how it affected their lives. It was therefore clear that a 
qualitative approach would meet this need to tell of others’ experiences. Flick et al 
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(2004) summarises this claim of what qualitative research can achieve, and what is an 
objective of this thesis- 
“to describe life-worlds ‘from the inside out’, from the point of view 
of the people who participate” 
Flick et al (2004) p. 3 
 
Within nursing practice, there are frequent encounters people with people who are 
experiencing similar physical problems and yet identifying and coping with it in entirely 
different ways.  When developing the research question, consideration was given on 
how best to recognise their experiences given that they were often so different? How 
could their different realities, as individual truths, be recognised as valid experiences? 
This began to further guide the methodological development towards an interpretive 
approach where the participants’ stories could be heard and an interpretation made 
about what the participants were saying. In this way, as a researcher and not a 
participant in their lives, an identification and understanding of experiences could be 
gained, and others told about their experiences, in order to increase awareness and 
understanding of PRD.  
 
Methodology 
As previously discussed, it was clear that a qualitative approach would be a step towards 
uncovering more about peoples’ experience of PRD and what living with the disease 
actually entails for them. Individuals’ experiences of similar events or symptoms can be 
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very different. To capture these experiences required a data collection method that 
allowed participant free voice to express their stories with minor guidance to keep the 
topic central. Therefore, a semi-structured interview was selected as the data collection 
tool. Another option considered was a focus group, but due to the personal nature of 
the anticipated stories this was not felt to be appropriate as it could have resulted in 
further distress to the participant. As it was a possibility that interviews could therefore 
identify multiple ways in which the participants recognised and dealt with their bowel 
symptoms, it was necessary to use a method that could help with handling the volume 
and complexity of data that would be collected. Using a framework analysis would 
support the research objective of exploring the data whilst at the same time allowing 
the participants’ voices and stories to be heard (Ritchie and Spencer 1994).   
 
From the beginning of the research development, it was clear that there would be 
elements of co-construction throughout. This would be through continual input of ideas 
and concepts between me as the researcher, the participants and their partners, if 
present, and obviously that of the research supervisors. Rather than ignore this, it was 
helpful instead to first recognise it, and then to use it as a positive contribution to the 
work. As the use of interviews becomes increasingly common, role play between the 
researcher and the participants is inevitable, but it needs to be recognised, and steps 
taken to avoid the researcher’s ideas becoming more important than the story the 
participant has to tell (Mann 2016). As a novice researcher, it was helpful to recognise 
from the outset that anxiety during the first few interviews might result in the interview 
being overly pressurised in an earnest attempt to ‘get to the truth’ as quickly as possible. 
One way of trying to overcome this was to encourage reflexivity during the research 
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process by using a diary, or field notes. In this way, ideas, concerns and questions could 
be noted in preparation for the following interviews and data analysis period, as 
suggested by Mann (2016).  
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Chapter 4: Methods 
 
This chapter will discuss the research design of using a descriptive and exploratory 
qualitative approach, to undertake applied health research, and how this influenced all 
methodological choices , including participant selection, the data collection tool as semi-
structured interviews, how the interview data was transcribed and the method of data 
analysis using framework analysis (FA). In order to demonstrate the scholarly value of 
the study, effort was made to promote quality and validity. This is one of the benefits of 
FA in that it encourages traceability of the management of often large amounts of data, 
as found in the interview transcripts. It is noted that other methods also provide this 
benefit. The most significant benefit of using FA, and one of the main reasons for its 
selection for this study, was its applied policy approach, one that provides specific 
information which can then be applied to policy development. Its step-wise approach 
also provides guidance and demonstrability of decisions made, ideas re-visited and 
connections made, which was ideal for a novice researcher. The following diagram 
shows a step-wise explanation of how FA was used to develop the analysis from the raw 
data. 
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Diagram 2: Process of framework development and application 
 
 
 
 
Sampling and participant recruitment 
As the requirement was to collect data about experiences of living PRD, recruitment of 
participants from a specialised clinic was necessary, where people were referred for 
investigation into bowel problems after receiving pelvic radiotherapy treatment. As 
usual for an out-patient clinic, there were many different characteristics of patients 
Stages 3 & 4: Indexing and charting
Interview transcripts coded as received, applied to the codes identified (as above) codes added/altered
Groups of codes categorised into themes: Stigma, Support & Healthcare
Stage 2: Identifying a thematic framework- combined literature review categories applied to and from 
the data (transcripts)- a fluid process back and forth. Codes identified:
GI symptoms, QoL, diarrhoes, FI, stigma, depression, impact on carers, information needs
Stage 1: Familiarisation of data Sources
Initial lierature review: GI symtoms, QoL, diarrhoea, FI
Additional literature review following start of iterviews: impact 
on lives of participants and partners, stigma, teamwork, 
healthcare issues
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attending these clinics, including age, sex, original cancer type and length of time since 
diagnosis. Where possible it was hoped to include participants’ partners, and this too 
would involve differences such as those who were single, married or in a partnership. 
Therefore, within the confines of the study, it could be difficult to ensure that each of 
these groups was equally represented. A return to the main aim of the study, which was 
to explore the participants’ experiences of living with PRD, identified that a fully 
representative group of each cancer group, sex and age was not only unlikely to be 
possible within a small study, but also unnecessary. Therefore, meeting the general 
criteria for inclusion was the main priority for sampling (Merkens 2004).  
 
Inclusion criteria 
• People attending for their first visit to the Late GI Effects Clinic 
• Ability to communicate in English  
Exclusion criteria 
• Comorbidities that may affect ability to participate, such as physical or language 
constraints 
• People returning for subsequent appointments, to reduce potential conflict of 
interest between the patient/participant and HCP 
 
As the participants would be recruited from the clinic that was run by the researcher, it 
was important to avoid any undue pressure on potential participants. Once the 
professional clinical relationship had developed, they may have felt under pressure or 
somehow obliged to participate because of the person asking them. Potential 
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participants also needed to be aware that taking part in the study would not offer them 
any clinical benefit, and this was clarified in the PIS. It was recognised that undertaking 
the research at the same time as being the HCP involved in their medical management, 
could contribute to unreliable data collection; the participant may talk about what they 
thought was wanted to be heard, rather than perhaps be more objective with an 
unfamiliar researcher undertaking the interview. Therefore, the out-patient clinic nurses 
gave out the PIS to patients if they met the inclusion criteria and the study was not 
discussed at the clinic appointment unless the patient asked for more details. Attached 
to the PIS was a page with the contact details if they wished for further information 
and/or to discuss taking part.  
 
In total nine participants were recruited, five of whom also involved their partners. 
Ethical permission to interview ten to fifteen participants had been granted, with 
partners if available, but it was clear by the eighth and ninth interview that no new 
themes were being identified, a process of saturation common to an inductive research 
approach (Cheek 2011).  
 
Data collection   
It was previously noted that using interviews as part of a qualitative approach would 
allow examination of the participants’ experiences of living with PRD. Interviews as a 
data collection method are widely used in qualitative analysis as they allow the 
recording and analysis of the participants’ perspectives (Hopf 2004). The aim of this 
study was to gain an insight into the participants’ experiences of living with PRD and so 
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using interviews to gain this information was appropriate. As previously discussed, due 
to the personal nature of the interview topic, other group interview/discussion 
methods, such as focus groups, were not considered to be appropriate.  
 
As the intention was to hear about experiences associated with PRD, it was identified 
that a semi-structured interview would allow the focus to be kept on the subject topic, 
whilst allowing the participants to talk around elements of this topic that they felt had 
particularly affected them or if they had a story that was particularly important for them 
to tell. The literature had demonstrated that the patient voice was rarely heard, and 
that in the majority of studies their experiences were only identified through a ‘tick-box’ 
process. For the purposes of this study, it was recognised that by using semi-structured 
interviews, the participants’ experiences would be clearly heard. As the data analysis 
method was to be framework analysis (FA), the initial themes identified from the 
literature review were to be used as a basis for guiding the interview, along with open 
questions to give space for other areas the participants wished to explore.  
 
Initially the plan was to begin with an open question such as ‘tell me about the time you 
began to notice things had changed since your radiotherapy’. The ‘things’ were not 
specified at that point as it was important to hear their stories, what they felt was 
important to talk about, hence the rather vague question to open with. As suggested by 
Mann (2016), a list of potential questions to consider during the interview was 
developed to help guide the interview in case of a blank mind due to nerves, or if 
perhaps the interview began to lose direction. These questions were: 
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• Can you tell me about the time you began to notice things had changed since 
your radiotherapy?  
• How did you feel about that? 
• Did this affect you in other ways? 
• Can you tell me more about this? 
• How did that affect you? 
• What is it like living with these problems?  
• Is there anything else you would like to add? 
 
 
It was important to realise that the data would be gained through the interviews, and 
that it needed to be prevented from becoming a counselling interview for the 
participants (Mann 2016). Not only would that not necessarily provide the information 
required, it would have been an unethical direction and one that needed to be avoided, 
although a relationship with the participants to some extent was necessary to help make 
them feel comfortable enough to talk about difficult experiences they may have had. In 
line with the study design and ethical approval, each potential participant was offered 
the option to be interviewed in a place of their choice, including either at the hospital, 
or in their own homes.  
 
Two digital recording devices were taken to the interviews, in case of failure of the first. 
As suggested by Mann (2016) a note book with a list of potential questions to consider 
during the interview, as well as space for note taking, was also used. The main issues 
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identified in the literature were also highlighted in order to identify if these were also 
important themes for the participants.  
 
The participants were offered a choice of where they wanted the interview to take place. 
The first participant asked to be interviewed just prior to his colonoscopy. He had 
travelled for thirty minutes and was still experiencing the effects of the bowel 
preparation. His frequent trips out of the interview room to use the toilet, anxiety about 
the impending procedure and the interview process itself combined with the fact that it 
was the first interview for the researcher, meant that it did not go well. The environment 
was not ideal and neither party felt relaxed enough to talk freely. This was evident in 
the recording and transcription, which was rather short and executed with too many 
questions and quick responses. The participant and his wife were not given enough time 
to stop and think. The silence seemed terrifying and so any pauses in the conversation 
were filled with my unnecessary small talk. Being so focused on obtaining information 
and getting through the interview with minimal inconvenience for the participants, 
caused it to be controlled too tightly, over-managing and strangling the free flow of 
natural conversation. Such was the unhappiness at the performance that the next 
interview appointment was postponed until the transcripts had been received to allow 
for reading and reflection and to learn from the mistakes.  
 
The lack of reflexivity from this first interview was very apparent in the typed transcript 
pages. In an attempt to re-think one’s perspectives on the research, a thinking task 
suggested by Etherington (2004) in Mann (2016) page 18 was undertaken. This involved 
a re-consideration of the influence of the researcher’s background history, including 
99 
 
presuppositions and personal positioning. This enabled a re-focusing on why the study 
was felt to be important and how best to gather information from the participants about 
their experiences. It was almost as though, through considering this prior to the 
subsequent interviews, there seemed to be less obvious pressure about what was 
needed from the interview and this allowed me to stop talking, to stop asking endless 
questions and confidence enough to be quiet and to only ask questions when it was 
really necessary. Fortunately, all of the other participants requested to be interviewed 
in their homes and this provided a much more suitable environment for them to relate 
their experiences.   
 
Stepping back and loosening control was not easy, but it became simpler as each 
interview took place. I was increasingly able to allow the participant to lead the way at 
times and I became more adept at gently bringing the conversation back to how the 
symptoms were affecting them when it seemed necessary. The participants talked and 
their voices were heard. Noticeably, the timings of the interviews became longer, even 
though the transcripts were not necessarily so; there were silences, but comfortable and 
thoughtful ones. After the first few interviews, there were opportunities to relax and 
even enjoy the process although many a painful story was heard and there were often 
tears, both the participants’ during the interview and mine in the car on the way home. 
 
Note Keeping 
A notebook was used to jot down my own thoughts both during and after the interviews. 
Immediately following each interview, either back in the office or mostly after moving 
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the car around the corner from the participants’ homes, further notes were written in 
the field note book. It was helpful to record how the interviews went, what went well 
and what did not go so well. Potential issues that were beginning to emerge were also 
noted, particularly as some had not especially been expected topics to be discussed, 
such as the extreme distress over episodes of FI. Attempts were made to note personal 
opinions, such as thoughts on the wonderfully varied homes I was so graciously 
welcomed into, initial thoughts on the relationships between partners when present 
and the perception of being treated differently as a researcher compared to a clinical 
nurse in uniform. These notes helped throughout the analysis period, reminding me of 
small nuances, like certain décor, which enabled thoughts to travel back to the interview 
itself. They were also used to guide subsequent interviews, with changes made, such as 
learning not to interject so frequently and to use long silences to promote further 
thoughts from the participants, rather than silences that had to be filled.  
 
Data transcription 
 
Before the research journey was fully begun, it was planned that transcription would be 
undertaken solely by the researcher. During previous study modules, there was 
recognition of the benefit of paying attention to the minute elements of written material 
and it was thought that this would encourage identification of the effect of one’s 
personal interactions within the interview, whether co-construction of the stories was 
too overwhelming and the participants’ voices were muffled. Other experienced 
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researchers advised that time was to be a struggle, and so fortunately, it had already 
been added to the research protocol and ethical agreements that, in all likelihood, a 
transcriber would be used for the interview data. Although initially disappointed to be 
unable to undertake the whole process, it was noted that transcription of interviews can 
be a significant undertaking and even with the greatest attention to detail, it is merely 
an attempt to represent speech (Mishler 1986). He agrees that even the recording itself 
is only “a partial representation of what ‘actually’ occurred” (p.48). With this in mind, 
along with a significant increase in clinical practice work load, it was deemed necessary 
that in order to achieve timely paper transcripts for reflection upon in preparation for 
subsequent interviews, that an experienced transcriber from the University would be 
used.  
 
Although there would inevitably be some loss of recall of events such as facial 
expressions, body language nuances and changes in voice tone, some mitigation of that 
loss would be made through using the field notes. There was also consolation from 
realising that it was the content of the stories that was of prime interest, and this could 
be more than adequately achieved through out-sourcing transcription. Cutler (2004) 
highlighted that one benefit of not performing one’s own transcription is that 
“erroneous assumptions” can be avoided, where the participants’ words could have 
been subsequently misrepresented. Some justification in this decision was felt when on 
a few occasions, the person who transcribed the interviews told of how she had been 
moved to tears during the process, and so through using independently typed interview 
transcripts, the data produced was as consistent and unbiased as possible.  
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Data Analysis  
With the main aim of this study being to gain insight into participants’ experiences of 
living with PRD, thus increasing awareness of the disease and influencing policy 
development so as to improve care provision, it was essential to use an analysis tool that 
would ultimately provide the findings to improve care. Originally developed by Ritchie 
and Spencer (1994), framework analysis (FA) was used to conduct qualitative research, 
the findings of which could have a direct impact on practice and policy implication. Its 
beginnings came out of a specialist unit within the Social and Community Planning 
Research Unit, where Government, Councils, and Universities for example could request 
research studies into areas requiring increased knowledge and application of findings. 
As Ritchie and Spencer (1994) state, “it has a key role to play in providing insights, 
explanations and theories of social behaviour” (p. 174), which fitted well with one’s 
methodological position and the study aims of gaining insight in to the participants’ 
experiences of living with PRD.  
 
Although there were pre-conceived expectations about what the participants were 
likely to talk about, it was important to be open to hearing about their experiences, as 
this was the aim of the study. It was also important that the participants’ voices were 
heard; the aim of the study was to gain insight into their experiences, to enable their 
stories to be told and so an analysis method was required that could keep individual 
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stories intact. Therefore, FA was chosen as not only would it provide a basis for using 
interviews to study the participants’ different experiences, but would also enable their 
voices to be heard, with interview extracts maintained, which could then be used to 
inform others using the powerful narratives obtained. With the application of a 
theoretical framework to the findings, it also allowed examination of the experiences of 
the participants through existing theories, or if indeed different concepts were 
presented. The fact that the authors insist it is not a 'fool-proof recipe” (Ritchie and 
Spencer 1994, p. 177), but one that relies on the ability of the researcher to consider 
concepts and connections, became evident early on the framework development. This 
will become apparent later in this chapter when discussing how the themes and theories 
were identified.   
 
As well as looking at the original work of Ritchie and Spencer (1994), there was also 
benefit in looking at how others had applied FA to their own work. Gale et al (2013) used 
a similar method to examine paediatric homecare and gave a useful description of not 
only how to apply the method but listed potential pitfalls which were useful to consider 
prior to starting. In their study, they also adapted some of the terms originally used by 
Ritchie and Spencer (1994), making the definition between codes, categories, sub-
themes and themes a little clearer to understand and define.  Ward et al (2013) also 
found FA a useful approach when managing interview data and recommend it as a 
beneficial tool for nursing research due to its transparency, rigour, and guided process.  
 
Other methods were considered including narrative analysis but further enquiry into 
this method suggested that in-depth linguistic analysis would have been necessary for a 
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richer analysis and the lack of information available about how to undertake narrative 
analysis made this a difficult option for a novice researcher. Denzin and Lincoln (2011) 
describe qualitative research as an activity that “locates the observer in the world” (p. 
3), however a full immersion in the field, such as an ethnographic approach described 
by Hammersley and Atkinson (2007) would not offer recommendations for 
policy/practice change. Interpretive phenomenological analysis (IPA) would have also 
offered the opportunity to look at the participants’ experiences. This method is 
particularly beneficial if the study is looking at how the participants are trying to make 
sense of what has happened to them. For this study however, the main aim is to hear of 
the participants’ experiences, what happened to them and how this made them feel, 
rather than how they understand the process of what has happened to them.  
 
Upon receiving the first transcript, it was evident that even early on there were certain 
themes that were standing out, and further exploration was required. Therefore, it was 
clear that the choice of FA as an analysis method, with themes at its core, would be 
appropriate. Whereas it was recognised that other qualitative methods would have 
enabled some of the benefits outlined above, framework analysis has a specific design 
and history to encourage an impact on and change of practice, the ultimate objective of 
this research project. Other suggestions of the potential benefits of my using FA 
provided by Ritchie and Spencer (1994), included the ability to provide a greater 
understanding of the issues, such as those experienced by people with PRD whist 
employing structure and transparency to the work if further examination of the process, 
or indeed further study in the future, was required.  In summary, to identify participant 
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experience, and to be able to use this knowledge to improve care, FA was selected as 
most suitable to meet these requirements. 
 
 
Stage 1: Familiarization  
 
Prior to starting any data analysis, it is important to become familiar with the wide body 
of knowledge that already exists around the subject under study (Ritchie and Spencer 
1994). The literature review formed the basis of current opinion on the recognition and 
management of PRD, and to some extent, the symptoms people with PRD describe. The 
literature search and the writing of the review, was an important stage of my 
familiarization with this existing knowledge; what studies had been done, their findings 
and what impact this was starting to have, if any, on patient care. At this stage, the 
framework began to develop. It was clear from the literature that people with PRD were 
experiencing troublesome symptoms, particularly FI. Hospitals and various healthcare 
establishments seemed to play a big role in the form that investigations and treatments 
were taking, although it was noted that awareness of PRD amongst HCPs was not 
considered to be acceptable or consistent.  
 
The process of familiarisation with the interview data began as soon as the first 
transcript was received. The transcript was edited to create line numbers, which would 
help with categorising, re-checking and general data handling. As well as repeatedly re-
reading the transcript, the recording was listened to several times, to check both the 
accuracy of the typed work and to be reminded of elements that took place during the 
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interview, such as a partner moving to sit by their loved one, an episode of depressed 
body language or tears spilt. In conjunction with the field notes, there was a 
development of a sense of immersion in the participant story. This was repeated for 
each subsequent interview.  
 
Stage 2: Identifying a thematic framework  
 
The development of a framework is performed by considering ideas that are starting to 
emerge, initially from the literature review, and then applied to and added to from the 
data collected through the interview transcripts. Ritchie and Spencer (1994) describe 
this as “beginning the process of abstraction and conceptualisation” (p. 179). This may 
occur differently in different studies depending on the size and time available. For some, 
all the data is reviewed, whilst for others, only a sample is used to form the initial review 
of the data issues. For this study, the literature review was considered in its entirety. 
The ideas highlighted from the literature review began to form the basis of the 
framework. 
 
As discussed, during the familiarisation stage, recurrent issues were becoming evident 
from the literature. The literature review had identified that PRD was relatively common 
in people following treatment for prostate, gynaecological and colorectal cancers and 
so the first key issue was ‘GI symptoms’. Many of the papers discussed that QoL was 
often affected and that frequent diarrhoea was one of the major factors. Therefore, 
‘QoL’ and ‘diarrhoea’ were also noted to be key themes. Due to the issues of ‘diarrhoea’ 
and ‘FI’ being noted as major concerns for people with PRD, these issues were further 
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explored within the literature and again identified as key codes, along with ‘stigma’, 
‘depression’, ‘impact on carers’ and ‘information needs’. The initial framework was 
developed from the literature, resulting in the first eight codes. This basic framework 
was then applied to the first interview, to help understand if these were major issues 
for the participants, or if indeed different issues were raised.  
 
Diagram 3 - Initial framework formed through the literature 
 
 
 
 
One of the main processes of FA is to develop and refine the framework through 
frequently re-visiting the data, in this case the literature initially, and then through 
application to the interview transcripts. The next stage, indexing, played a significant 
role in the further development of the framework.  
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Stage 3 & 4: Indexing and charting 
 
Although Ritchie and Spencer (1994) have these as separate stages, for this study it 
seemed natural to undertake these steps as one process as the steps occurred 
concurrently and steps were frequently re-visited. Others have also altered the stages 
slightly to suit the progress of their analysis. Gale et al (2013) and Ward et al (2013) use 
similar terms but in a different order and it was useful to use their stages as an 
accompaniment whilst following Ritchie and Spencer’s (1994) method, noting 
suggestions to enable provision of a clear, demonstrable pathway.   
 
Indexing is the process whereby the initial framework is applied to the data, developing 
the framework further. It is a fluid process that involves constant return to previously 
indexed transcripts, and throughout this, judgements are made on meaning, and 
potentially alterations made to the framework, until consistency has been achieved. This 
process must be visible to others, a particular requirement if multiple researchers are 
working on a larger study, to ensure each researcher is using similar thought processes, 
but also to allow traceability and justification of decisions made for every study.  
 
Each of the interview transcripts were coded as they were received. This not only 
enabled the framework to develop in a measurable way, through annotations in the 
margins, but also allowed subsequent interviews to be guided. With the use of coloured 
felt pens, many hours were spent poring over the transcripts, noting issues and marking 
similar elements. Because this was done as each new transcript was received, recurrent 
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ideas were recognised and considered if there were connections or diversities across 
the interviews.  
 
Small stories and sometimes just phrases or sentences, were identified from each of the 
transcripts using the initial code identified. Groups of codes were beginning to emerge 
at this point, particularly as I was noting that some of the codes were often inseparable 
from others. Gale et al (2013) suggests beginning to group the identified codes into 
categories, then subsequently into themes (p. 4). To help guide this process I used the 
diagrammatic process seen in Table 5 as a guide. 
 
Through the use of coding, recurrent topics, many of which had not been particularly 
expected, clearly began to emerge, particularly after the first two or three interviews 
were analysed. Although there are computer packages to assist with coding, this process 
was undertaken by hand, and indeed was found to be a necessary and natural step in 
getting to know the data. At its simplest, coding is an aid to begin categorizing and 
sorting (Charmaz 2006), although the process itself provides much more than just a 
‘filing system’; it is another important step in the analysis process that can lead to 
expansion and transformation of data (Coffey and Atkinson 1996). Even at this early 
stage, I used my own judgement to consider the relevance of individual narratives, 
phrases and use of words and to decide which code to apply. Ritchie and Spencer (1994) 
describe this as requiring “both logical and initiative thinking” (p. 180) and Gale et al 
(2013) highlight the need for “reflexivity and rigour” (p. 2). An example of how coding 
was undertaken, is shown in Appendix 3.  
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The coding process further developed the framework and Table 5 below shows how 
each of the original codes either developed into, or was added to, during the coding 
process.   
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Diagram 4 - Code development 
 
 
 
 
During the first few interviews, although the initial eight codes were at the forefront of 
thought for purposes of identification, the main aim was to identify what the 
participants were telling me, rather than, at that point, purposefully look for what was 
expected, and so an inductive approach was used. Induction takes place when patterns 
are identified from observation (Snape and Spencer 2003). Talk around GI symptoms 
such as diarrhoea, abdominal pain and faecal incontinence was expected, yet these 
words were rarely used, as is shown in the above diagram where ‘GI symptoms’ is not 
followed by further coding. It became apparent that many of the participants were 
talking of their shame and embarrassment, rather than the symptoms themselves and 
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so further reading of literature about the psychological impact of living with chronic 
diarrhoea/FI was necessary.  
 
The work of Goffman (1963) appeared regularly in the literature about the effects of FI.  
As I read more of his work on stigma, elements were noted that had not appeared so 
clearly to me initially and I identified that his existing theory was beginning to fashion 
my thinking and helping me to understand the participants’ experiences through that 
lens. Other authors also considered how an excretory event that defers from the ‘norm’ 
is considered antisocial, illicit and unacceptable. From that point onwards, deductive 
coding was also used, keeping a clear mind for isolated and repeated experiences, yet 
also focusing on areas around stigma, as Goffman’s’, Inglis’s (2000) and Douglas’s (1966) 
work had provided evidence to support the conclusion that stigma was a major factor 
in people’s experiences. Coding in this way encouraged a greater recognition of the 
feelings and experiences with which the participants identified.  
 
As refinement of the framework developed through coding and development of the 
thought process, the codes began to emerge into categories which in effect, were 
groups of codes. The table below gives examples of extracts that were coded initially 
and how they further developed into the categories. Both the reference of interview 
and the line number have been kept intact for purposes of traceability as they were 
throughout the original work saved in the note pad. This was particularly helpful when 
reflecting and conducting further analysis, looking at patterns, similarities and 
differences across the data.    
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Table 4 - Development from code to categories 
 
Codes and examples quote Categories 
 
Distress: “It was a nightmare” Int 2, line 31 
 
Embarrassment: “I wished there was a big hole and I just could 
have been swallowed up in in” Int 3, line 208 
 
Anger: “Why didn’t they look after me?” Int 4, line 531 
 
Upset: “well I’m thinking this is not living, it’s just existing” Int 6, 
line 230 
 
Anxiety: “I’m frightened of being on 2 trains to get to town” Int 9, 
line 23 
 
Stigma: “that’s how he is, he thinks it’s a stigma, it’s terrible” Int 
3, line 533 
 
Shame: “He’s such a private person he do say this is the worst 
thing that could ever have happened to me” Int 3 line 494 
 
Impact: “my daughter gets upset because he won’t even go over 
to her house for a cup of coffee” Int 6, line 166 
 
Worry: “you’re keyed up all the time…I wouldn’t want to stain the 
seat of a blooming taxi” Int, 6, line 267 
 
Concern: “Still in my mind isn’t it. You know, what damage has 
been done because it can cause cancer can’t it?” Int 4, line 317 
 
 
How this made 
them feel  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect on their 
lives  
 
The need to 
avoid 
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Accidents: “I have had accidents and the pad hasn’t been 
sufficient” Int 8, line 102 
 
Control: You know I don’t really want people staying here either 
because they might be in the bathroom when I want to use it” Int 
8, line 130 
 
Planning: “I’ve got to know where we’re going….and I’ll think to 
myself where are the toilets in town?”  Int 9 line 104 
 
Careful: “So I always make sure I know where the toilets are, I will 
not make the mistake again if I have food out” Int 9, line 124 
 
Resignation: “I just try and get on with things” Int 8, line 249 
 
Family: “I definitely wouldn’t give up” “Wouldn’t let her” 
(husband) “Oh definitely, I would have got through it otherwise” 
Int 7, line 177 
 
Friends: “I’ve got another friend, she’s been brilliant, absolutely” 
Int 8, line 225 
 
Colleagues: “they all know in work, my condition, and they’re very 
good about it, I say you can’t go in the loo I’m off, you know, they 
know about my wind, because everywhere I go I’ve got sprays and 
they all laugh you know, good as gold in work” Int 9, line 82 
 
Teamwork: “I’m going to make sure he gets through this” Int 1, 
line 161 
 
Difficult 
experiences  
 
 
 
 
 
The need to 
plan  
 
The need to 
avoid  
 
Support of 
family 
 
Support of 
friends  
 
 
 
 
 
 
Teamwork  
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Positivity: “I try to see it positive because they’ve cured one thing 
but given me another” Int 5, 104 
 
Work: “(husband) was lucky enough where he worked, they gave 
him the full six weeks off” Int 7, line 186 
 
Coping: “I think it’s the way I’ve got to cope with it” Int 4, line 377 
 
NHS: “They don’t cater for people with my type of cancer. -the 
chair, I couldn’t even sit down. Some days I was in so much pain 
with my skin and everything and they expect you to sit on those 
hard plastic chairs. I think there was one comfortable chair in the 
whole department because you just can’t sit on them” Int 7, line 
196 
 
GP’s: “I had a bit of a performance with my GP over that, to get 
back to see the Consultant. He wasn’t very helpful” Int 3, line 161 
 
Charities: “There’s a charity, Tenovus, I went to one of the mobile 
clinics in the car park and I spoke to the clinical nurse and they 
gave me his card and he said straight away I think you’ve got 
prostatitis” Int 1, line 108 
 
Back & fore: “Even when I was going back and fore to the hospital 
every three months and every six months, I mentioned it but no 
one said anything” Int 9, line 30 
 
Long-time: “Every time I went back like three months, they’d 
obviously ask you oh how’s your bowel, and I’d say well I can’t 
control them, oh try this or try that or, and they were giving me 
different medications to try and help thing like that. But I mean 
 
 
 
 
Problems with 
healthcare 
services  
 
 
 
Lack of 
awareness, 
understanding  
 
 
 
 
 
Difficulty in 
accessing the 
right services 
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this is like eighteen months down the line from when my 
treatment finished” Int 7, line 206 
 
Hospital visits: “Well I’m just taking it one day at a time really, 
trying to get well, dealing with physiotherapy and more scans and 
visits to the hospital and yeah, that’s all it looks like at the minute 
is just hospital visits and see what they can do for this or that” Int 
7, line 160 
 
 
 
As suggested by Ritchie and Spencer (1994), the framework was developing from codes 
identified in first the literature, then the interview transcripts. The codes were then 
focused into categories, which were then further developed into themes. The table 
below demonstrates how the framework was developed using this process:  
 
Diagram 5 - Development from categories to themes- format 
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Table 5 - Development from categories to themes- in practice 
 
Categories  Themes  
How this made them feel  
Effect on their lives  
The need to avoid 
Difficult experiences  
The need to plan  
The need to avoid  
 
Stigma 
Support of family 
Support of friends  
Teamwork  
 
Support 
Problems with healthcare services  
Lack of awareness, understanding  
Difficulty in accessing the right services 
 
Healthcare 
 
 
The volume of data was increasing. As a personal preference I like to work from pieces 
of paper rather than a computer package, a large art pad was purchased that allowed 
actual cutting and pasting of individual stories from each category and for them to be 
stuck into the pad, enabling the different categories to be clearly visible for further 
analysis. Blue tack was used rather than glue, so the coded sections could easily be 
moved the around themes if appropriate. The individual stories and phrases were placed 
on pages using the three main themes identified: stigma, support and healthcare. Data 
volume alone clearly demonstrated that experiences around stigma issues were the 
major theme in the study; this took up 6 large pages in the art pad, compared to two for 
‘support’ and three for ‘healthcare issues’.  
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Various authors have noted slightly differing methods of charting their data (Ritchie and 
Spencer 1994, Gale et al 2013 and Ward et al 2013), however it was important that a 
suitable method was chosen that would work well with the data. It was noted that the 
original developers of framework analysis (Ritchie and Spencer 1994) were somewhat 
critical of a “cut and paste” process (P. 184), and used more extensive headings and 
sections, believing this helped with synthesis. However, using the art pad during the 
charting process, helped to develop a fluid process, supporting the aim to identify 
individual experiences and one that would support the further analysis journey.  
 
Stage 5: Mapping  
 
Initial FA studies grouped mapping and interpretation together (Ritchie and Spencer 
1994) but to help a clearly defined research process, the mapping and interpretation 
will be discussed separately. The process of mapping informed the method of data 
handling and this is discussed below. It was identified that data interpretation was a 
fluid process that inevitably began with the literature review and then followed 
throughout the interviews and framework development, as this is where ideas and 
thoughts began to be constructed. It was decided however to present the interpretation 
process separately, which is discussed in the following chapter- “Findings”. 
 
Although the later stages of the framework development had identified the three 
categories of stigma, support and healthcare, it was vital to again return to my research 
question to examine how these categories would be used to begin to provide answers 
to the question. Associations, patterns, differences and a structure to further work were 
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needed. There are various approaches with which to do this, and the more visual 
method of the traditional ‘mind map’ was used and initially undertaken in pencil in the 
art pad. This became a fluid process, looking back at the charts, the original transcripts 
and the field notes. This process validated the earlier decision to use blue tack, pencil 
and a rubber as thoughts developed. The questions were developed through a joint 
utilisation of the developed framework and personal thoughts. For example, with 
‘stigma’, an exploration was needed to define what constituted stigma for some, such 
as feelings of upset or embarrassment, and to discover if they applicable throughout the 
data set.  
 
Below is a simple diagram of the final stages of development of the FA. It is shown how 
the three categories of stigma, healthcare and support could be construed as quite 
separate yet are also closely linked throughout, with the participant at the centre of the 
three main themes, of which stigma is by far the most prominent.  
 
Diagram 6 - The final framework for analysis 
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The framework was the applied to the data set and the process begun of identifying the 
findings from the participants’ interviews. This is discussed in the following chapter. 
 
Ethical considerations 
 
Ethical permissions 
 
Ethical approval was sought and gained initially from The Research Ethics Committee at 
Cardiff University (Appendix 4). Approval was then gained from The Research Ethics 
Service at Health and Care Research Wales following attendance at the ethics 
committee meeting with minor amendments being made (Appendix 5). Health Board 
Research and Development permission was also sought from, and granted by, the 
Health Board where the research was undertaken. Up to date attendance and 
certification of Good Clinical Practice (GCP) training was ensured  
 
Informed Consent 
 
Those who met the inclusion criteria were provided with the study Participant 
Information Sheets (PIS) (appendix 6 & 7) In order to minimise any risk of perceived 
coercion, the PIS were distributed by out-patient nurses, and not discussed with the 
potential participant unless they themselves requested more information. Stamped, 
addressed envelopes were provided with each PIS with contact details if they wanted to 
find out more about the study or arrange an interview. Prior to each step of the 
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interview process, including date arrangement, Consent Form completion (Appendix 8), 
commencement and completion of the interview, the participants were reminded that 
their involvement was voluntary and their permission could be withdrawn at any time 
without affecting their medical treatment in any way.  
 
Data Management 
 
As outlined within the ethical and research applications, all data was managed in 
accordance with the requirements of both the Health Board and University and Health 
and Care Research Wales. This is equally in line with the GCP principals. Any files were 
stored on Health Board password protected computers until anonymised. The consent 
forms were stored in a locked filing cabinet in a locked department in the Health Board. 
The participants were also provided with a copy of their completed consent form.   
 
Confidentiality 
 
Participant confidentiality was maintained at all times, as is mandatory for the above 
mentioned organisations and also the Nursing and Midwifery Council (NMC) Code of 
Conduct (2015). Following completion of the consent process, each interview was 
assigned a study number, from 1-9. At the outset of each interview it was explained that 
I would avoid using their names when asking questions, to protect confidentiality. As 
soon as I received each transcript, any remaining names were replaced to ensure 
anonymity.  
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Chapter 5: Findings    
 
Three key themes, stigma, healthcare and support, were identified. Table 9 
demonstrates how these themes are inter-related, and that the participants’ 
experiences are at the core. The diagram below offers a visual presentation of how the 
categories were linked to one of the three main themes, and how the participants’ and 
their partners’ experiences, remain at the core of the analysis. 
 
Diagram 7:  Categories to themes to findings 
 
 
 
 
 
 
 
Participants 
& Partners
Stigma
HealthcareSupport
effect on their lives 
how this made them feel the need to avoid 
difficult experiences 
the need to plan the need to avoid 
support of family 
support of friends 
teamwork  
problems with 
healthcare services  
Lack of 
awareness, 
understanding 
Difficulty in accessing 
the right service  
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For the purpose of clearly describing and interpreting the findings, each of the main 
themes will be discussed independently, and at the end there will be a summary of how 
the three themes are often all linked and can impact on each other, which then affected 
the participant experience. The themes were developed from the framework analysis 
process, where the findings were identified to be related to overarching themes of 
stigma, healthcare and support. The main theme of stigma was seen throughout the 
participants’ experiences. Although the word ‘stigma’ was vocalised on only a couple of 
occasions, synonyms such as “upset”, “devastated” and “embarrassed” were noted 
thorough out. Stories of the participants’ experiences of healthcare services also played 
a big role in their journey. This included struggles to have their new symptoms taken 
seriously with subsequent referrals for further investigation and treatment delayed. 
Each of the participants spoke of their support network of either close friends and/or 
family. Generally, these were positive experiences, but there were also stories that 
described a drop-off of support once the actual cancer treatment was finished. This 
meant that there was often a lack of understanding about the impact PRD was now 
having on the participants’ lives. These will now be explored in more detail.   
 
Key theme 1- Stigma  
 
From the Greek, the word ‘stigma’ related to something physical about a person that 
signified something different and bad about the person (Goffman 1963). Originally 
thought of to be evident as an actual bodily mark, inflicted to define, or mark the person 
as a slave or prisoner, the concept was developed over time to reflect something 
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distasteful about that person, a difference that is considered unacceptable within their 
social position. Another term used to describe those as different, in a negative way is 
‘deviant’ (Falk 2001). Although each of these sociologists has written of different ways 
that unpleasant attributes are developed and regarded in society, for the purpose of this 
thesis they shall be regarded as holding a distinct characteristic; in general, the person 
is unlikely to find it a comfortable and highly regarded title.  
 
Whilst considering the theme of stigma and how it was present in the data, the following 
areas were explored: 
 
• What did the participants consider as being stigmatising? 
• How did this make them feel?  
• Did anything in particular contribute to causing the stigma, and was this the same 
or different for all of the participants? 
• Was there anything in particular that helped to reduce the feeling of stigma? 
 
Within my interviews the actual word ‘stigma’ was not spoken until the third interview- 
“that’s how he is, he thinks it’s a stigma, it’s terrible” (Int 3, line 533). There were 
elements of stigma within the preceding two interviews that were only noted upon 
returning to them again during the framework development. In the first interview, David 
had talked about being “disturbed” that he had soiled his clothes, and then later that he 
was embarrassed. Tony, in the second interview, had mentioned that it was “a 
nightmare” having to use the enemas. In both cases, the relevance of what the 
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participants were saying was unclear until the framework was applied, and the concerns 
of stigma became clearer. As the theme of stigma became clearer, it was evident that it 
was also a major theme for the other participants’ experiences.  
 
As demonstrated in the codes concerning stigma (table 6) there were several elements 
of unpleasant experiences identified, such as embarrassment and worry. The majority 
of these codes were identified within stories of loss of bowel control. The participants 
identified with the understanding that adults should not soil themselves and so when 
this does occur, it was deeply distressing. In the very first interview, David describes how 
this made him feel:  
 
David: “We’d go for a walk each day and it involves a hill which is quite steep 
and I used to find that I’d get feelings in the back passage that I needed to go 
quite urgently. Sometimes I would have an accident. Being quite a clean person 
it’s quite disturbing really to soil your clothing…. the embarrassment of it all…” 
 
David had mentioned that he lived on a hill leading down to a beautiful park where he 
and his wife often walked. He spoke as though despite the fact he knew he might have 
an episode of FI, he would still go out, although he “needed to be quite careful”. Being 
“quite careful” describes a particular plan of action used to avoid something, in his case 
either actually experiencing FI in public, or being seen, or witnessed having FI. David 
spoke of ‘we’, meaning him and his wife. So this was a joint walk, a joint trip out and one 
that for whatever reason he still continued the pattern of, despite the possibility of 
soiling himself, which he commented was very embarrassing.  
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Several of the participants related stories of times when they had had an ‘accident’. 
Jenny recalled one incident when she had been out with her daughters and 
granddaughter, and was unable to get to the toilet in time. This resulted in an episode 
of faecal incontinence, where not only her clothes but also the toilet floor was soiled: 
 
Jenny: “We went to a zoo somewhere, just my two daughters and myself, out 
for the day, I took all the necessary stuff I thought with me, we went out and 
this was not long after I stopped the treatment and I had, they only did healthy 
eating, so I had a sandwich with brown bread, oh that was, I was really 
embarrassed that day. I had that, fine we walked down and I thought oh my 
god and it literally was rolling down my legs so I walked back up and I managed 
to clean myself in the toilet, I came out and it started again. Well my daughter 
was there, she had to go into the toilet next door, she had to take off her 
knickers for me to put a pair, but literally pouring off me and it was all over the 
floor in the, luckily I managed to get into the disabled toilet but it was all over 
the floor, then I felt awful, I really felt awful.  I cleaned it all up but I felt awful”  
 
Jenny had made an effort to leave the house with her family despite the fact that she 
knew she may experience FI issues. She commented that the café only sold “healthy 
eating” which suggests this is in contrast to what she normally ate. People often become 
aware that high fibre foods may cause further upset for bowels and so try to avoid them. 
In this case Jenny suggested that she could not avoid “healthy eating” and so hints that 
this may have been the cause of this episode, even though she spoke of other episodes 
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where “healthy eating” was probably avoided, but the FI still occurred. Jenny goes on to 
describe a situation where diarrhoea is running down her legs. She cleans herself up but 
it happens again. Her daughter comes to the rescue and takes off her own underwear 
to give to her mother, ensuring that her mother’s modesty is returned, perhaps at her 
own expense.  
 
Many of the participants spoke about their attempts to hide from others what was 
happening to them. This included family, friends and even complete strangers. When 
going out was necessary, planning was required to ensure bowel accidents or trips to 
the toilet were minimised. Some avoided going out altogether. John and Barbara 
explained how he rarely went out socially anymore because as soon as he was invited 
he wondered how quickly he would be able to get home if necessary: 
 
Barbara:  “and you know if we want to plan to go anywhere or if we’re invited 
to different places and I say shall we and he will hesitate straightaway and 
know it’s because what’s going on in his mind, will I be able to get back If 
anything happens or... and it do spoil your social life really, it does affect your 
social life”  
John: “You’re afraid to go anywhere you know”  
 
Even when John did leave the house, it generally was only for a short period of time. He 
found being away from his own toilet facilities too distressing, and admitted that he was 
struggling emotionally because of this: 
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John: “it’s embarrassing to me but I don’t like using the toilet anywhere because 
it’s a real, with this mucus it’s a horrible smell. It’s not like normal toilet use, 
there’s a real strong horrible smell to it as well. So I’m embarrassed even to use 
the toilet out and I won’t, you know. I never use the toilet; I come home, if 
possible. It do affect me terribly on times and I do, she don’t even know this 
until now, it do, I do suffer with a little bit of depression over it as well but I keep 
it away from her and from the kids, I don’t want to worry them any more than 
I’ve already worried them, you know.  But I do, it do pull me down like you 
know, it do” 
 
At this point, as recorded in the field notes, Barbara moved from where she was sitting 
to hold John’s hand. His eyes were beginning to fill with tears but he composed himself 
with his wife’s support. It seemed that this was the first time John had admitted to 
anyone just how much of an impact the FI was having on his life. Up to now he appeared 
to have been hiding it well, as he mentioned that his wife had not known this “until 
now”.   
 
John was not alone in avoiding going out. Ken described that although he used to enjoy 
going to the pub with his friends, the only time he went anywhere now was shopping 
with his wife. He spoke as though he was looking at his diary, seemingly quite concerned 
about days and length of time out of the house. This indicated that his life was structured 
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around when he felt comfortable enough to leave the house, or when he realised this 
was impossible for him. 
 
Ken: “Well I used to go out then, I don’t go out any more, you know it’s sort of 
the only time I go out now is if I go out with my wife shopping. Because when I 
get the urgency now to go to the toilet, if I don’t get back and I have an 
accident or if I just make it, I’m home but if I was out and it happened, I’d be too 
embarrassed because I can’t walk that far so if I do go out socially which has 
been like three times in the last year, it’s only been local and it’s been just over 
an hour and I can’t sort of plan to say right I will next Thursday, I’ve got to wait 
until next Thursday comes to see if I’m up to going out or if I’m not up to going 
out.  But from like the November, it might have been October, when I was, the 
hospital put it down to prostatitis but then I find that as I say I’ve got no control 
over my bowels at all, the urgency was there and it sort of haven’t gone from 
that. I try to control it with people like yourself and the waterworks is under 
control with urology who I’m seeing as well but it’s not enough for me to go 
out. You know I was in the supermarket the other day and we had to stop 
shopping because I needed to go to the toilet and because we were around the 
corner I said it’s quicker to get home than me trying to get there and have an 
accident or make a mess in the supermarket.  So I wouldn’t go out socially, I 
don’t go to the pub to see my mates or nothing like that” 
 
Although this meant for some of the participants that they rarely went out, others made 
significant efforts to ensure they carried on normally as much as possible. Bev still tried 
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to see her friends when she felt up to it, however did comment that she did not want 
them to know that she was struggling. Bev used self-developed techniques to hide what 
was happening to her, perhaps as a protective mechanism for herself, or perhaps for the 
sake of her friends and family. This however, also made it difficult to see her family at 
times: 
 
Bev: “I haven’t really told them about the accidents. I’d rather not talk about it 
to them really because….” Did her family know? “No, not really, not about the 
accidents, they know that, you know, when I’ve stayed up there it’s. They 
always ask me if they can have a bath because the toilet is in the bathroom, you 
know do you know do you want to go and use the loo because I’m going to have 
a bath and there have been times when I’ve stayed and one of them is in there 
and I’m like oh just hurry up, hurry up.  You know I don’t really want people 
staying here either because they might be in the bathroom when I want to use 
it” 
 
Instead of staying home, Bev planned her days around how she felt and how to reduce 
the chance of accidents. She described how mornings were particularly difficult and so 
ensured that any shopping or social activities were restricted to the afternoons. Planning 
did not always result in a good outcome however. Bev spoke of a time she went out with 
friends and had to ask the driver to stop repeatedly so she could use the toilet. As she 
had not told them about her problem, they were not particularly helpful and she found 
this difficult. So even though Bev made significant efforts to continue as normal, this 
was not always possible and she found this upsetting: 
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Bev: “When I’m home, yes I have had accidents and the pad hasn’t been 
sufficient but  you know if I know I’m having one of those days and I feel awful, I 
so say oh sorry  I’m not coming out tonight and I feel as if I’m, I think sometimes 
as much as they try to understand what, they haven’t really got a clue and it’s 
not something that, you know oh sorry I don’t want to come out because I’ve 
got an upset stomach and you know I might have an accident and it’s horrible, 
absolutely horrible” 
  
Bev was not alone in her meticulous planning in an attempt to carry on with her life, 
despite having bowel problems, and this will be further discussed in the following 
chapter. Jenny explained how she was obsessive about using perfumed sprays to mask 
any smells she might emit. She also used an element of humour and said that her co-
workers laughed with her about her use of perfume. Although she laughed when she 
told me this, she also described how she clearly found it no laughing matter: 
 
Jenny: “They all laugh you know, good as gold in work.  No one has ever said 
anything to me and I’m always conscious you know, I’m always spraying myself, 
cleaning myself, changing, but you’re always conscious. I find myself always 
conscious. Where some people are conscious about their deodorant, I’m not, it’s 
not that that worries me, it’s always down below that worries me in case 
there’s a smell”  
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I asked Jenny if this was something that was always on her mind-  
 
Jenny: “Always, always, like today I was in the shop today and I had to alter all 
the shop around so I’m up and down off ladders and I think oh I hope I’m not up 
here now and something happens and someone passes. How embarrassing 
would that be. So as soon as I feel a little inkling I go, I get off and I go upstairs 
and then when I feel alright then I’ll come back down but all the time, all the 
time, behind the till sometimes and I’ll think is that me, you know and I say to 
my kids am I smelling and they say no mam, but I’m thinking about it, you 
know. I’d hate to think of my customers coming in the shop and thinking oh my 
god she smells because that would crack me up, that would crack me up. But 
it’s always there, always there”. 
 
Knowing where the toilets were if venturing away from home was important for all the 
participants. Known as ‘toilet mapping’, for some this made going out possible: 
 
David: “That’s right because if we’d go say to town for instance we’d plan out 
basically where the toilets….”  
 
Gary limited his time out of the house depending on how long he felt he had between 
needing to use the toilet. His wife Marie spoke for him, so clearly, she knew at least 
some of the struggles he was facing and at one point acknowledged how he had become 
fearful of experiencing FI when out: 
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Marie: “You always had to make sure that you went to the loo before you went  
out because then you could go three or four times. You’d walk through the door   
and then you’d have to rush back again and it would, you know you could delay 
going out for an hour or two. You were scared to go anywhere. I know it doesn’t 
sound very much but you then got quite fearful about it didn’t you because you 
thought you were going to have an accident” 
 
Jenny not only knew where the toilets were but also ensured that she had a bag of clean 
clothes with her in case she had an accident. Although she recognised the possibility of 
having a problem when out, she decided that, for whatever her reason, she would make 
plans to minimise the risk of being FI in public: 
 
Jenny: “She’ll say (her sister) come on we’ll go out and I’ll say yes but where are 
we going? I’ve got to know where we’re going because like she’ll say we’ll go to 
town and I think to myself right where’s the toilets in town, ah there’s a couple 
of cafés I can run in and I’ll say to her buy a coffee and I’ll run into the loo. But 
all the time I’m thinking where’s the toilets, the nearest toilets, you know, can I 
make them if I do have an accident and my bag is always full of everything, 
everything in case and the same with the car, if we go out for the day I’ve got a 
little bag in the car with everything in case I have an accident. But it’s all the 
time, all the time. 
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John and Barbara talked about a deeply distressing event that happened at an airport. 
Their story was interlaced with times when John put his head in his hands when 
describing his shame and laughter between them both looking back on it. They had 
decided to book a holiday to try to relax and recover from recent events but John had 
recently been prescribed medicated enemas to try and relive his symptoms.   
 
Barbara: “With the enemas we nearly got arrested at the airport- they had to 
take them away because when he was prescribed them we booked a holiday to 
Benidorm so he had to take them because of course he couldn’t stop taking 
them and they’re liquid as well so I said well we’ll have to pack them so I said 
we’ll put them all in a clear bag and he said well put the box in, I said no don’t 
put the box in because your name and everything is on it that they’ll know your 
name or your medical numbers so I took them out of the box. Well of course in 
the airport they didn’t know what they were did they because there was no 
prescription so, well they tested them with this, they tested them with that, oh 
my god” 
 John: “In the airport, in the security and everybody is there and they’re all 
going and I had to explain what they were for and what I done with them”  
Barbara: “Oh he was mortified”  
 
Interviewer: “So you’re laughing now but…..”  
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Barbara: “Oh he was terrible” John: “At the time I wished there was a big hole 
and I just could have been swallowed up in it” 
 Barbara: “And I felt terrible then because it was my fault really because I took 
the box”  
John: “I said you never ripped the label off, saying it was mine and who 
prescribed them and what have you and she said oh there’s no need for that 
and I wanted to strangle her” 
 
Despite them telling such a difficult story, when John felt his wife’s actions had 
contributed to his embarrassment, the closeness between them was evident; they 
glanced and smiled at each other throughout, and when John became visibly distressed, 
Barbara moved seats to hold his hand. It was an obvious display of affection, of 
teamwork in difficult circumstances.  
 
In contrast to John and Barbara going away on holiday, Ken had a very different story to 
tell. He had other chronic health problems which he had said caused him some 
difficulties but I had asked him if his bowel problems had affected his family as well as 
him. He particularly identified his concern about travelling through the airports, just as 
John had. 
 
Ken: “We always had holidays; I haven’t gone on holiday now since, well since 
the stroke really. 2013 was the last time we went, I went on holiday”  
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Interviewer: “Okay, with your bowel situation, would that prevent you going away”? 
 
Ken: “Well yes, because how could you go through airports or anything like 
that, you know?” 
 
Interviewer: “What does your wife think about all this”? 
 
Ken: “Well it’s hard because we don’t have a holiday together, she goes on 
holiday, she goes with my daughter but then that’s the only time I do see 
people, they’ll call or they’ll ring and my sister or whatever will ring to check I’m 
okay because while they’re away for the week or my friends will ring, my 
neighbour will knock, just to check that I’m okay and is everything alright do I 
need to go to the doctors or I might need any medication which is normally in 
hand but like I say I haven’t had a, the last time we went on holiday it was 
October 2013 and we went on a cruise and that was a disaster because even 
then I couldn’t do things. I was learning to do what I could do, this was before I 
was diagnosed with the cancer and even then it was limited”  
 
Interviewer: “So it was limited before and this has just made things that much worse”? 
 
Ken: “Yes, it’s made it worse”  
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Whereas John and Barbara went on holiday as a team, despite them knowing their time 
away might be difficult with him needing to use enemas, they had not let it stop them 
from going. For Ken this was different. He and his wife no longer went away together. 
Their last holiday on the cruise ship had proved too difficult to try and repeat. Ken did 
not say whose choice it was that he wouldn’t go with his wife from then on, and he 
seemed to accept it without any obvious bitterness, at least during the interview. 
 
Harry had also decided that it was best not to leave his house unless absolutely 
necessary. I asked him if he went anywhere: 
 
Harry: ‘Only to bed”  
 
When asked why, what was his main problem, he replied: 
 
Harry: “Well I mean it’s embarrassing, and when that wind starts you’re 
emptying your bowel then you know. It’s the staining and….”  
Gwen: “That’s the worst thing that you’ve found, it’s this wind problem isn’t it”  
Harry: “Oh yes well that’s embarrassing enough and the problem with the fact 
that you know, I could be anywhere and suddenly this comes on and you know, 
quite honestly when I go down the hospital, I’m right there aren’t I, I get there 
about half an hour before, you go to the toilet, and then check my, I take a 
spare pad, and then if it’s stained at all well I put it in whatever it is and I put 
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another one, you know I’m thinking ahead all the time to try and think well I 
don’t want to get in there in an embarrassing situation”   
 
Whereas Ken had lived for a good few years with other chronic health problems 
affecting his ability to carry on as normal, Harry had always been in good health. He and 
Gwen wondered if this was why he was struggling so much, but both Ken and Harry 
seemed to struggle with their change of circumstances with the same amount of 
difficulty:  
 
Harry: “I mean I’ve been a lucky man all my life”  
Gwen: “I think that’s, in a way made it worse for him because touch wood, he’s 
been so lucky with his health over the years, he’s had flu, he’s had shingles, he 
had a sebaceous cyst removed from his back and I think in his 86/7 years that’s 
about it so he has been extremely lucky and I think sometimes that can be 
harder then, when something does go wrong you know, to cope with. If you’ve 
had niggly things going on and on and on, I think you think oh here’s another 
thing but I think it’s hit him hard because he’s been so lucky you know”  
 
Although some of the participants used various ways of coping, trying to continue their 
lives as normally as possible, they all have experienced significantly difficult changes. 
From avoiding any situation that might leave them vulnerable to having faecal accidents, 
to trying to manage their lives around their bowel problems, each of the participants 
spoke of the difficulties. This stigma, as some referred to it as, impacted on all aspects 
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of their lives, from interacting with family and friends, to trying to cope with work. Some 
like Jenny and Bev appeared to cope better than others like John and David. However, 
when hearing all their stories, it was evident that they all struggled to some extent. It 
was difficult to identify why some tried to carry on as normal while others almost gave 
up. This could be due to factors such as age, where the younger people found it 
important to have a life outside of their homes, while this may not be as vital to the 
older participants, although Jenny was a similar age to many of the participants who 
avoided going out. Therefore, perhaps this difference is more down to personality, that 
some just cope better than others. Jenny and Bev certainly came across as highly social 
people, often mentioning family and friends, although both ladies were single. This 
could mean that they wanted to have more social contact than those who had a partner 
at home and this could also identify that having a partner does not necessarily equate 
to a better coping and managing outcome. This would be an interesting area to examine 
in future research.   
 
The participants and their partners became adept at managing and hiding their difficult 
experiences. Their days were often spent planning how they could continue going about 
their everyday business, working out where toilet facilities were available and how to 
minimise the risk of having faecal accidents when away from home. Despite meticulous 
planning, occasionally their worst scenarios actually occurred. When they experienced 
faecal soiling in public places their humiliation was clear and in some, but not all cases, 
this then reduced even further where they felt able to go.  
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In conclusion, when considering Goffman’s (1963) description of the original use of the 
term ‘stigma’, physical differences of people experiencing GI late effects of radiotherapy 
are not obviously on show but remain as a stigma for them. This is contributed to by the 
presence of issues that may or may not be obvious to others around them, such as 
flatulence, smell and the behaviour felt necessary to hide what is happening. This 
concept of stigma was noted throughout the interviews and was seen to impact on the 
participants’ everyday activities and experiences. 
 
Key theme 2- Healthcare 
The second theme developed from the FA was healthcare. This included contacts with 
primary care, secondary care, private and charitable sectors. The participants frequently 
spoke about their medical care, both in positive and negative ways. This was a group of 
people who had been through significant health issues, yet were now ‘the other side’ of 
their cancer treatment. Exploration of how interactions with healthcare services had 
impacted their experiences of living with PRD was an area of particular interest for this 
study. The ideas considered were: 
 
• What experiences did the participants have with healthcare services when 
symptoms were beginning to develop? Where these good or bad experiences?  
• Did their experiences identify aspects of healthcare that could be improved? 
 
There was a wide variation in the acknowledgement by healthcare professionals of the 
need for further assessment of symptoms with which the participants presented. The 
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speed of referral for some was immediate, for others, it was a long frustrating journey 
with multiple re-presentations at the GP’s.  For Tony, the experience was quite positive: 
 
 
Tony: “I was happy with the speed all the way along the line in the sense that 
after seeing the GP, referral was very, very quick. In the same way that referral 
back this time, when I saw this, was very quick” 
 
For most of the other participants however, the story was very different. John had begun 
to experience rectal bleeding. I asked him if he had thought his cancer might be back? 
 
John: “Yes definite, I thought there’s no doubt so I made arrangements then to 
go and I had a bit of a performance with my GP over that, to get back to see the 
consultant” 
 Barbara: “Oh the GP is not very good” 
 John: “He wasn’t very helpful. I went and explained this to him and he wrote, 
he said here you are, he said there’s the surgeon’s secretary’s phone number, 
ring her and she’ll sort you out and I thought I haven’t seen her for like nearly a 
twelve month, she’s not going to do it like so I rung the secretary and she said 
oh (name) have you been with us in the last four months, I said no, she said I 
can’t do nothing for you you’re going to have to go back through your GP so I 
had to wait another fortnight then to see the GP because that’s how it is, you’ve 
got to wait a fortnight isn’t it and eventually I said look she won’t do anything 
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and he said oh right, I’ll write to her and so he wrote so eventually I got back to 
see her and then straightaway she gave me a colonoscopy you know, an 
appointment for a colonoscopy and that took about two weeks or so and then 
when they was looking and they said we don’t think it’s the cancer, this 
inflammation and ulceration in your bowels like you know”    
 
Even though John’s GP acknowledged that they may be a problem, the suggestion for 
John himself to contact the Consultants secretary was incorrect and resulted in a 
significant delay.  
 
Ruth experienced similar indifference from both her GP and the oncology clinic: 
 
Interviewer: “Did it take you a long time to get some help for your bowel problems now, 
were people listening to you”? 
 
Ruth: “I would say no at first. Well at first they wouldn’t even listen that there 
was a problem, if I didn’t keep on going back to my GP saying look I know that 
there’s something there, I can feel it”  
 
Interviewer: “But after the treatment, once you’d had your treatment, and things 
weren’t settling down, was anyone interested? 
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Ruth: “Every time I went back like three months, they’d obviously ask you oh 
how’s your bowel, and I’d say well I can’t control them, oh try this or try that or 
and  they were giving me different medications to try and help and things like 
that”  
Jason: “Nothing specific”  
Ruth: “It was like, that was more like for diarrhoea and I said I haven’t got 
diarrhoea, so it’s pointless like bulking everything up because obviously it’ll be 
more painful to pass, because my skin is always sore and things down there 
anyway”  
  
Interviewer: “So you felt perhaps they weren’t really listening or not understanding”? 
 
Ruth: “I don’t think they were, probably a little bit of both, they seem to think 
oh well take this but it was more like diarrhoea related, like with the control, I 
said to them it doesn’t matter what the bowel movement is, I can’t control it. 
I’ve got no muscle there at all to hold anything in, we went to Tesco’s this 
morning didn’t we and I said I’ve got to go to the toilet, and I’ve got to go, I 
can’t wait and say oh I’ll just pay for my shopping first and then go, because I 
won’t make it”  
 
Interviewer: “And how long then did it take for them to think about getting you some 
specialist referral”? 
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Ruth: “Probably the last time I saw Mr (name), wasn’t it”?  
Jason: “Two months ago”  
Ruth: “because I know I’m due to, yes a couple of months ago. But I mean this is 
like eighteen months down the line from when my treatment finished”  
 
Interviewer: “So ideally this all should have happened earlier for you”? 
 
Ruth: “yes, yes”  
 
Not all participants had problems with their GP, or accessing healthcare after their 
cancer treatment. Bev commented on how helpful her surgery had been since her 
cancer diagnosis: 
 
Bev: “If I’ve got any problems but I also know that if I have got a problem and 
I’m  worried I’ve only got to phone (oncologist) and they’ll bring my 
appointment forward.  So that’s really reassuring for me. My GP has been really 
good in the sense when I have contacted them for an appointment they’ve 
always  managed to fit me in that day. I don’t know whether that’s because of 
what’s happened but I don’t feel that they really understand the side effects of 
what’s you know”  
Interviewer: “Do you feel that, particularly perhaps with (cancer hospital) and your GP      
that they have listened to your worries about your bowels or have you had to fight at 
all”? 
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Bev: “Well I think initially with (cancer hospital) it was sort of at the 12 months, 
just after the 12 month mark so you know when I sort of said about, that’s 
when they said they’d refer me. So yeah, I think up until then they were most 
probably hoping it would settle back down, it’s what they sort of said and that”  
 
Bev said that the cancer hospital had referred her at about 12 months when she had 
raised the issue- “when I sort of said..” even though it sounded like they did know she 
was having problems but were “hoping it would settle back down”. It was unclear 
whether this was due to lack of awareness of problems such as PRD by the HCPs, or due 
to a clinical set-up where the patients simply were not asked about such things, nor had 
a plan in place when such patients should be referred for specialist help.  
 
Jenny also mentioned her telling the oncology team at her cancer hospital that she was 
struggling with symptoms, but that nothing was done about it for some time: 
 
Jenny: “I just thought it was through the treatment, but no one ever said 
anything. I kept seeing different people. Even though when I was going back 
and fore to the hospital every three months and every six months. I mentioned 
it but no one said anything”  
 
There was very little mention about involvement with the cancer charities. Only one 
participant, David, mentioned anything at all regarding them. Following completion of 
his radiotherapy, David was experiencing pain when passing urine. One morning, whilst 
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out with his wife, he noticed a Tenovus mobile clinic in a supermarket car park. The 
Clinical Nurse Specialist on board recognised his symptoms straight away and sent him 
to see his GP with a note that he was probably experiencing prostatitis. Several patient 
information booklets have been produced by groups such as Macmillan about late 
effects of cancer treatment including PRD, as discussed in the literature review. These 
are suitable to be on display in hospital and GP waiting rooms as well as to be given to 
patients at various points of their cancer treatment journey and so it is noteworthy that 
none of the participants mention them. 
 
There appeared a difference in the expectations of the participants in the giving of 
information by HCPs, about the possibility of developing problems after the cancer 
treatment. Tony seemed quite accepting of the risk of effects of treatment saying: 
 
Tony: You accept that apart from anything else you’ve got to sign up to the 
risk…” 
 
Gary noted that even though he was given information about the potential side effects 
of the radiotherapy treatment, he had not really taken it all in: 
 
Gary: “I think you can give somebody a leaflet and you can read it but you’re  
not actually absorbing that” 
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Ruth also commented on the lack of information she received about the possibility of 
experiencing problems such as PRD, prior to her cancer treatment: 
 
Ruth: “I think they should go into the side effects and the long-term side effects 
in a bit more depth than what they do, I mean they just say oh it could bring on  
the menopause, you might have aching joints or but I don’t think they go into it 
enough” 
 
Likewise, Bev noted that she was not really aware of the potential of late effects of the 
treatment. She commented that she had just been told that she had cancer and so was 
focused on doing whatever was necessary to survive. However, Bev also noted that 
maybe if she had been told about all the potential side effects that it would probably 
have been too much information to take in at that point: 
Bev: “Well you know before the treatment, you sign a consent form you know, 
there could be short, long term side, I can’t even, you know and at the time if 
they were listed on there I signed the consent form because I’ve just been 
diagnosed with cancer so it’s all too much info sort of to take in but it was very 
vague anyway, whatever I signed, I can’t remember you know but. But there 
again, do you want to know all of that, you’ve got so much to take in and I am 
one of these people I wanted to know what stage it was, you know, you know 
what the out, the likelihood of curing it and things and yeah maybe the long 
term side effects in great detail would have been too much info at that stage” 
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Unlike the others mentioned, Jenny was quite certain that she had not been told about 
the possibility of late effects of treatment, either verbally or by a leaflet: 
Jenny: “But no, no one ever mentioned there could have been problems, I’ve got 
to say that, no one did mention” 
 
A few of the participants spoke about what they had found helpful and suggested ways 
in which the various healthcare services could be improved. Tony talked about the 
benefits of Specialist Nurses. When he was telling a friend that he was going to be seen 
in the hospital, his friend commented: 
  
Tony: “well with any luck you’ll see the Specialist Nurse…they usually have 
more time to spend with the patient than the Consultant or Registrar”  
 
Ruth spoke about the practical problems of sitting on the hard-plastic chairs at the 
hospital following radiotherapy for rectal cancer.  
 
Ruth: “I couldn’t even sit down, some days I was in so much pain with my skin 
and everything and they expect you to sit on these hard-plastic chairs. I think 
there was one comfortable chair in the whole department because you just 
can’t sit on them”  
Jason: “You had to fight to get that chair”  
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Although this sounds almost humorous now in a written form, when they told this story, 
neither Ruth nor Jason even smiled. They looked at each other and shook their heads. 
Ruth had been amongst a group of patients who had received radiotherapy directly to 
sensitive areas of skin, which would obviously suffer the weight and friction of sitting 
down, yet this did not appear to have been taken in to account. As Jason had 
commented that Ruth had to ‘fight’ to get the one comfortable chair, this implies that 
all of the other patients in that room were experiencing the same problem.  
 
There was a consensus amongst many of the participants that healthcare staff should 
be more aware of the potential of bowel problems after radiotherapy and to ask patients 
if they are experiencing symptoms. Harry’s wife Gwen commented that it was up to 
healthcare staff to ask about symptoms, rather than wait to be told. Jenny talked about 
how she had told them about her symptoms, but they did not offer any help. Bev 
recalled signing a consent form prior to the radiotherapy and that she thought it 
mentioned the risk of short and long term side effects, but at the time she just wanted 
the cancer to go away. She said that even if she had been aware of the subsequent 
problems she still would have gone ahead with the treatment, as it offered a chance to 
be cured from the cancer.  
 
In conclusion, for some participants, the journey from the end of their cancer treatment 
to the point where action was taken regarding the late effects of their treatment was 
not straightforward. The term “back and fore” was frequently used and describes a 
difficult and long process. Most spoke of difficulties they had experienced in getting 
healthcare professionals to listen to their problems. Even when those healthcare 
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professionals were based in the cancer hospital, the very place where it could be 
expected that they would be aware of the potential late effects of the cancer treatment, 
it was not uncommon for the correct knowledge and support to be unavailable. Either 
the professionals did not ask the participants about late effects, or, when they were 
made aware, did nothing with that information.  Even when timely and appropriate care 
was available, there was still room for improvement. The issue with the hard, 
uncomfortable chairs was an area that was relatively easy to resolve. Most participants 
also spoke highly of their healthcare teams. The fact that they were still alive to tell of 
their stories was noted by many. There were elements of exceptional care, such as 
Tony’s and Bev’s prompt treatment through their GP, although overall, several areas 
where improvement could be made, were highlighted.   
 
Key theme 3- Support  
The third of the major themes identified within the FA was ‘support’. Each of the 
participants spoke of involvement of the significant others in their lives, including family 
and friends. I was keen to understand what impact this support had on their 
experiences. Ideas to consider included: 
 
• What types of support were there and what form did this take? 
• Did the support help? Did it not? 
• Were there any obvious gaps in the level of support? 
For those participants whom I interviewed along with their partner present, I was struck 
by the atmosphere of teamwork between them. This was evident through both the 
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language used and more subtle expressions of support; glances between them and 
physical contact, particularly when one of them became upset. All of the couples spoke 
in terms of “we decided”, “we did this...” and “we went to the GP”. It was also clear from 
the interviews with the couples, where the man was the patient it was their wives that 
took on the caring role: 
 
David: “That’s right, they told me to drink plenty and (wife), she’s always 
chasing me get on with the next drink”  
 
Interviewer: “Yes, has it meant a lot for you to have the support of your wife, because 
obviously not everybody has got that. You seem like a good team” 
 
David: “Yes that’s right, we are, in fairness to Megan she’s very good to look 
after me really and because I sometimes forget to take my drinks and within 
half an hour after she’s saying have you had your drink?  
 
Interviewer: “Has it caused you as his wife much concern to see him going through all 
this? 
 
Megan: “Yes it has because we’ve been very close, we’ve been married 46 years 
and we’ve always done everything together. We’re a small family aren’t we? 
And I was sixteen, he was seventeen when we met so we’ve more or less been 
together always. So to not, how can I put it, to have your partner that’s not 
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100% it does worry you and you’re very concerned that they are going to come 
out, you’ve got to think positive and you’ve also got to think well I’m going to 
make sure that he gets through this”  
 
Ruth and Jason were the one couple interviewed where the wife had been the patient. 
He showed his support in different ways: 
 
Jason: “Well just, be there for her basically, anything she wants, even just a lie 
in”  
Ruth: “He was lucky enough where he worked, they gave him like the full six 
weeks off”  
Jason: “I’d have took you anyway, simple as”  
 
Those not in a relationship spoke of others as being their main givers of support. Tony 
spoke of how his friends offered practical help by driving him to his hospital 
appointments. Bev told a story about when her toilet flush broke she went to stay with 
a friend, whose husband then mended the toilet. Jenny was particularly close to her 
daughters, one of whom still lived with her. Her family made sure she could go out and 
enjoy times with her grandchildren, and then offered practical support, such as 
swapping underwear when she’d soiled her own, as previously mentioned. As discussed, 
those couples interviewed together described a close, supportive relationship. Ken was 
interviewed alone, while his wife was out. Although he had mentioned that she now 
went on holiday without him, he described how his wife still showed that she was 
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sensitive to his needs, although it also suggested that she now planned her life to go on 
without him by her side, recognising that he was no longer able to play much of a part 
in it: 
 
Ken: “There are days I just, my wife will come home and say you’ve been crying     
again and there’s, I just say it’s getting me down and I say perhaps I’ll ring up so 
and so and go out for an hour and then she’ll say well you’re not really well 
enough to go” 
 
The support from families and friends is not always harmonious however. Although I 
sensed a great love between most of the couples I interviewed there was also a palpable 
air of frustration at times, which was often only noticeable in the vocal tone of what was 
said, and eyes cast upwards when looking at me. As these were not captured on the 
voice recorder I made notes where possible in my field notes. I asked Harry’s wife, Gwen 
if she struggled at times with the difficulties inherent in them going out together: 
 
Gwen: “You feel impotent because you can’t do anything, if I say anything he 
gets  his knickers in a twist you know and I mean I don’t understand…. well 
maybe I don’t”  
Harry: “Gwen laughs at me, even when we’ve been to the hospital and I say 
now  let’s have a bag, and a little cushion for me to sit on because if you go in 
the taxi  and something happens…”  
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Gwen: “yes but you’ve got a pad on, you’re not going to soil anything, you’re 
not going to soil anything when you’ve got a pad and underpants and trousers”  
Harry: “I don’t know” Gwen: “well of course you do”  
Harry: “look Gwen, better be safe than sorry”  
Gwen: “mmm.…”  
 
Gary’s wife Marie spoke about how she had told one of her friends what was happening, 
because she later said it helped her to talk to others about it, but he was not happy: 
 
Marie: “Initially when all this happened, when we came back from France I think 
I might have told one of my friends, somebody you know, and you were really 
angry about it because you didn’t want anybody to know”  
Gary: “I don’t share it with my friends or family. I find it difficult to talk about 
anything really you know.  I can talk about other people but I can’t talk about 
myself that much”  
Marie: “I  mean I know that it’s a problem bothering him but Gary is like a 
closed door but  you ask too many questions you get angry about it don’t you”  
 
The drop-off of support once the cancer treatment was finished was noticed starkly by 
Bev. Her friends played an important part in trying to keep her life as normal as possible, 
despite her bowel problems. She explained that she often replied at short notice to say 
she could not go out with them, but she would not tell them it was because her bowel 
155 
 
problems were particularly troublesome that day. She sensed they were becoming less 
patient with her: 
 
Bev: “Some of my friends say oh I’m not even asking you to come out again, 
because I’ve changed my mind sort of at the last minute, it’s sort of half-
heartedly, but you know, I’m like, are you moaning again? Are you not well 
again?” 
 
Bev went on to explain that she feels her friends think she should just get back to how 
things were before now: 
 
Bev: I’ve got to the stage now here I think oh just don’t say anything about how 
I’m feeling because yeah, it’s like, they just don’t understand that, they think 
you’ve  had cancer, you’ve had the treatment, and that’s it, you know I should 
be back you know, I should be my normal self now” 
 
In conclusion, each of the participants spoke of how someone had supported them 
through the difficulties and practicalities of living with late effects of the radiotherapy. 
For some this was provided by family members, and for others, it came via close friends. 
It was evident however that the type and level of support differed, often depending on 
the understanding and tolerance of the support giver. Whereas at times it may have 
appeared that family and friends were less than supportive, it was clear that this was 
often because the participants, including Gary and Bev, had chosen to not fully disclose 
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the difficulties they were experiencing to protect themselves from what they perceived 
to be the stigma of bowel problems. Even in the close supportive partnerships of some 
of the couples, there lay a hidden frustration between them, as displayed by Harry and 
Gwen. Although outwardly Gwen was fully supportive of Harry’s struggles, it was 
evident on a couple of occasions that she was becoming frustrated by his apparent lack 
of coping with his problems and that this this was now impacting upon both of their 
lives. It would seem that whilst the partner can offer support to the one experiencing 
the late GI effects, there is no support for the partner themselves.   
 
  
Stigma, Healthcare and Support; the experience of living with PRD 
 
There are elements of each of the main themes of the experience of stigma, healthcare 
and support seen with all the participants. There were some clear descriptions of where 
one element clearly impacted upon the other. For example, healthcare interventions 
occasionally contributed to feeling of stigma. A prime example of this is when John and 
Barbara were caught up at the airport when suspicion was aroused as to the nature of 
the enemas he was taking with him: 
 
 John: “In the airport, in the security and everybody is there and they’re all 
going   and I had to explain what they were for and what I done with them”  
Barbara: “oh he was mortified oh he was terrible”  
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John: “at the time I wished there was a big hole and I just could have been 
swallowed up in it”  
Barbara: “and I felt terrible then because it was my fault really because I took 
the box”  
John: “….and I wanted to strangle her”  
 
John was following instructions from the hospital to use the enemas. It would suggest 
that John had not discussed the holiday with his HCP, else the practicalities of taking 
them would ideally have been discussed. Either John had not mentioned he was hoping 
to go away, or the HCP had not enquired if any holidays or journey were planned. For 
whatever reason, John felt he needed to take the enemas away with him, rather than 
leave them at home. This resulted in a deeply embarrassing situation for him at the 
airport.  
 
Both Gary and Bev explained that they did not want their friends knowing about their 
health problems as they felt it was a private matter. This however may have affected 
their friends’ perceived lack of support at times: 
 
Gary: “I’m a bit of a private guy, I told you that I don’t share it with my friends 
or family” 
 
Bev: “as much as they try to understand they haven’t really got a clue”  
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Other participants made a big effort to avoid their friends due to the perceived stigma 
and the need to hide their problems. This often left them feeling isolated and missing 
the support they may otherwise have received:  
 
Gwen: “I mean two of his friends, well people we know, called over the last day 
didn’t they”  
Harry: “Well, that’s another thing, if somebody comes here and I think oh God”  
Gwen: “he’s on pins”  
Harry: “family, I’m not being unkind but I wish they weren’t here because I’m all 
on edge you know, oh God, now I’ve got to go or something”  
 
The data presented shows that aspects of stigma, healthcare and support are inter-
woven in the participants’ experiences. Some of these experiences are good and 
demonstrate love and support between the participants and their family and friends. 
Others tell of how the perceived stigma has driven wedges between those who they 
care about and who cared about them. Many healthcare encounters left a lot to be 
desired. It was a common theme that the participants had to battle to get the help they 
needed. Even those healthcare professionals who cared for people with and after cancer 
did often know what was happening. The most obvious feature of all the interviews is 
that these experiences had a significant impact on the participants’ and their partners’ 
lives. The next chapter will discuss these findings in further depth and consider what this 
may mean for people experiencing PRD in the future. 
 
159 
 
Chapter 6: Discussion  
 
The aim of this study was to gain an insight into the participants’ experiences of living 
with PRD. To achieve this, the objectives of the research study were to provide an insight 
into the experiences of living with PRD. This included the physical, psychological and 
social impact, examining what this means for the person with the disease as well as their 
friends and families.  
 
The literature review focused on PRD and the effects of FI. The framework was initially 
developed through the literature and then refined by applying it to the first few 
interview transcripts. Using this FA approach, the three key themes identified were 
stigma, healthcare and support. The theme of stigma was undoubtedly the most 
prevalent amongst the participants. Each of them made some reference to elements 
linked with stigma, either directly using the word, or describing times when they were 
distressed, embarrassed or humiliated. By re-visiting the framework shown in Table 9, 
the branches from each of the three themes focused the further reading of other study 
findings and theories to help develop discussion around the findings from this work.  
 
This chapter will explore issues raised in the findings, considering each of the three main 
themes. Where appropriate, other literature will be discussed alongside the study 
findings.  
Following the section about stigma, there is a further section about QoL. This was not 
considered to be a fourth theme for the framework for a specific reason. Although the 
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inclusion of quality of life scores was noted time and time again in the literature of 
studies about PRD, as will now be discussed, this seems to be quite removed from the 
actual experience of the participants, and so it will be argued, QoL scores may not be as 
helpful in gaining insight into the experiences of people with PRD as they might, at first, 
appear to be.   
Stigma 
The concept of stigma was not initially prevalent in the review of the literature but 
negative experiences were often hinted at through the description of poor QoL scores. 
Further investigation into the topic revealed that stigma, or ideas around stigma, was 
not uncommon with people with bowel problems, particularly FI. Throughout the initial 
reading of the transcripts, and then during the subsequent interviews, the theme of 
‘stigma’ began to become even clearer. The participants used different words to 
describe experiences that were clearly difficult including accidents, distress, 
embarrassment, upset and worry. 
 
The distress of the participants was particularly noted when relating their stories of 
faecal accidents. The impact of this upon their lives was distressing both for them to tell 
and to listen to. Tears were often shed, or at least silences as they tried to compose 
themselves when they talked about how such incidents made them feel. It was difficult 
to hear such distressing stories and following some of the interviews, I often cried in the 
privacy of my car, before then making additional field notes while the experiences were 
still raw and real. As with my clinical work as a nurse, it is important to be able to show 
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the patients, or in this case the participants, that I am empathetic with them, yet to also 
have the professional ability not to let one’s own distress to further impact upon them.  
 
As the framework was applied to the findings in the interviews, the work of Goffman 
was given particular attention, as he was referenced in many papers looking at the 
distress of symptoms and how the perceived stigma can impact on every area of life.  
 
Goffman (1963) believed that society generally categorises people, often based on their 
first appearance. For example, if someone looks and behaves as one would expect, then 
they possess a ‘virtual social identity‘  (p.29). What the person is actually like, 
considering any nuances, problems and  hidden disabilities, is what Goffman calls their 
‘actual social identity’(p. 29). When these two categories reveal someone with a 
difference, something that at that time is thought of as unpleasant, or unnatural, they 
are seen to have a stigma. The term ‘stigma’ refers to something that is deeply 
discrediting, and therefore someone with a stigma is seen as being ‘discredited’ (p.13), 
and can often be ostracised, either by society, or even choosing to isolate themselves in 
an attempt to hide what is happening to them.  Goffman describes those without stigma 
as ‘normals’ (p.15) which then equates that those with a stigma are abnormal, “are not 
quite human” (p.15). It was these expressions of stigma that were identified throughout 
the interviews.  
 
The role society plays in ostracising people who are different has been also recognised 
by other writers, including Durkheim (1895), Falk (2001) and Douglas (1996). Durkheim 
(1895) was one of the first sociologists to identify the power of stigma to not only 
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discredit people, but then to empower the dis-creditors, holding the society together 
with their shared values and beliefs. Determined to develop sociology as a science, he 
recognised that the individual’s behaviour was directly impacted on how society at large 
viewed the phenomenon under study. For example, by creating a group labelled as 
‘different’ people, boundaries are drawn, and solidarity amongst those considered 
‘normal’ is protected. Falk (2001) also noted the benefits of having certain groups with 
a stigma label, in that it creates a feeling of solidarity amongst everyone else. The theory 
of socially structured rules created by stigma was also developed by Douglas (1996) who 
noted the dominance of symbols, through which society functions. Societies are guided 
by symbols, both good and bad, which construct the rules of that society. She identifies 
that dirt, including faeces, holds different symbolic meaning in different cultures and/or 
time periods.  
 
Previously some anthropologists have described the use of faeces in magic (p. 146) 
although Douglas argues that rather than seeing faeces as a positive element, which, 
she feels, was developed through informant and observer bias, faeces was actually used 
as a negative magical force. Freud famously noted that prior to having their culture 
ingrained in to their everyday belief and culture system, children focus on bodily 
excretion, particularly faeces, in a positive way (Inglis 2002). Freud, and then later 
Douglas (1966) claimed that this pleasurable element was forced aside through toilet 
training, where faeces was from there on to be seen as dirty and only to be expelled in 
private. Bourdieu (1992) describes the development of defecation from an unhidden 
event to the private act it is today through the birth of the bourgeois, those who were 
deemed more civilised through their city dwelling. Within the modernising society of the 
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11th century, it became ideal to act as someone who did not defecate, but that if they 
had the need to do so, then certain rules should be adhered to; these rules included the 
use of privacy, to minimise faecal odours and for any language used to describe the 
bodily output to be wisely chosen, preferably using a “euphuism” (p.54). Through 
further development of society, many of these ‘rules’ became necessary to help prevent 
the spread of disease but this also saw the rise of derogatory faecal-related terms used 
to describe others in a negative sense. Inglis (2002) noted that although faecal terms 
had been used in a negative sense towards enemies since medieval times, the 
development of class-related toileting improvements provided the opportunity to 
enhance the insulting of others by highlighting their superior methods of hiding and 
disposing of faeces. This is why, according to Freud, faeces is now considered “morally 
dirty” (Inglis 2000, p. 122).   
 
The majority of the participants expressed feelings of experiencing a stigma of some 
sort, related to their bowel problems. Some used the word ‘stigma’ directly, such as 
Barbara, John’s wife: ‘he thinks it’s a stigma”, whilst others used terms that described 
its effect upon them, such as distress and embarrassment. The events they described 
and the concerns about potential loss of bowel control were very upsetting for them. 
This was evident through their words, their body language and their facial expressions. 
In an attempt to reduce the impact of their perceived stigma, participants and their 
partners went to great lengths to try to avoid situations where they may encounter a 
problem, or where others may discover what was happening to them. This avoidance 
often took the place of intensive planning on where and when it might be ‘safe’ to 
venture, where there would be toilet facilities or from where they may be safely and 
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quickly able to return home. For others, avoidance meant just that; they avoided going 
out, just in case they had an episode of FI. The impact of the perceived stigma was 
different amongst participants, or at least presented by them as being different. Many 
of the interviews involved tears and descriptions of lives on hold, or even that happiness 
with their lives had now ended. Others made great efforts to try to continue as normal, 
although behind the outward display of coping, there were often hidden feelings of 
shame and hurt from the impact they were experiencing.  
 
Some of the participants, including David and Harry, had commented on how distressing 
it was to soil their clothing, with Harry describing it as “staining”. Norton (2004) 
discusses how we are taught as we grow up that passing stool anywhere but in a toilet, 
is “naughty and socially unacceptable” (p. 85). Using the criteria of social acceptability 
then, faecal incontinence identifies with Goffman’s (1963) attribute of a ‘stigma’. In this 
major work, Goffman defined early on what he means by stigma- “an attribute that is 
deeply distressing” (p. 13). This certainly concurs with the stories of my study 
participants, where terms describing “accidents’”, “embarrassment”, “distress” and 
being “mortified” were frequently expressed. Olsson and Berterö (2014) found similar 
levels of distress and shame in their study. Some of their participants spoke of their 
fears: “I feel ashamed” (p. 145). This was also seen in John’s distress at the airport when 
the security person held his enema aloft- “at the time I wished there was a big hole and 
I just could have been swallowed up in it”. If faecal incontinence is therefore considered 
to be a social stigma, then those who experience it may have little choice but to either 
accept it as a stigma or to learn to hide it from others and cope as best they can. 
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Earnshaw et al (2011) examined the experiences of people living with various chronic 
illnesses.  They found that where the illness was considered to be related to a stigma, 
such as bowel problems, epilepsy and other neurological conditions, the participant was 
likely to experience a lower quality of life than those with a condition that was 
considered by society as less stigmatising, such as heart or lung conditions. They found 
that even just the knowledge that their condition involved areas of stigma was enough 
to affect how they perceived the impact of stigma on their own lives, whether or not 
they actually experienced the stigmatising symptoms.  John seemed to particularly 
struggle with this perceived stigma, and the shame of it: 
 
John: “I do think then, sitting by here and I think to myself why can’t I just feel 
normal, not feel…”  
Barbara: “And he do always say, this is the worst thing that could have ever of 
happened to me” 
 
So John believes FI was the worst thing that could have ever happened to him. The 
transcript goes on to show that this is qualified further on, that the cancer he could deal 
with, but the shame of the late effects, including FI was overwhelming for him. If as 
Earnshaw et al (2011) suggests, this ‘anticipated stigma’ develops through reaction by 
healthcare staff, as well as family and friends, as Earnshaw et al (2011) hypothesised, 
then this may be one way of addressing the root cause of the perception of stigma, thus 
increasing quality of life of those experiencing it. Goffman (1963) suggests that one 
method of reducing stigma, both the experience of it and the public recognition of it, 
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can be through the development of groups for people with similar conditions. He noted 
that stigmatised individuals may become “speakers” to groups of stigmatised and 
“normals”, raising awareness that even though they may have these problems they “can 
be a good person” (p. 37). This perception is seen daily in gastroenterology clinical work. 
One clear example of this is the “Get Your Belly Out” campaign for ostomists, supported 
by Crohn’s and Colitis UK (CCUK 2018), an organisation that supports people living with 
inflammatory bowel disease (IBD). As well as providing group support around the UK 
they also have several celebrity ambassadors, showing the public that even though they 
have IBD, they still have valuable and productive lives. The Pelvic Radiations Disease 
Association is a support group for people with PRD, but it is a very small group with 
limited members and finance to make a significant impact at this point in time.   
 
Another potential reason for reduced quality of life amongst those with a chronic illness 
may be that those with stigmatised conditions often conceal their problems and so 
receive less support. This may be due to a simple desire for privacy or even a coping 
mechanism described “protective buffering” (Langer 2009). In a perceived attempt by 
the person with illness to protect their loved ones from the consequences of the disease, 
they hide what is happening. They may also try to protect themselves from their own 
distress, as though to pretend it is not really happening, and also to buffer themselves 
from the distress caused by the loved one adding to their problems. The authors found 
however that this coping strategy rarely had a good outcome; the family and friends 
they were trying to protect, can be very hurt and upset at the deceit. The study 
recommends that clinicians identify such behaviour and address it with open dialogue 
and counselling. 
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Most of the study participants spoke of how their family and friends often did not know 
the full extent of their health problems. Gary, in particular, did not want anyone to 
know. When his wife had inadvertently told her friend, Gary had become angry with her 
for discussing his private business. He had previously mentioned that he had received 
treatment for a heart condition, and when asked if he had ever mentioned that to his 
friends, he gave a wry smile and replied “Yes you’ve got me there, yes, I’ll talk about 
that”. Gary’s acknowledgement that not all conditions have the same level of stigma 
attached to them is an interesting point. It is helpful to revisit Goffman’s (1963) original 
concept of what constitutes a stigmatising condition. He uses the term “normals” to 
describe those without differences, which in turn implies that those with differences are 
not ‘normal’ and “not quite human” (p. 15). Goffman goes on to discuss how some 
individuals will attempt to correct what they see as their problem, but this is not always 
possible, as is often the case of chronic illness. When correction of the ‘abnormality’ is 
not possible then one may then develop strategies to cope, to hide, or to manage the 
condition which, as will be discussed, was seen in the actions of many of the participants.   
 
By hiding bowel problems there is an element of control maintained, perhaps in an 
attempt to self-manage. Avoidance of a difficult situation is a form of coping, and one 
that many participants utilised to some extent in both my own and Olsson and Berterö’s 
(2014) study. The lives of both participants and their partners revolved around strategies 
to maintain some form of normal existence. For some like John this involved attempting 
to open his bowel before going out, often going back and forth- Barbara: “(he) will go 
about fifty times before we leave the house just making sure”. Although “fifty” is almost 
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certainly an exaggeration, it gives an idea that not only does John go back to the toilet 
many times before going out, but that also Barbara notices this and feels it is excessive 
and abnormal.  
 
Toilet mapping, as described by Ness (2012), was a common theme throughout the 
interviews, including Bev, Jenny and Harry, as described in the findings chapter.  This 
occurs when people plan their days around where there are toilets. In clinic, patients 
often say that the first thing they do when they arrive at a new location is find out where 
the toilets are, if they have not already planned this out in advance. There are several 
smart phone Apps available for this purpose.  Sometimes however, even meticulous 
planning was not enough, and what they saw as humiliating faecal incontinence was 
experienced, such as what happened to Jenny at the zoo.  
 
If the person is able to hide it, to act as though there is no problem, then they have 
regained an element of control over their lives. For some participants though, the 
anxiety created by the stress of social interactions means that it is easier to avoid social 
contact whenever possible. Returning to John’s distress at the airport- “at the time I 
wished there was a big hole and I just could have been swallowed up in it”, it strikes a 
similar chord to a man quoted in Goffman’s work (1963); “it seems to me…that 
everybody is pointing at me with his finger” (p. 28). These men express the same feeling 
of being exposed, being outed as being different, with their stigma displayed to all. 
John’s experience, as well as all of my study participants, matches those described by 
Goffman (1963), as the additional problems of experiencing the onset of a new stigma 
later in life. He goes on to describe how this group of people may have particular 
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problems in accepting their differences, as they often have a long-life experience of 
previously being ‘normal’. Goffman believes that in such scenarios it is a specific role of 
healthcare professionals to “inform the infirm who he is going to have to be” (p. 49). 
Although this belief suggests that it is the role of healthcare professionals to be involved 
in supporting people with chronic health conditions, Goffman’s comment seems to 
dismiss the significant work that should come before this statement; the work to ensure 
that any potential improvements are made, and that the ‘infirm’ are as confident as 
possible that all that can be done has been done. Of course, this opinion of Goffman’s 
decree may be a little unfair; however in this study it appears to be an important 
element in the care and reassurance of the participants.   
 
The participants in the study each presented stories and examples describing how they 
experienced stigma because of their bowel condition. This was a common finding 
amongst the literature, where faecal incontinence was frequently linked with feelings of 
disgust and distress. Participants in this study were in a different group than most of 
those previously presented in the literature. These participants were experiencing 
bowel problems as a consequence of cancer treatment, rather than a stand-alone 
condition. They were asked about their experiences of this, not just what symptoms 
they were dealing with. As demonstrated in the literature review, there is a growing 
body of evidence looking at the prevalence of PRD. Most of the studies used quantitative 
methods to identify what physical problems were experienced and when they occurred. 
Disease and QoL scores were used in abundance however very few used a face to face 
qualitative interview approach to ask people about their experiences.  
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The study by McSorley et al (2013) used both quantitative and qualitative approaches 
to enquire about coping strategies in men following prostate cancer. They found that 
that although some used avoidance techniques, the men generally coped well, and 
accepted any permanent alterations they needed to make to their everyday routines.  
When considering the differences between their findings and the findings within this 
study, of the great difficulties amongst the participants, it was noted that the 
participants in this study were people who had already been referred for help due to 
experiencing particularly bothersome symptoms, compared to the cohort in the 
McSorley et al (2013) study who were recruited from a general prostate cancer clinic. 
One of the other few qualitative studies to look at late effects of cancer treatment was 
the dietetic-led study by Abayomi et al (2005). They too presented their findings under 
the headings of long term side effects such as diarrhoea, weight gain and abdominal 
pain, as opposed to the themes of participant experience, such as those encased within 
stigma, healthcare and support. Their interviews however, of women post treatment for 
cervical cancers, found a high occurrence of bowel symptoms that affected their quality 
of life. Although there was no mention of stigma related issues, there was a comment 
that there were some cases of “social withdrawal” (p. 360), although no further 
explanation of what was meant by this was given. When examining the participants’ 
experiences of the study presented in this thesis, this withdrawal found by Abayomi et 
al (2005) could have been similar, attempting to either not go out at all or to limit any 
outside socialising to times where any episodes of FI could be prevented or managed 
privately.  
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Quality of life  
 
As mentioned in the introduction of this chapter, although QoL was a major issue 
running through the literature review looking at the different late effects of pelvic 
cancer, it was not noted to be a main theme in the framework. The reason for this is 
simple; the participants rarely mentioned QoL in the way the term was expressed in the 
studies, especially the specific ways described in the various papers looking at QoL 
measurement tools. They did, of course, throughout their interviews, mention 
distressing events that were impacting on their QoL, but this was often expressed in 
narratives of difficult experiences, and these were identified within the framework 
under the three main topics. Returning again to the definition of QoL shown previously, 
it is noted that it describes perceptions and concerns, the impact of their environment 
and so on, rather than just a list of physical symptoms:  
 
“an individual’s perception of their position in life in the context of the culture  
and value systems in which they live and in relation to their goals, expectations, 
standards and concerns. It is a broad ranging concept affected in a complex 
way by the person's physical health, psychological state, level of independence, 
social relationships, personal beliefs and their relationship to salient features of 
their environment” 
The World Health Organisation (1997, p.1)  
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Whereas it is appreciated that measurement tools can be useful for  brief interventions 
to identify if the person is experiencing difficulty, it is also noted that often an 
individual’s problems may not fit neatly into a tick box method, where discrete issues 
are concerned and needs could be missed.  
 
It is helpful to consider the work of Koller et al (1996). They noted the rise in use of QoL 
questionnaires in clinical studies and care planning, but that also unexpected results 
from the use of such questionnaires often arose. The authors suggested that there are 
variables not normally connected, or at least not in 1996 when their paper was 
published, to health related QoL scoring systems, hence some questionnaires may not 
be fully addressing issues which can impact upon QoL. Their study aimed to examine 
what other elements could be affecting QoL but were not currently at the heart of 
existing questionnaires. The results of the study, of which they used three different 
analytic measures to improve validity, showed that what mainly impacted upon cancer 
patients’ QoL were not necessarily their health problems, but their emotional and social 
distress. This was based around the participants’ experiences of stigma. The discussion 
around whether QoL measurement tools are able to fully capture the extent of distress 
is an area where further research would be helpful.  
 
Another example again taken from the literature review, of how QoL measurement tools 
may not be truly capturing the true patient experience, comes from a narrative 
researcher who was particularly interested in people’s stories-   
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“Disease is the problem from the practitioner’s perspective”  
 
Kleinman (1998, p. 5) 
 
This would suggest that if you are looking for a diagnosis of a disease, then QoL scores 
may help. If you are looking for an understanding of the impact of the disease, or of 
symptoms, then something else is required to gain the information that QoL scoring 
systems alone, cannot.  This is seen in those studies examining PRD however, having 
been found lacking in stories of patient experience, whether they experience stigma 
similar to people with other bowel conditions that result in continence issues, and also 
how their physical symptoms impact on their everyday lives. The literature surrounding 
studies of faecal incontinence and chronic illness make a direct or indirect link with 
issues of stigma and these are comparable with the experiences found with this study’s 
participants.  
Healthcare 
Discussion around the various roles of healthcare interventions was frequently noted 
during the literature and throughout the interviews and was highlighted as the second 
major theme in the framework. Most participants described difficulties in accessing the 
required healthcare services. There has been increasing awareness of the consequences 
of cancer in recent years, but clearly there is still much work to do (Andreyev 2014 and 
Henson 2011). As both John and Jason described in the findings section, they were both 
“going back and fore” to their GP to try to get them to address their problems. Even 
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when cancer healthcare professionals were still involved, often the problem continued 
to go unrecognised, as previously described by Bev. 
 
There are several policy documents that mention the ongoing needs of people following 
their cancer treatment. The Wales Cancer Network Cancer Delivery for 2016-2020 
(Wales Cancer Network 2016) highlights key points as:  
 
35. The consistent application across Wales of elements of the ‘recovery 
package’ as appropriate 
 
38.  To offer timely, high quality and accessible information… 
including…complications of treatment  
 
39. To establish routine liaison mechanisms between primary and specialist care 
to meet people’s ongoing and post-treatment care needs  
 
Cancer Delivery Plan for Wales 2016-2020 (p. 13-14) 
Although this document appears to note potential issues with late effects of cancer 
treatment, the wording is rather vague and could be interpreted as giving very little 
acknowledgement to the need. The Recovery package mentioned includes a holistic 
needs assessment and an individualised care plan, both of which, if used appropriately 
could be used to identify late consequences of treatment. In contrast, under the 
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umbrella of the National Cancer Survivorship Initiative (2013), the Department of 
Health, Macmillan and NHS Improvement jointly developed a document looking to 
direct cancer survivorship work development in England- “Living with & Beyond Cancer: 
Taking Action to Improve Outcomes” with an entire chapter devoted to consequences 
of cancer treatment. Their key messages are much more strongly worded in improving 
care for people with late effects of cancer treatment, including PRD: 
To design and commission pathways and services that minimise consequences 
and address need  
Begin the assessment and monitoring of patients for consequences of 
treatment during the active treatment phase, and continue for as long as 
necessary  
Empower patients and primary/community care professionals to manage the 
consequences of treatment  
National Cancer Survivorship Initiative (2013) 
Many of the papers examined referred to the above document in their introduction, 
demonstrating that in England at least, healthcare teams are recognising the need to 
address the area of consequences of treatment. The NHS England (2015) Cancer 
Strategy also recognises the need to identify research priorities for late effects of cancer 
treatment, and then to make sure the research is undertaken. The NHS Wales logo and 
endorsement did not feature in the document, despite it being led by the National 
Cancer Survivorship Initiative, suggesting that perhaps Wales will follow the Cancer 
176 
 
Delivery Plan for Wales 2016-2020, with the limited mention of late consequences of 
treatment as shown above.  
Despite the Government documents declaring that cancer care does not finish at the 
time the treatment ends, the literature continues to show a general lack of awareness 
among healthcare professionals.  An online survey of GP’s attitudes towards cancer 
survivorship care was undertaken by Walter et al (2015). Only 29% of the 500 
respondents felt very confident in managing treatment related side effects, of all cancer 
treatments not just pelvic radiotherapy. Despite the recommendation of undertaking 
Cancer Care Reviews, as recommended by the National Cancer Survivorship initiative 
document (2013), only just over half felt they were useful, although those GPs who used 
a pre-set template to undertake the review were more likely to find the whole process 
beneficial. They did however feel that further education in this area would be beneficial. 
The participants in my study did not comment on whether they had a Cancer Care 
Review. Jason commented that his GP would not listen to him despite being sure there 
was a problem and attending the surgery repeatedly. Others, including Tony and Bev, 
had better experiences. They both mentioned that their doctors had acted quickly when 
ongoing problems were discussed. It was evident that the participants’ stories and 
journeys very much depended on the way their GP dealt with them when they began to 
have problems. 
It is not only primary care however where awareness of late effects is poor. Henson et 
al (2011) conducted a study to examine awareness of late GI effects among clinical 
oncologists who undertook pelvic radiotherapy.  Although the Oncologists recognised 
that a significant proportion of their patients went on to experience late GI effects, they 
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generally did not know how best to manage them. Indeed, 55% said that they would 
manage rectal bleeding symptoms with steroids, a practice which is now known to be 
ineffective (Stacey and Green 2013). The ability to refer such patients on to specialised 
gastrointestinal services was inadequate. Over half of the respondents did not have 
access to anyone with a specialist interest in late effects. 90 % of the oncologists who 
took part felt this was a vital service provision requirement. In my study, Jenny had also 
found a lack of awareness amongst the oncology follow-up team. She commented how 
she saw different people each time she went and even though she mentioned her bowel 
problems to them nothing was acted upon.  
In a follow up study, Henson et al (2012), gastroenterologists were asked about their 
confidence in treating people with late GI effects. Just 47% said they were “confident 
treating basic cases” (p.2131). It was also noted that any cases they encountered were 
few and far between, meaning that they did not feel able to develop any form of 
expertise in the area. The study concluded that there needed to be improved 
development of and access to such specialist services.  
It is evident from the above discussion that there is non-uniformity of healthcare 
provision regarding where people are most likely to have their concerns of late GI effects 
identified and directed to the appropriate care. A qualitative study by Brown et al (2016) 
examined patients’ knowledge about late effects of treatment for colorectal cancer. 
Using framework analysis, they identified three main themes; merit of self-
empowerment, the importance of a teachable moment at the end of treatment and the 
value of MDT working. They identified that with the support of the MDT, patients could 
be educated and supported towards the end of their treatment and empowered to 
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know how to look after themselves and identify when they needed to seek expert care. 
However, they found that most participants felt they had been insufficiently warned 
about late effects of their treatment and that often they had received what they called 
“false reassurance” (p. 196) from clinicians, that any such problems would settle 
eventually without treatment. The authors concurred with Harrison et al (2012) and 
one’s personal observations from the above discussion that if clinicians themselves did 
not fully understand the consequences of treatment, then they could not be expected 
to adequately inform patients of the possibility of such problems. Although a valuable 
paper on the issues surrounding identification of late effects, no mention is made of the 
need to identify specialist referral centres for those requiring further investigation, but 
merely expounds the value of self-care.  
Taylor et al (2012) also examined follow-up for people after colorectal cancer care, 
specifically looking at the role of the health needs assessment, and the role it could play 
in identifying late effects of treatment. They suggested that a “Post Treatment Clinic” 
was the ideal place to identify any on-going issues. It was noted that people who had 
recently completed their treatment had more problems than those who had finished a 
while ago. The authors also found that a benefit of using the HNA was that more in-
depth discussions could take place around areas most concerning the patients, be that 
physical, social or psychological. Two main issues are raised regarding using the HNA at 
an early clinic. Firstly, the HNA needs to specifically enquire about late GI effects. In the 
development of my own clinical role, the expression “don’t ask, don’t tell” has been 
heard numerous times, specifically when clinicians were discussing what to do if patients 
mentioned problems that, at that time, had no direct referral route. Patients will often 
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not talk about things they find embarrassing unless specifically asked. Harry’s wife Gwen 
had commented in their interview that she felt healthcare staff should ask about 
symptoms rather than waiting to be asked, although Harry himself answered saying 
“well unless you tell them I suppose… you know…”. It seems that even a close married 
couple are unable to agree whose duty it is to make sure the problem is aired. Studies 
of late effects of cancer treatments involving other organs identified similar problems; 
sexual problems following gynaecological and prostate cancers were often not openly 
discussed by patients and it was deemed necessary to include specific questions to 
address potentially sensitive issues (White 2015, Sekse et al 2010, Fernandes et al 2015 
and Jakobsson et al 2000).  
Secondly, it has been shown that late GI effects of cancer treatment can occur up to 29 
years after completion of treatment (Dunberger et al 2010, Andreyev 2007 and Olopade 
et al 2005). Therefore, if the HNA is only conducted as early on as within the first six 
weeks of treatment completion, as suggested by Taylor et al (2013), then it can be 
concluded that many patients will not have begun to experience late-onset symptoms 
and so could be missed.   
The best time to discuss the issues of late consequences of treatment is unclear, even 
before treatment is given. Bev recalled being given a consent form to sign before her 
treatment and recalled that it may have mentioned side effects, but felt that her only 
priority at that time was to give whatever consent was required to try to survive her 
cancer diagnosis. Doyle and Kelly (2005) believed that by developing a treatment and 
aftercare plan early after the initial diagnosis, then discussing issues such as potential 
consequences of the intended treatment could be a more formal process. By treating a 
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cancer diagnosis as a chronic disease, rather than just the acute episode, then long-term 
health needs can be better anticipated and catered for (Phillips and Currow 2010). 
Taylor et al (2013) also identified that managing patients’ expectations regarding their 
long-term symptoms should be a priority before the onset, ideally well before treatment 
commences. They believed that educating patients about normal bowel function and 
how this can be interrupted by the cancer treatment can be a helpful intervention. 
Husson et al (2011) and Nikoletti et al (2008) recognised that addressing the issues early 
on may reduce uncertainty, improve coping with bowel changes and prompt more 
timely access to treatment of late effects when necessary.   
To facilitate identification of people experiencing late GI effects, a study group was set 
up to create a tool, quick and simple enough to be used at any healthcare episode. This 
was discussed in detail in the literature review. The ALERT-B Tool (Assessment of Late 
Effects of Radiotherapy- Bowel) (Taylor et al 2016) (See table 10) has provided a 
validated screening tool that can be used in clinical practice to trigger a referral to a 
gastroenterologist for investigation into late GI effects of pelvic radiotherapy. Four 
simple questions identify individuals for whom further investigation may be beneficial. 
If the person responds “yes” to any question then further conversation can be had 
regarding the potential for specialist referral.  
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Diagram 8 - Alert B Tool 
 
Another reason why simple tools such as the ALERT-B may be so useful is the current 
failure to identify accurately which patients may go on to develop significant late effects.  
A systematic review of prediction models examined fourteen studies where statistical 
methods predicted the risk of developing late effects (Salz et al 2015). These were not 
restricted to GI effects but included all known late effects of cancer treatment. The 
reviewers noted that only two of the studies used validated prediction tools, and that 
these were rarely accurate in predicting who would experience severe late effects. 
Therefore, a quick and easy tool could help to ensure that a vast group of patients could 
be screened to identify late GI Effects. In the local area, all GPs now have access to the 
ALERT-B tool, with many choosing to display it in the patient waiting rooms so in effect, 
people have the opportunity to ‘self-screen’.  
Finally, ongoing attempts are being made to reduce the direct radiotherapy damage by 
refining the target dose. Nicholas et al (2017) discusses how adaptations to radiotherapy 
Following your pelvic radiotherapy: 
 
1. Do you have difficulty in controlling your bowels? 
2. Do you have bleeding from your bottom? 
3. Have you had to adapt your lifestyle because of your bowel or tummy 
problems? 
4. Do your bowel or tummy problems affect your mood, social functioning or 
relationships? 
Taylor et al (2016) 
See Appendix 10 for the complete tool 
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techniques are showing dose reductions to healthy tissue, and it is anticipated that 
newer radiotherapy techniques will minimise normal tissue exposure to radiotherapy, 
so reducing late effects (Macmillan 2016). Andreyev et al (2012) believes however, that 
more targeted treatment will only alter the time and severity of effects in the GI tract. 
A recent study by White et al (2018) appears to confirm Andreyev’s concern. The study 
examined the use of new technology volumetric modulated arc therapy that reduces 
the radiation dose to the organ itself, although results in a larger full body dose. It was 
anticipated that the reduced radiotherapy dose for gynaecology cancers would 
therefore reduce the number of late GI effects. Unfortunately, there was no reduction 
seen in the level of GI toxicity compared to conventional radiotherapy techniques and 
this is an ongoing area for research. 
In conclusion, the literature has shown that there remains inconsistency as to awareness 
of the consequences of cancer treatment amongst healthcare professionals. In addition, 
there does not seem just one single method of ensuring the patients’ experience of late 
effects is heard unless they are specifically asked. People like Harry may feel 
uncomfortable raising the subject and so it is important that healthcare professionals 
ask the patients themselves, either verbally, using a prepared tool, such as the ALERT-B 
or Macmillan’s HNA, or a combination of methods. Increasing patient awareness may 
also empower them to recognise when they are experiencing late effects and to seek 
advice form the healthcare provider at the time. 
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Support 
The participants in this study had a variety of support structures in their lives. Some, like 
Harry and Gwen were married whilst Bev was divorced but spoke warmly of her son and 
close friendships. As discussed, the element of ‘teamwork’ was clear amongst the 
couples interviewed. There were however a few notable, yet barely visible, 
demonstrations of frustration between the couples, where there seemed a mismatch of 
expectations.  
There were relatively few articles looking at issues of on-going family and friends’ 
support of long term cancer survivors, although there was work on the need for some 
form of support in one form or another. The family/friends support for participants in 
this study was demonstrated in the term frequently used- “we” (did this, went there.. 
etc.), indicating a joint approach. This was demonstrated by both the couples and those 
interviewed alone. Mellon et al (2006) found that those cancer survivors who had a 
greater element of social support described a higher quality of life than those who were 
less supported. In their study of 123 cancer survivors with an average of three years 
post-diagnosis, they found that those participants who were married identified higher 
QoL than those who were not. The authors suggest that marriage may offer some 
protection from the stresses of cancer. It would be wrong to even try to identify a similar 
theory from my own study, due to small numbers and study design. From this study it 
was noted that each participant commented on the benefit of support they received 
and it was not noted to be particularly relevant whether this support came from a 
spouse, other close family or friends.  
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From the same study as that discussed above, Mellon (2002) found that although the 
person no longer has cancer, the effects of having had the cancer were long lasting. This 
was often due to late effects such as fatigue but also due to changes in the dynamics of 
relationships. These changes were positive and negative; positive because of a chance 
of a new future ahead but also negative due to ongoing concerns having had cancer. 
This potential change in relationship appeared evident with Harry and Gwen. Although 
they physically demonstrated to me a loving relationship, with hand holding, facial 
expressions and stories of concern, it was also evident that Gwen was struggling with 
the change in Harry- 
Gwen: “Yes, frustration as much as anything you know because you feel 
impotent because you can’t do anything, if I say anything he gets his knickers in 
a twist you know… This is why I haven’t clocked you one before….I mean my 
daughter gets upset because he won’t even go over to her house for a cup of 
coffee or whatever..”  
Gwen appeared to find the impact of Harry’s problems difficult to cope with and clearly, 
they had previously had words about this. Maybe it was affecting her own activities, and 
certainly she noted that it also was upsetting her daughter. Perhaps Mellon’s (2002) 
observation that the ability to carry on as normal was important, explains why Harry’s 
inability to do so was causing some conflict between him and Gwen.    
Jefford et al (2008) utilised a focus group to look at the perceived needs of twenty-two 
cancer survivors and twenty participants from various groups of healthcare 
professionals. It was noted that there was a perception of loss of support from the 
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hospital staff once cancer treatment was over and that participants felt they were being 
told, by the healthcare professionals to “go back to your life” (p. 23). This was noted to 
be difficult to do, particularly if they had ongoing effects of the cancer treatment such 
as fatigue, anxiety of cancer recurrence or late effects from the radio/chemotherapy. 
Bev noted that this expectation to ‘get on with things’ was part of her experience, and 
was causing difficulties. Having previously been a very sociable person, Bev was now 
struggling keeping up the persona she once had. She had commented a few times that 
her friends felt that now the cancer treatment had finished that she should get on with 
her life and that “I should be my normal self now” (line 220). In a study looking at issues 
of cancer survivors returning to work, Nachreiner et al (2007) found that Bev’s 
experience was typical.  Friends and work colleagues tended to judge one’s ability to 
carry on with their life depending on how they physically looked. Two examples of this 
are the comments- “like, you’re fine now, aren’t you?’ and “I heard tons of ‘you look 
wonderful’, ‘you look fantastic’ and ‘I can’t understand why you’re so tired’” (p. 293). 
The fact that people like Bev also felt the need to hide was they felt were stigmatising 
symptoms, meant that friends and colleagues were even less likely to know that 
something was wrong; Bev was hiding how she felt, so people thought she should be 
back to normal.   
Whilst looking at the literature about support after cancer treatment, one element 
found, that was not identified in this study, was the role that support networks can have. 
Taking place whilst being physically present in a room or through on-line groups, this 
seems to be a place where many found others in similar situations to their own. Ussher 
et al (2006) examined the role of peer support groups, although participants were either 
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still undergoing or had recently completed cancer treatment. The authors examined 
multi-cultural studies regarding such support mechanisms which identified consistent 
findings; people found it helpful to identify with others going through similar 
experiences. In their own study, participants commented that they could say things to 
others in the group which they could not say to their own family and friends; 
‘Oh, I’ve gone to meet someone and they make excuses to get away from you 
because they don’t want to hear what you’re going through, whereas here, 
everybody listens and everybody talks”  
Ussher et al (2006) p. 2569 
There may be several reasons why the participants in the study did not mention such 
support groups. Firstly, they were not actually asked if they had used such groups. There 
is only one group for people with late effects of radiotherapy that currently exists, and 
this is generally publicised and managed via the internet. Most participants were at least 
in their mid-seventies and so may not be computer savvy. Also, it maybe that the timing 
of study participation was not suitable for attending this type of group; the participants 
were asked to share their experiences soon after referral to the late-effects clinic and so 
it may have been too soon for them to be thinking about alternative support and 
perhaps they were busy concentrating on coping with their physical symptoms. 
Whatever the reason, the benefits highlighted in Ussher et al (2006) show an element 
of support that may be useful to consider in the future for supporting people with late 
GI effects of radiotherapy.  
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Findings conclusion 
When considering the participants’ experiences and referring back to the FA utilised for 
this study, the link that holds them all together is the participant and their partner, if 
present. Each of the three main themes, stigma, healthcare and support, impacts on the 
other and ultimately, the participant. Each of the participants spoke about the stigma of 
experiencing late GI effects of radiotherapy. As Goffman’s’ (1963) work showed, bowel 
function in particular is highly stigmatising.  People with such symptoms after cancer 
treatment find this problem extremely difficult to cope with, both physically, socially 
and psychologically. For those whose cancer was not involving their bowels, it was likely 
that they did not have bowel symptoms prior to their treatment. As Ken said, “they’ve 
cured one thing but given me another.” (line 104).  
 
The participants’ experience of healthcare during the initial stages of recognising late 
effects of the cancer treatment was often not a positive one. They often had to return 
time and time again to access the help they needed. Their GP and even the oncology 
teams often did not recognise there was a problem. This issue was identified in the 
literature, and further adds to the distress of the patient. The apparent lack of 
awareness amongst HCPs of PRD further adds to the perceived stigma. The participants 
often found it difficult to talk about the symptoms, particularly if they felt they were not 
being acknowledged. By having to talk frankly about the distress and impact of their 
bowel problems, seeking the help they knew they needed, may have made the 
embarrassment even more acute.  Practical considerations by HCPs were sometimes not 
seen. Ruth’s experience of feeling intense pain when sitting on hard chairs at the cancer 
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hospital could have, and should have, been identified prior to her interview. It was not 
clear why this was allowed to happen, but it has since been rectified as a direct result of 
this study. 
 
The third element of support equally impacts upon the issues of healthcare and stigma. 
The main origin of support available to the participant was family and friends. Yet, due 
to the stigmatising nature of the symptoms, the participants often tried to hide their 
problems, particularly from those from whom it was possible to hide: their friends and 
family who did not live with them. This meant that they sometimes felt isolated, which 
worsened feelings of shame and depression. If HCPs are unaware of the potential of late 
GI effects, then the ability to support this group of people will be limited. Other forms 
of support such as peer groups have not been widely available for this group of people 
and this is an area that warrants further exploration. 
 
The FA encouraged identification of the participants’ experiences of PRD around three 
main themes noted in the literature and the interviews as being of greatest significance- 
stigma, healthcare and support. Each of the participants had stories to tell of how these 
issues had affected them, their family and friends. The symptoms of PRD caused 
significant distress resulting in many different expressions of impact on their everyday 
lives. Their contacts with healthcare services had not always been positive, mainly due 
to delays in identification of PRD, lack of knowledge by the HCPs they met and lack of 
information about potential problems on completion of radiotherapy. Family and 
friends were a great source of comfort to the participants but there were often times of 
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frustration on all sides, mainly due to the ongoing nature of the symptoms when 
everyone was hoping the cancer journey had been completed. PRD was found to be a 
difficult condition to identify, to ensure the appropriate investigations and treatment 
was provided and that resulted in a significant impact on the participants’ lives.  
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Chapter 7: Conclusions  
 
As this thesis draws to a conclusion, the aims of this study, the findings and the 
discussion of the issues around findings will be examined. The limitations of the study 
will be discussed, and also the contributions to better understanding, demonstrated. 
Recommendations for practice will then be made, and the thesis completed by outlining 
the benefits already obtained through the development of the thesis on both a personal 
and clinical level. The aim of the study was to gain an insight into the participants’ 
experiences of living with PRD and to achieve this, the objectives were:  
  
• to consider the current literature surrounding PRD and to identify gaps in 
knowledge  
   
• to provide an insight into the experiences of living with PRD. This included the 
physical, psychological and social impact, examining what this means for the 
person and their friends and families  
 
• to develop recommendations that encourage the identification of people with 
PRD, through the use of existing guidelines and assessment tools. This included 
promoting access to HCPs with specialist knowledge of PRD, so enabling 
appropriate assessment and treatment, as well as further support for those 
people affected 
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The literature review looked at PRD, including how the disease came to be recognised, 
what the symptoms are and how they were ideally investigated using an algorithmic 
approach to enable diagnoses of individual conditions. PRD following the three main 
pelvic cancers, prostate, gynaecological and colorectal, was found to be not uncommon. 
Various QoL scoring tools were used although very few allowed the patients to talk 
about their experiences. Despite growing numbers of studies concerning late effects of 
cancer treatment, there was a significant lack of awareness of PRD amongst HCPs. This 
included oncologists and gastroenterologists. Faecal incontinence was frequently found 
to be a major problem for people with PRD often resulting in difficult experiences which 
caused feelings of distress and shame.  
 
The framework identified three main issues: stigma, healthcare and support.  Stigma 
was found to be a major issue for each of the participants. This impacted on their lives 
in different ways. Some like Bev tried to hide it and attempted to carry on as normal, 
whereas others like Harry and Ken experienced such major changes in their lives that 
they felt unable to continue as they were and instead carved out a new way of existing. 
Both coping mechanisms had positive and negative elements. Bev still had a generally 
active social life although this was often based around where the toilets were and she 
had little support as she chose to hide her problems from her friends. Harry on the other 
end of the spectrum decided to not go out. In this way he avoided embarrassing toilet 
accidents but also upset his wife and daughter as he withdrew from family occasions. 
Bev, Harry and the other participants each developed coping mechanisms to continue 
their lives, although with varying levels of satisfaction as to how they now perceived 
their existence. When asked how he saw his future, Harry replied “none” (line 185) 
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whereas Jenny was trying to live as normal life a possible- “I love working… the thought 
of staying home.”  (line 132).  
 
Awareness of late GI effects of radiotherapy amongst healthcare professionals was poor. 
More and more people are now surviving cancer and so the issues of consequences of 
the cancer treatment will also grow. The participants had differing experiences of 
seeking help when they began to have symptoms. For some like Tony, the 
acknowledgement of the need for referral to specialist services was relatively quick, 
whilst for others including Garry, Ken and Harry, the experience was very different, with 
each commenting on the need to go back and forth several times before they were 
listened to. Some participants were asked about possible late effects at follow-up 
appointments, whilst others were not. There was disagreement whether it was up to 
healthcare professionals to ask, or if was up to patients themselves to bring it up. There 
was also disagreement regarding how much information about the potential of late 
effects should have been provided; Gary and Bev’s comments on this provide 
explanations as to why there is not a ‘one size fits all’ solution to this issue: 
 
Gary: “You can give some a leaflet and they can read it but you’re not actually 
absorbing that” 
 
Bev: Before the treatment, you sign a consent form. There could be short, long 
term effects. I can’t even, you know….. I signed the consent form because I’ve 
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just been diagnosed with cancer so it’s all too much info sort of to take in, but it 
was very vague anyway, whatever I signed, I can’t remember”   
 
 
Listening to the participants’ experiences highlighted a relatively simple to solve 
problem within the healthcare setting; Ruth’s comment about the hard chairs has since 
resulted in all patients attending for treatment/follow-up of anal cancer, and other 
cancers involving the perineum, being offered an appointment with the Occupational 
Therapists to be measured and advised on obtaining an inflatable cushion. The patients’ 
can then bring with them to hospital appointments and also use elsewhere when 
helpful.  
 
The support from family and friends was clearly important for all the participants. This 
was demonstrated in different ways, from enabling a lie-in some mornings, car lifts to 
appointments, ensuring a good diet and fun nights out. There were several examples of 
how these support mechanisms were sometimes problematic. The effects of stigma 
resulted in the participants hiding their problems from loved ones, resulting in reduced 
awareness and subsequent lack of support. The perceived need to avoid any potential 
embarrassing situations sometimes caused relationship difficulties, where family events 
were affected and spoiled. The participants noted that now they no longer had cancer, 
people were less understanding. They acknowledged that this was because they often 
hid their bowel problems and so others thought they should get back to their normal 
lives. There was a noticeable lack of alternative forms of support, such as peer groups. 
This therefore resulted in only those closest to the participants being aware of the 
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struggles they were facing, thus reducing the possibility of being able to talk freely about 
their problems and concerns, resulting in further isolation. 
 
Study limitations  
Qualitative research is not immune to the criticism of being weak in its method of 
knowledge production (Silverman 2000) and it can be difficult to define criteria of what 
qualitative research is, and therefore how to demonstrate reliability (Hammersley 
2013). There are however, accepted criteria to demonstrate quality in qualitative 
research including credibility, transferability and reliability (Steinke 2004). FA utilises 
these criteria and helps to ensure that the methods and steps taken are documented to 
allow explanation of how the research was performed, such as the identification of 
codes and themes, encouraging clarity, openness and validity of findings.  
 
The decision on which was the most appropriate time point to select and then interview 
the participants was important in order to hear of their experiences prior to any further 
investigations and treatment. The potential group of participants were those attending 
PRD for their first appointment. Prior to this, they were unknown to the clinical team. 
One option would have been to send study information out to potential referrers, to 
allow a wider audience to have the chance to participate. As a single researcher 
however, this would have complicated the process and was therefore not chosen. It was 
recognised though that by only offering the study to those who were being seen for the 
first time may have put some pressure on the clinic patients to participate, even though 
this was addressed in the PIS that they were not under any obligation to participate, and 
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that by not responding, their clinical care would be unaffected. The small sample size 
allowed the study to be more manageable by reducing the amount of data collected. 
This meant that the participants will not have been a full representation of the types of 
people/cancer types affected by PRD. A larger sample size that included a wider range 
of age, cancer types and length of time of experiencing PRD symptoms, may have 
provided more varied narratives, but it was recognised that this was not achievable 
within the confines of this study. The principles of purposive sampling were therefore 
adhered to, allowing a representation of people with the phenomena under 
examination, in this case people who have PRD (Silverman 2000).  
 
The interview process required careful consideration of how best to reduce participants’ 
potential perception that they should provide answers that they felt were expected of 
them. The ethical considerations of ensuring that the participant felt safe in the 
knowledge of confidentiality, that the interviewer’s ‘power’ was not misused and that 
co-construction was appropriately used, were important. At the beginning of each 
interview, the PIS and consent forms were again discussed before signing. They were 
reminded of the confidentiality statements and use of their data, as well as reassuring 
them that they could withdraw at any time without it affecting their clinical care.  Smart 
but relaxed clothing was worn by the researcher, rather than uniform, to help draw a 
distinction between the study and the clinical contact. This was vital as the researcher 
would have by then already seen the participant in a clinic consultation and there was a 
need to reduce any feeling of obligation of the participant to take part, or reduce any 
parts of what they were talking about, especially if it was criticism of care they had 
received. A potential way of reducing this further would have been for a second 
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researcher to perform both the recruitment and interviews, but this was not feasible 
within the confines of this study. Edwards and Holland (2013) spoke of the power held 
by the interviewer in qualitative research. This was necessary up to a point to help guide 
the interview towards the development of required data, but must not be misused and 
the well-being of the participants must be maintained. The recording devices were kept 
out of line of sight as much as possible following the first interview.  It was identified 
when reading the first transcript that the devices were checked several times during the 
interview to check they were working, mostly as an anxiety-driven concern. Not only did 
this interrupt the flow but kept drawing attention to the fact it was being recorded, 
which could then influence how the participant responded.  
 
Co-construction of the interview process can be improved through recognition that the 
interview process is an event between at least two people. Reflection during, and 
following each interview, helps to consider the impact the interviewer’s behaviour may 
have, in both positive and negative ways. Notes taken throughout each interview, as 
well as those written in the office/car immediately afterwards, supported this process. 
One note in particular stood out after both the first and second interview- STOP 
TALKING!!! It was recognised that in an anxiety-driven attempt to get the information 
required, too many questions were asked, silences were immediately filled and the 
interviews were perhaps cut too short to enable it to be finished. The notes also helped 
to reduce bias in subsequent interviews; leading questions were replaced with ones that 
were more open. An example of this was changing “tell me about your symptoms” to 
“tell me about what it was like for you…”. Some researchers choose to re-visit the 
participants for a second interview. This can provide more detail in areas noted after 
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listening to the recordings, or reading the transcripts where particular areas of interest 
are noted. For this study, it was decided that this could further compromise the 
research/clinical relationship. Soon after the initial interview, the participants would 
have undergone investigations and would have had further telephone/face to face 
appointments, and this could have undone the work around reducing any perceptions 
of coercion to take part by the participant.  
 
Transcription of the recordings was done by a typist linked to the university. This was to 
reduce time from interview to transcript readiness, to promote recollection of non-
spoken occurrences, such as participant and partner hand holding, glances and smiles 
and so on. Undertaking one’s own transcription however, may have helped to develop 
analysis earlier on and allowed more linguistic transcription to be made, noting voice 
tones, laughter and sighs to be placed within the transcription. Applying language study 
to the analysis would have increased the work load enormously, and this was not time 
that was available, although may have provided an additional useful viewpoint.  
 
FA provided the structure with which to examine the data. Gale et al (2013) highlights a 
number of limitations to using this method. The framework approach may encourage 
novice researchers to apply quantifiable measurements to their findings, such as “50 % 
of the participants said….”. Even though the step-by step approach directs the process, 
it may also encourage an over-reliance on ‘rules’ rather than encouraging a freedom to 
interpret the data. The perception of it being an easy method, due to the step-wise 
guidance, could also result in new researchers misapplying the steps if adequate training 
is not provided. The research education received in the first two years of the 
198 
 
Professional Doctorate went some way to addressing this, as did the support of the two 
supervisors throughout the study. The approach can be time heavy, as with all 
qualitative data. By using the services of the professional transcriber, this helped to limit 
the length of time to transcript production.  
 
Involving a second or more researchers in the coding process is a common feature in 
larger studies and helps to harmonise perceptions of what each code means. Saldaña 
(2016) identifies that as “inter-coder agreement or interpretive convergence” (p. 37) and 
encourages consistency and reliability. Galman (2007) in Saldaña (2016) however, 
recognises the benefit of the lone researcher- being “intimately involved with her data” 
(p. 36). During the development of the FA, the large art pad that was used to present 
the data in a visual way was discussed at supervision meetings and an explanation of 
codes and FA process development agreed. Interpretation of both the codes, 
development of the framework and analysis were explored jointly throughout the 
process.  
 
Original Contribution to knowledge  
This research has provided an original contribution to the knowledge of the experiences 
of people with PRD that has not been previously demonstrated. The literature review 
recognised that whilst the symptoms of PRD have been extensively explored, there was 
very little awareness of what it is like to live with this disease. While QoL scores are 
included in many of the research papers, the progression from symptom identification 
to patient experiences has not been determined. The FA was developed from the 
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literature, applied to and refined through the first few interviews and then applied to 
the interview transcripts. The study found that the participants experienced significant 
problems with various issues around stigma, healthcare and support, and these issues 
had not been particularly recognised and/or discussed in previous studies looking at 
PRD. 
 
• People with PRD experience a significant impact on their everyday lives. This 
includes various distressing feelings of stigma, which results in depression and 
social avoidance. Current QoL scores are useful in identifying symptoms but 
often do not offer the opportunity to learn of the impact these symptoms have 
on the patients’ lives, thus resulting in an unmet need.  
 
• Getting timely access to appropriate healthcare services for identification, 
investigation and treatment for PRD is often a slow, difficult and frustrating 
process. Although there has been improvement in HCPs knowledge of PRD over 
recent years, the general level of awareness remains poor. This inevitably 
impacts upon the patients’ ability to receive timely assessment, investigations 
and treatment for PRD.  
 
• A sense of teamwork provides a great deal of support for people with PRD, from 
their family and friends. These relationships however can be strained due to the 
on-going nature of PRD following completion of cancer treatment and patients 
may notice a drop off in their support systems over time. Cancer charities such 
as Macmillan have made significant developments in the support of people with 
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late effects of cancer treatment, however it appears that patient awareness of 
this information and support services, may be poor.  
 
Recommendations for future research 
Further research into the barriers of HCP awareness of PRD would be useful. This could 
then be used to design an educational programme to improve the identification of those 
people who may be at risk of developing PRD, to improve recognition of those with PRD 
and to then have the knowledge of where to refer onwards for appropriate care. Further 
understanding into the complex psychological needs of people with PRD would also be 
a useful area for further research. These are a group of people who have already 
undergone the trauma of a cancer diagnosis and subsequent treatment. Just as they 
anticipate that their lives are about to return to some sense of normality, they then 
experience distressing symptoms which often go unacknowledged and untreated. 
Support from family and friends is important throughout this time and yet, due to all the 
support given during the cancer treatment, there may be a reduced level of support 
available. Understanding the best way to offer support, such as one to one counselling, 
group therapy or perhaps on-line sessions, would go some way to helping these people 
through a difficult period in their lives.  
 
The following diagram outlines the steps of the whole study, ending with a summary of 
the key recommendations that are addressed in more detail in the subsequent section. 
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Diagram 9 - Study Outline 
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Key recommendation 1: 
Further research is required to examine what are the psychological needs of patients, 
family and friends and what is the best way to support them. It is clear that this is a 
group of people who have difficulties that are unlike people with other bowel 
conditions. There needs to be a continuous drive to promote the needs of people with 
PRD. This includes identification of research needs and the ability to take these forward 
to develop robust studies. The publication of articles and studies around PRD will 
encourage the growth of awareness amongst HCPs and so ultimately, an improvement 
of services.  
 
Organisations such as Macmillan, Prostate Cancer UK and Cancer Research UK play a 
tremendous role in providing information, support and research funding for cancer. It 
would be helpful for them to consider a national campaign to raise awareness of PRD 
and other late effects of cancer treatment, particularly considering the significant 
number of people surviving their cancer diagnosis as presented at the beginning of this 
thesis.  
 
Key recommendation 2: 
 
There is a need to change policy and practice in managing patients pre and post 
treatment, using evidenced based research. This study has identified several areas 
where policy and practice could be improved: 
 
Pre-radiotherapy 
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Some of the participants had mentioned the lack of information about the potential of 
late effects of the radiotherapy treatment. They did however recognise that often the 
information that was given to them may not have been fully absorbed because at that 
time their main priority was treating the cancer with the sole aim of survival. To meet 
the differing and changing information needs of people throughout their diagnosis, 
treatment and follow-up care, it may be helpful to ensure that a wide range of 
information is available, perhaps through a list of topics/titles given to them, a display 
of leaflets/booklets at clinics and to ensure the patient has a point of contact to discuss 
any concerns over the weeks, months and years of their cancer journey.  
 
Oncology follow-up 
As well as the Holistic Needs Analysis being undertaken, other screening tools such as 
ALERT-B should be used to identify people with PRD. All tools, but particularly general 
QoL tools, should be only used as a basis for further discussion about the impact of 
symptoms, rather than simply a disease status gathering exercise.  
 
Education and awareness must be improved for primary and secondary care health 
organisations, including GPs, Practice Nurses, Oncology HCPs, radiographers, CNSs, and 
endoscopists. This could be done by presentations at training days and meetings, 
newsletters for professional groups, such as GP clusters and posters for staff rooms and 
patient waiting rooms. This then links into the final recommendation that investment is 
necessary to achieve these changes  
 
Key recommendation 3: 
204 
 
In order to improve services for patients with PRD and their families, there is a level of 
investment necessary. As well as services such as the clinics mentioned above, there is 
a need to consider the diverse nature of this group of patients, as well as others with 
late effects of any cancer treatment.  This must take into consideration specific needs 
such as difficulty in leaving the house to attend appointments and so perhaps 
telephone or Skype could be utilised, at least for the initial assessment.  
The third sector also has a strategic role to improve networking for HCPs with an 
interest in PRD. Macmillan has produced several PRD information booklets aimed at 
both HCPs and patients. Raising awareness and providing information in the monthly 
HCP newsletters has already gone some way to achieving this.   
 
 
Secondary care/Gastroenterology Services 
There should be named gastroenterologists in each Health Board/Health Trust with a 
special interest/knowledge in PRD, and involvement made with the specialist 
multidisciplinary group “Macmillan on-line MDT”. These groups should meet perhaps 
yearly to discuss any new advances in diagnosis and treatments, potential areas for 
research and case discussions.  
 
Tick-box forms should be used with care. Although useful to identify specific symptoms 
and to steer the clinical assessment, ensure they are used only as an additional tool and 
not purely for information gathering.  
 
As people with PRD often have a complex medical history and may be experiencing 
significant physical and psychological distress, as highlighted by this study, it would be 
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helpful to ensure ‘new patient’ time slots are of longer length to provide the time 
required for this group of patients.  
 
Ensuring the patient with PRD is seen by the correct HCP requires planning. The referral 
letters should be carefully vetted and the appointment made in a clinic where specialist 
interest and knowledge is available. For example, have a dedicated PRD clinic code, to 
prevent the appointment being made in a junior Registrar’s clinic. These clinic codes can 
then be used to generate the longer ‘new patient’ slots as suggested above. This will 
also help to ensure these patients are seen promptly, and by the appropriate clinician, 
rather than simply being added to the general waiting lists.  
Links should be developed and maintained with specialist services that will be able to 
provide additional assessment and support to people with PTD. This includes 
physiotherapists, dieticians, psychology services and colorectal/pelvic floor services. 
 
A personal reflection  
The development of this thesis has provided rich experiences and learning opportunities 
unlike that which have been achieved throughout my career until now. As well as the 
benefits personally afforded, small changes and improvements have already begun to 
emerge that will, I hope, ultimately go some way to improving the experiences for those 
with PRD. This section will discuss these changes, and it will be explained how I believe 
this thesis has already demonstrated a benefit, at least to me as a passionate clinical and 
now academic nurse.  
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Personal achievements 
Having undertaken several degree level courses over recent years I was comfortable 
studying and writing to the required standards. Working towards the Professional 
Doctorate has however taken this to a whole new level. I think I may have declared 
several times to my husband that if or when I attend the graduation ceremony, I will be 
receiving an award for persistence and resilience. My mantra has become “this is a 
marathon, not a sprint”, words that have been repeated at most fellow student group 
get-togethers. I have developed my study skills, learning that ‘little but often” has been 
the way forward. Ideas and direction have often come to me whilst in the strangest of 
places, often when I am most relaxed. This has resulted in me carrying either my journal 
or a note pad with me wherever I go, although I must admit that many of my night-time 
written notes have become illegible by the morning. This may sound to some that the 
process has been unpleasant, but although difficult at times, it has been both a pleasure 
and an honour. To be given permission and reason to study a fascinating topic so in-
depth and one that is trying to achieve improvement for others, has been a remarkable 
opportunity for which I am extremely grateful. Having to do all the studying in my 
evenings, weekends and holidays has been a struggle, but one I believe that has been 
worthwhile.  
 
My now grown-up children and I have studied together; both have completed or almost 
completed degrees during my own time at University. We have all studied together, 
procrastinated together and achieved together, taking it in turns to ‘give up’ and then 
to pull each other through. What a wonderful experience this has been. Moving 
207 
 
forwards, I would say that I have definitely caught the ‘research bug’ and as a clinician, 
my next challenge will be to find a way of combining my new passion for research with 
my life’s passion of nursing.  
 
During my time working towards this award, my clinical career has progressed rapidly. I 
have become the clinical lead for IBD, not also for my Health Board (HB), but also as the 
lead nurse on an all-Wales IBD Development project. My endoscopy skills have also 
improved significantly; I am the first nurse in my HB to move from flexible 
sigmoidoscopy to colonoscopy. Throughout this I have also developed my work within 
the world of PRD, being the only nurse in Wales, and one of only a handful in the UK, 
within this specialism. 
 
Having little allocated time with which to do this has been difficult, but using the 
knowledge I have gained from developing my other clinical roles has taught me to be 
political and savvy to ensure the service can withstand an on-going difficult period in the 
NHS.  
 
Patient care achievements 
From the very first interview for this study, my interaction with my patients has changed. 
I thought I knew nearly everything there was to know about bowel problems, given my 
long GI nursing career but as a result of this study, I now have a greater understanding 
of what it might mean to live with bowel problems, and the effect this can have on 
people’s lives. Usually working within a busy clinic, many consultations begin with the 
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patient completing a symptoms assessment tool. This is a tick-box form, enquiring how 
troublesome various symptoms are, such as diarrhoea, incontinence and urgency. On 
the back is a small Likert-scale question- asking “how much does this affect you”? Prior 
to the study interviews, I would concentrate on the symptoms, as after all, I felt the 
patients were there for me to resolve their symptoms, to find out what was wrong and 
to correct it. Since interview 1, I have changed my viewpoint and the way I conduct the 
clinic consultations. I now believe that an important part of the patients’ first attendance 
at clinic is to have their symptoms, and the impact of these on their lives, acknowledged. 
I am frequently asked “am I the only one like this”, and now I believe that I can address 
their concerns in an entirely different way.  
 
With some shame, I now acknowledge that before interview 1, I wrongly assumed that 
the bowel symptoms only occasionally affected their lives causing minimal disruption. 
After all, having incontinence would affect anyone’s life to some extent. Having now 
gained a deeper insight into my participants’ experiences, having heard their stories, 
been a witness to the distress and shame this has caused, I feel that I can support my 
patients in a different, more insightful way. Although the tick-box form is still used as it 
supports application of the guidelines algorithm, I now use it as a platform to guide the 
consultation. The way I ask the questions has changed; previously I would enquire how 
often they have FI; I now ask, “What affect does having FI have on your everyday life?” 
The detail of their answers has now changed from a numerical total of FI incidents, to a 
deeper explanation, and therefore understanding, of the effect of their FI; does it stop 
them going out? Does it mean they have had to give up work?  
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Over the last year or two, I have noticed a change in the way my patients respond at this 
first clinic appointment. Tears of relief that finally someone is really listening to them 
are frequent. I have been told that I am the first person they have spoken to that 
understands. What an honour that is. I have been able to share stories of others’ 
experiences, of the bad times, but also the good. The hope that this can bring is priceless. 
I have learnt that tick-box forms have a place, but listening, really listening and asking 
about impact and experience is what makes the difference.  
 
The findings chapter revealed that Ruth talked about the hard-plastic chairs in the 
follow-up radiotherapy and oncology clinics. Ruth and her husband had joked about 
having to fight for the one soft chair in the department. Following that interview, I 
contacted the team in charge of the department to discuss this experience.  A small 
group including myself and departmental nurses, radiotherapists and occupational 
therapists (OT), collectively discussed how to improve this situation. From then on, each 
person attending their first appointment for radiotherapy that was likely to include the 
perianal area was assessed by the OT. Soft, inflatable cushions are now provided, or 
suggested for purchase, which the patient can keep for hospital and home use. Unless I 
had specifically asked Ruth to tell me of her experiences, it is likely that this issue would 
not have been raised or addressed. If my research provides just that one benefit alone, 
then I believe I have made a difference, however small this may seem.   
 
Having published an article in a peer-reviewed journal (Ludlow 2016), I have been asked 
to present my work on several occasions. As discussed in this thesis, the consequences 
of cancer treatment are a growing area of interest amongst relevant clinicians. I have 
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been invited to present my clinical work and research findings at two conferences where 
they hope to develop similar services. The objective of my presentations is not only to 
discuss the practical aspects of setting up such a service, such as the tick-box forms, but 
to impress upon the audience that, from the very outset they need to enquire about and 
include the patients’ experiences in the consultations. As busy clinicians, it is often too 
easy to see the patient in front of you as just another set of symptoms, a puzzle to solve, 
but they are human beings with stories to tell.  
 
Due to my PRD nursing role and this research project, I was invited to take part in the 
final research priority workshop for the “What is Living with and Beyond Cancer Priority 
Setting Partnership”. Supported by the James Lind Institute, this project was led by the 
National Cancer Institute and was as a direct result of the NHS England (2015) Cancer 
Strategy that includes the need to identify research priorities for late effects of cancer. 
Using the knowledge gained in this thesis on the significant impact of PRD on my 
participants’ lives, I could ensure that the need for further research that would support 
this group was high up in the list of research priorities. This included improving the 
understanding of why late effects happen, to support improvement in treatment 
delivery and so reduce the risks of late effects happening, as well as improving the lives 
of those affected. I have also been involved in updating the Macmillan Late Effects 
booklets, ensuring that the suggestion to inform their HCPs about symptoms that affect 
their everyday lives was included.  
 
Lastly, one insight I have gained from studying the experiences of my participants is that 
they have different stories to tell than people with other bowel conditions, such as IBD. 
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Patients attending the PRD clinic frequently tell me that their bowels were fine before 
the cancer treatment, and indeed this is an important question so ask when trying to 
assess when their symptoms developed. I recognise this group as people who had no or 
few bowel problems prior to their cancer treatment. The very treatment they received 
for their cancer has now left them with often devastating bowel problems. Jon’s story 
has stuck with me in particular. As described in the findings chapter, the tale of 
humiliation at the airport sums up the devastation of the effects of PRD: 
 
John: “At the time I wished there was a big hole and I just could have been 
swallowed up in it” 
 
It is for people like John that I have a strong sense of professional responsibility to play 
my part in improving the care and support available to people with PRD.  
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Executive Summary 
 
The number of people being diagnosed with cancer is increasing year on year. With 
19,088 new cancer diagnoses in Wales in 2015, this was a 10% increase from the 
previous ten years (Welsh Cancer Intelligence and Surveillance Unit 2017a). Cancer 
survival in Wales also continues to grow, with an average increase of approximately 3% 
for both one and five year survival (Welsh Cancer Intelligence and Surveillance Unit 
2017b). As well as radiotherapy treating the cancer itself, there will inevitably be 
collateral damage to nearby tissues. When this affects the pelvis it is known as pelvic 
radiation disease (PRD) . This has a significant impact on the lives of people who 
experience it. 
 
The document above- Guidance: The Practical Management of the Gastrointestinal 
Symptoms of Pelvic Radiation Disease (Andreyev et al 2014) gives a step by step 
approach to the assessment, investigation and treatment of PRD. In findings from the 
EAGLE study (Taylor et al 2016b), where men developed PRD following prostate cancer, 
a Specialist Nurse-led clinic was found to be an effective care delivery model, with 
It’s really disturbing to soil 
your clothing….the 
embarrassment of it all..
Your afraid to go 
anywhere you know 
I wished there was a big 
hole and I could have 
been swallowed up in it I don’t go anywhere 
now, only to bed…
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costings of £117 per clinic visit with a total cost of £2390 for investigation and 
management of these patients. Considering the impact on the patient and their family 
as shown above, this cost could be considered minimal if it allows people to get back to 
their pre-cancer lives.  
Recommendations 
There is a requirement for investment into PRD Services. This includes: 
• A dedicated PRD clinic in every Welsh Health Board, with ability to use innovative 
services such as telemedicine/skype 
• Improved education and awareness of PRD for Healthcare Professionals both in 
Primary and Secondary care 
• Support for research into preventing, identifying and managing late effects of 
cancer treatment 
• Improved support services for people affected by PRD and other cancer 
treatments  
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Appendices 
 
Appendix 1: Literature of QoL Tools Review Table 
 
 Brief Title How QoL Assessed/Tools 
etc. 
Comments 
Das (2010) Long-term QoL after 
radiotherapy for treatment of 
anal cancer 
Questionnaire mailed 
Functional Assessment of 
Cancer Therapy- colorectal 
(FACT-C) 
 
Medical Outcomes Study 
(MOS) Sexual Problems 
Scale 
FACT-C : is self-
administered, 34 items- 4 
domains of QoL: physical, 
social/family, emotional and 
functional & colorectal sub-
scale 
 
MOS: 4 item Q max score 
100, higher score=worse 
sexual function 
Sunesen 
(2015) 
Long-term anorectal, urinary 
& sexual 
dysfunction…Danish multi-
centre 
Questionnaire mailed 
 
Developed own anal-cancer 
specific questionnaire, using 
existing grading resources. 
Parts of LENT_SOMA used 
(for subjective symptoms & 
management/medical 
intervention) 
Part based on the St Marks 
score for faecal 
incontinence 
Symptoms distressed used 
a 4-category verbal scale 
(no, little, moderate or great 
distress) 
 
Engel 
(2003) 
QoL in rectal cancer 
patient’s- a 4 year 
prospective study 
Says Q “administered”- to 
detail of how/where 
Patient invited/consented at 
primary treatment then 
posted questionnaires  
 
European Organization of 
Research and Treatment of 
EORTEC QLQ-30: 30 
questions, 5 functional 
scales (physical, emotional, 
cognitive, social and role 
functioning), global QoL 
measure, symptom 
assessment  
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Cancer (EORTEC) generic 
and rectal & specific Q’s-  
EORTEC CR38- designed 
for rectal cancer patient’s 
questions including body 
image, sexual 
function/enjoyment, future 
perspective, GI & urinary 
problems 
Stephens 
(2010) 
Impact of short-course pre-
op radiotherapy for rectal 
cancer on patient’s QoL 
(Canada) 
Medical Outcome Study 
Short-Form 36 item 
 
 
 
EORTC QLQ-CT38 
IMOS- SF-36 (general 
health Q, 8 subscales 
(physical function, role-
physical, bodily pain, 
general health, vitality, 
social function, role-
emotional and mental health 
EORTEC CR38- designed 
for rectal cancer patient’s 
938 questions including 
body image, sexual 
function/enjoyment, future 
perspective, GI & urinary 
problems 
Bentzen 
(2013) 
Impaired health related QoL 
after chemoradiotherapy: 
late effects 
Q’s sent and telephone 
interview 
EORTEC (QLC-C30) 
EORTEC (QLQ-CR29) 
 
EORTEC (QLC-CR29)- 4 
scales assessing urinary 
frequency, faecal seepage, 
stool consistence, body 
image and also urinary 
incontinence, dysuria, abdo 
pain, buttock pain, bloating, 
anxiety, flatulence, faecal 
incontinence, sexual 
interest, impotence and 
dyspareunia 
Telephone interview- 
structured, pre-defined 
questions, yes/no not at 
all/very much 
Knowles 
(2013) 
Long term effect of surgery 
and radiotherapy for 
colorectal cancer on 
defecatory function and QoL 
Postal questionnaires  
Memorial-Sloan-Kettering 
Cancer Centre (MSKCC) 
Bowel Function Instrument 
EORTC-C30 
EORTC QLQ-CR38 
 
MSKCC- 18 items, 3 
subscales- frequency, 
urgency/soilage/dietary 
Cameron 
(2012) 
A descriptive study of 
functions, symptoms and 
perceived health state after 
radiotherapy  
Pre-treatment surveys 
Post-treatment 
questionnaire via telephone 
European QoL scale- 
EuroQoL: EQ-5D- 5 
 
 
Identical content in pre and 
post treatment surveys 
 
European QoL scale 
(EuroQoL: EQ-5D- 5 
domains of patient function 
(mobility, self-care, usual 
activities, pain/discomfort 
and anxiety/depression and 
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Expanded Prostate Cancer 
Index Composite (EPIC) 
a rating of global health 
state 
 
EPIC- 50 item health-related 
QoL specific to prostate 
cancer patients 
 
Crook 
(1996) 
 
Effect of pelvic radiotherapy 
for prostate cancer…the 
patients perspective  
3 page 20 point 
questionnaire posted 
Questionnaire based on 
questions from an earlier 
study (Fowler et al 1993) 
where post prostatectomy 
patients were asked about 
symptoms via 
mail/telephone/personal 
interview 
Pinkawa 
(2010) 
 
 
Consequential late effects 
after radiotherapy for 
prostate cancer- a 
prospective longitudinal 
study 
EPIC questionnaire was 
used, given at clinic 
appointments  
EPIC- see before 
Nguyen, 
(1998) 
Late effects after 
radiotherapy for prostate 
cancer in a randomized 
dose-response study…….. 
Posted questionnaires 
 
Questionnaires adapted 
from those used by Crook et 
al (1996), Jonler et al 
91994) and Fowler et al 
(1993) 
Nout (2011)  
 
5 year QoL of endometrial 
cancer patients treated in 
the PORTEC-2 trial 
Questionnaires give out at 
1st clinic appointment 
EORTC (QLQ-C30) 
EORTC- see before 
Nout (2009) 
 
QoL after pelvic 
radiotherapy or vaginal 
brachytherapy for 
endometrial cancer- 
PORTEC-2 trial 
Questionnaires give out at 
1st clinic appointment 
EORTC (QLQ-C30) 
EORTC- see before 
Abayomi 
(2009)  
 
The prevalence of chronic 
radiation enteritis following 
radiotherapy for cervical or 
endometrial cancer and its 
impact on QoL 
Questionnaire based on a 
previous study (Bug et al 
(2001) 
Questionnaire was adapted 
from the King’s Health 
Questionnaire (a condition-
specific health-related QoL 
questionnaire to assess 
women with urinary 
incontinence. It was then 
tested for acceptability, 
reliability and validity by 
postal survey. 
Abayomi 
(2005)  
 
qualitative 
 
 
A study to investigate 
women’s experiences of 
radiation enteritis following 
radiotherapy for cervical 
cancer  
One to one interviews at 
home/hospital 
Interviews lasted 30-120+ 
mins. ‘Interviewer guided 
approach’, open questions. 
Covered: experiences of 
diagnosis/treatment, 
problems during/after 
treatment, impact of 
symptoms of everyday life, 
attempts to control 
symptoms, professional help 
sought/received regarding 
symptoms  
Holmes 
(2010) 
 
 
Identifying side effects of 
pelvic radiotherapy 
Posted questionnaire 
developed on the Royal 
Marsden Hospital for 
radiation-induced bowel 
injury 
2 patients reviewed the 
questionnaire and 
amendments were made 
(not said what/why). Note 
made that the questionnaire 
was to confirm level of 
bowel/bladder function but 
did not measure QoL or 
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Comment box on 
questionnaire 
other late effects. After 
some people received the 
questionnaire they rang to 
see if they could have more 
help for their symptoms 
Free-text comment box 
provided useful data 
Atherton 
(2013) 
 
Assessment of patient-
reported measures of bowel 
function before and after 
pelvic radiotherapy…. 
At 4 weeks, 12 & 24 
months: 
  
Bowel Function 
questionnaire  
 
Uniscale QoL measure 
 
 
Content validity 
questionnaire (CVQ) 
 
 
BFQ- created by Mayo 
Clinic to assess bowel 
function after resected rectal 
cancer yes/no answers  
 
0-10 scale (0=as bad as it 
can be, 10= as good as it 
can be) 
 
CVQ- determines 
importance score patient 
rates each BFQ symptom 
on a 5 point scale (0= not v 
important to 5= v important)  
Gami (2003)  
 
How patients manage GI 
symptoms after pelvic 
radiotherapy 
Face to face interview,  30 structured questions. 
Questions developed from a 
previous audit. If patients 
reported a symptom they 
were asked if it affected 
their quality of life  
Gillespie 
(2007)  
 
The clinical needs to 
patients with chronic GI 
symptoms after pelvic 
radiotherapy  
Posted a questionnaire  24 structured questions, 
with option of giving free text 
answers. No in-depth 
explanation of 
questionnaire, but seems to 
ask about impact of 
symptoms on QoL- )no 
effect, very much…) 
 
Henson 
(2013) 
 
Structured GI intervention 
and improved outcome for 
patients with chronic GI 
symptoms following pelvic 
radiotherapy  
Inflammatory bowel disease 
questionnaire (IBDQ) 
 
 
Vaizey incontinence 
questionnaire (VIQ) 
 
 
IBDQ previously used for 
PRD- 32 questions on 
symptoms and effect on 
social functioning and QoL 
 
VIQ- to detect faecal 
incontinence, 7 questions, 
used before with PRD 0-24 
(0= prefect continence 24= 
severe 
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Common terminology 
criteria for adverse events 
(CTCAE) 
 
 
 
Hospital anxiety and 
depression score (HAD) 
 
EQ-5D 
All at baseline, 3 & 6 months  
CTAE- to detect side effects 
of pelvic cancer treatments 
with bowel, bladder and 
sexual domains. Separate 
male/female questionnaires. 
Extensive validation. 0-4 4= 
more severe symptoms 
 
HAD- 14 items, 2 subscales 
of anxiety (HADS-A) and 
depression (HADS-D). 
Extensively validated.  
EQ-5D- 5 item patient 
reported questionnaire plus 
a visual analogue scale 0-
100 for general health state. 
 
Brown 
(2013) 
 
Assessment of long-term 
rectal function in patients 
who received pelvic 
radiotherapy…. 
Bowel function 
questionnaire  
 
 
Uniscale QoL 
BFQ- created by Mayo 
Clinic to assess bowel 
function after resected rectal 
cancer yes/no answers  
 
0-10 scale (0=as bad as it 
can be, 10= as good as it 
can be) 
 
Adams 
(2014) 
The effects of pelvic 
radiotherapy on cancer 
survivors: symptom profile, 
psychological morbidity and 
QoL 
A department al developed 
questionnaire which 
incorporated:  
Late effect of normal 
tissues- subjective, 
objective, management and 
analytical measure- LENT-
SOMA 
 
EORTC QLQ- C30 
 
HAD score 
 
 
LENT-SOMA- a framework 
for assessment and grading 
of late effects due to 
radiotherapy. Male & female 
versions 
 
See before 
 
See before 
Jung (2001) 
 
Quantification of late 
complications after radiation 
therapy  
Questionnaires:  
Modification of EORTEC 
and LENT-SOMA 
 
See before 
Olopade 
(2005)  
 
A modified Inflammatory 
Bowel Disease 
questionnaire and the 
Vaizey incontinence 
questionnaire are simple 
ways….. 
Questionnaires: 
IBDQ 
Vaizey 
LENT-SOMA 
 
See before 
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Bye (2009) 
 
Health related QoL and 
occurrence of intestinal side 
effects after pelvic 
radiotherapy… 
Questionnaires: 
EORTEC QLQ-C36 
 
See before 
NHS 
England 
(2015) 
 
Qualitative 
Quality of life after colorectal 
cancer survivors in England 
 
 
 
 
 
 
 
 
 
 
 
 
 
Postal questionnaire  
Patient recorded outcome 
measures (PROM’s) 
 
Euroqol 5 level (EQ-5D) 
 
Functional Assessment of 
cancer therapy (FACT) 
 
 
 
Social difficulties inventory 
(SDI) 
 
 
Free text comments 
 
76 questions 
 
Eq-5D: Generic health 
related QoL measure 
 
FACT: Cancer specific 
questions from a larger 
survey to assess physical 
and emotional impact on 
QoL-statement scale (no 
issues, very much)  
 
SDI: impact of cancer on 
issues such as family life, 
social activities, finances 
and work 
 
Thematic framework 
analysis 
 
 
National 
Association 
for Crohn’s 
and colitis 
UK (2006) 
 
Qualitative 
Living with bowel problems 
following radiotherapy- a 
scoping study 
Interviews: telephone, 2 
written accounts 
Interview data no longer 
available 
Danielsson 
(1991) 
Chronic diarrhoea after 
radiotherapy for 
gynaecological cancer: 
occurrence and aetiology 
Questionnaire  No details given of how 
questionnaire was 
developed 
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Appendix 2: Diagnosis related to PRD 
Radiation Proctopathy 
 
Radiation-induced tissue damage to the rectal tissues can result in mucosal damage, 
inflammation and fibrosis (Stacey and Green 2013). Diagnosed endoscopically, 
telangiectasia are where fine walled vessels are attempting to re-vascularise the 
damaged tissue often with poor effect due to the afore mentioned fibrosis, and this is 
known as proctopathy . Previously wrongly described as ‘proctitis’, this often led to 
inappropriate treatment with anti-inflammatory medications. Treatment depends on 
the severity of symptoms and occasionally no intervention is required.  Endoscopic 
treatment includes argon-plasma coagulation or instillation of formalin but both of 
these have a high risk of side effects such as ulcer formation and further tissue damage 
(Stacey and Green 2013). Sucralfate enemas act as a mucosal barrier and may stimulate 
healing. This treatment generally requires 2 applications a day via an enema and is 
recommended by both Andreyev et al (2013, 2014) and Gibson et al (2013). 
 
Radiation Enteritis 
 
Stacey and Green (2014) define radiation enteritis as injury to the small intestine 
following radiotherapy. Damage to the colonic tissue is known as radiation colitis, and 
proctopathy if the rectum alone is affected, as discussed above. More accurately, this 
condition should be known as radiation enteropathy, but this is less well known. The 
majority of patients may describe symptoms of acute enteropathy during or shortly after 
radiotherapy, including abdominal pain, diarrhoea and nausea but chronic enteropathy 
can continue for many years later or indeed present later (Andreyev 2007a, 2007b and 
Stacey and Green 2014). Moussa et al (2016) describe the complex injuries to healthy 
tissue caused by radiotherapy, but go on to describe what they call “encouraging” 
research in animal models with cell therapy as a means of repairing this damage. Theis 
et al (2010) describe how this damage can lead to small bowel dysfunction and 
structuring, leading to long-term problems such as obstructive symptoms. Treatment of 
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radiation enteritis, or enteropathy, depends on the symptoms and any further diagnosis, 
which will be discussed below. 
 
Bile Acid Malabsorption 
 
Bile acid malabsorption (BAM) occurs when the normal reabsorption of bile in the 
terminal ileum (TI) is affected, and is seen in conditions such as TI Crohn’s disease, 
previous small bowel resection, post cholecystectomy, overproduction of bile acid and 
post radiotherapy (Walters and Pattni 2010). A systematic review of the management 
of BAM diarrhoea by Wilcox et al (2014) describes how the presence of the un-absorbed 
bile increases colonic mucosal permeability that then increases fluid and mucous 
secretion and also increased colonic contraction and transit time resulting in symptoms 
including watery diarrhoea and bloating. Diagnosis is made via a scan to measure bile 
acid re-uptake, using selenium-75 labelled homocholic acid conjugated with taurine 
(SeHCAT). Smith et al (2000) describe normal re-uptake of the bile at >10% although the 
sensitivity can depend on the equipment available. The review by Wilcox et al (2014) 
describes how access to SeHCAT scanning remains poor and diagnosis may be made via 
response to treatment without obtaining an initial test result. Treatment generally 
depends on symptom severity and includes a reduced fat diet, symptom management 
such as anti-diarrhoeals or bile acid sequestrants.  Colestyramine and Colestipol are 
licenced treatment for BAM but are often described at unpalatable. Newer treatments 
such as Colesevelam are thought to be advantageous due to their tablet form (Walters 
and Pattni 2010) but at this time are not licensed for BAM and access may prove difficult.  
 
Small Intestinal Bacterial Overgrowth 
 
Dukowicz et al (2007) define small intestinal bacterial overgrowth (SIBO) as “the 
presence of excessive bacteria in the small intestine” (p. 112). It occurs due to changes 
in the normal bacterial population and this can result from reduced gastric acid 
production and/or altered gut motility; It is recognised that pelvic radiotherapy can 
result in both and that SIBO can result (Andreyev 2007a and Andreyev et al 2014). 
Symptoms include bloating, diarrhoea, abdominal pain, vitamin B12 and iron deficiency 
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and weight loss (Dukowicz et al 2007 and Grace et al 2013). Grace et al (2013) describe 
the difficulty in symptom clarification as their review highlighted the lack of validated 
questionnaires in most of the studies they looked at. There is a lack of evidence for a 
gold standard of diagnosing SIBO, which can cause problems in identifying the most 
appropriate treatment (Grace et al 2013 and Andreyev et al 2014). Gasbarrini et al 
(2007) cited that Corazza et al (1990) describes that the culture of jejunal aspirate as the 
diagnostic gold standard. However, a working group in which both Gasbarrini and 
Corazza took part, (Gasbarrini et al 2009) actually summarised that breath testing was 
the most accurate method. This discrepancy continues in clinical practice today 
(Dukowicz et al 2007) and so the diagnostic tools are likely to be whichever are most 
easily available. Treatment is two-pronged: if possible treat the cause and/or treat the 
overgrowth of bacteria with antibiotics. Andreyev et al (2014) recognises that even with 
direct analysis of jejunal aspirate, it may not be evident which antibiotic to use and so 
the guidelines recommend 5 different antibiotics to use, one at a time, to see which is 
most effective. Unless the cause of the SIBO is reversible it is likely that repeated courses 
of antibiotics may be necessary.  
 
Carbohydrate Malabsorption 
 
Carbohydrates, which include lactose, fructose and sorbitol, are a major source of 
calorific intake in a typical diet (Born 2007). They are broken down by enzymes during 
their transit through to the small bowel where brush boarder enzymes will further 
convert them into monosaccharides to allow them to be absorbed and utilised 
(Drozdowski and Thomson 2006). There can be many reasons why the absorption 
process is affected, such as Coeliac and Crohn’s disease (Born 2007) and it is recognised 
that pelvic radiotherapy can also result in a reduced ability of the small bowel to perform 
this important function (Andreyev 2007). Stone et al (2003) recognises that the small 
intestine is particularly susceptible to late effects of radiation damage due to the “slow 
turnover within tissues that contain rapidly-proliferating cells” (p. 530). Carbohydrate 
malabsorption is generally diagnosed by breath testing, although less common methods 
include blood tests or biopsies of the small bowel mucosa. Management is to avoid, or 
at least reduce the amount of the particular carbohydrate and ideally this should be 
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managed via a specialist dietician to prevent dietary deficiencies such as inadequate 
calcium (Andreyev 2007).  
 
Pancreatic Insufficiency 
 
Although the pancreas sits above the pelvic organs within the abdomen, in rare cases it 
may be subject to varying amounts of radiation during pelvic radiotherapy (Wydmanski 
et al 2016). The pancreas has both endocrine and exocrine functions with the exocrine 
part secreting enzymes to aid the process of digestion. Irradiation of the pancreas can 
affect this function (Andreyev et al 2005 and Mitchell et al 1979), so reducing the 
production of the enzymes and therefore the breakdown and absorption of nutrients 
including fats, which may then result in steatorrhoea- fatty, frothy stools which patients 
report can be difficult to flush away. Diagnosis is generally performed via measurement 
of faecal elastase in a stool sample and treatment is usually life-long replacement of the 
enzyme via supplementation (Andreyev et al 2005).  
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Appendix 3: Example of Coding/notes 
 
(Interview 3, line numbers removed)  
 
Wife: With the enemas we nearly got arrested at the airport, they had to 
take them away because when he was prescribed them we booked a  
holiday to Benidorm1 so he had to take them because of course he  
couldn’t stop taking them2 and they’re liquid as well so I said well we’ll  
have to pack them so I said we’ll put them all in a clear bag and he 
said well put the box in, I said no don’t put the box in because your  
name and everything is on it that they’ll know your name or your  
medical numbers3 so I took them out of the box. Well of course in the  
airport they didn’t know what they were did they because there was no  
prescription so, well they tested them with this, they tested them with  
that, oh my god4. Resp: In the airport, in the security and everybody is 
there5 and they’re all going and I had to explain what they were for and 
what I done with them. Wife: Oh he was mortified6. Int: So you’re laughing 
now but  
Wife: Oh he was terrible. Resp: At the time I wished there was a big hole 
and I just could have been swallowed up in it. Wife: and I felt terrible then 
because it was my fault really because I took the box. Resp: I said you never 
ripped the label off, saying it was mine and who prescribed them and what 
have you and she said oh there’s no need for that and I wanted to strangle 
her7. 
 
Hospital/medical 
Shame/embarrassment 
Teamwork/togetherness 
Conflict 
                                                        
1 Trying to continue as normal by booking a holiday  
2 He had been told to take the enemas so was following instructions, even though this 
would cause him a problem 
3 Very concerned about his medical number/information- why? Is this an age/era 
concern/lack of trust 
4 Mortified that the enemas were tested for illegal drugs- such shame 
5 “Everybody is there”- public humiliation  
6 “Mortified”- again, shame, humiliation 
7 When he said this is glared at his wife, then they both laughed and held hand. 
Teamwork amongst humiliation  
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Appendix 4: Cardiff University Permission Letter  
 
School of Healthcare Sciences Head of School and Dean Professor Heather 
Waterman  
Ysgol Gwyddorau Gofal Iechyd  
Pennaeth yr Ysgol a Yr Professor Heather Waterman  
20 January 2016  
 
Cardiff University Eastgate House 13th Floor 35 – 43 Newport Road Cardiff CF24 0AB  
Tel Ffon: +44 (0)29 20 688559 Email E-bost HCAREEthics@cardiff.ac.uk  
Prifysgol Caerdydd 13ed Llawr Ty Eastgate 35 – 43 Heol Casnewydd  
 
Helen Ludlow  Dept of Gastroenterology Uni of Llandough  CF64 2XX  
Dear Ms Ludlow  
Using a narrative analysis, what is the lived experience of people who have 
gastrointestinal symptoms following pelvic radiotherapy for pelvic cancers?  
At its meeting of 19 January 2016, the School’s PGT Research Review and 
Ethics Screening Committee considered your research proposal.  
The decision of the Committee is:  
The Research Governance & Ethics Committee is unable to give approval 
to this application as it should be submitted for NHS Research Ethics 
approval.  
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The Committee has asked that the comments of the reviewer be passed 
onto you and your supervisor, please see below.  
1. Social or scientific value; scientific design and conduct of the study 
e.g.  
The impact of long-term radiation toxicities, from the patient’s perspective 
– is an important area of scientific and clinical value. It is also an under-
researched area. The study should generate information that is useful 
beyond raising awareness, to elucidate how the toxicities impact on the 
individual and cause distress/have a detrimental effect on QoL – this may 
be through individual symptoms or as a cluster of seemingly insignificant 
symptoms in combination. Particularly interesting findings could point to 
how physical symptoms relate to other experiential domains or 
psychosocial impacts. The chosen methodology and methods are 
interesting and appropriate. As someone who is not familiar with narrative 
methods, I wondered how problematic it is if the two people having the 
‘dialogue’ have differing ontologies - as acknowledged in the 
methodological section.  
2. Recruitment arrangements and access to health information and 
participant selection Reviewers comments/issues for discussion:  
Cardiff University is a registered charity, no. 1136855 Mae Prifysgol Caerdydd yn elusen 
gofrestredig, rhif 1136855  
Caerdydd  
CF24 0AB  
The proposed recruitment procedures are fine. It wasn’t clear if carers 
would be full participants or just invited to accompany the patient 
participant at interview.  
In terms of the patient population, a number of related thoughts come to 
mind, which are presented purely for the applicants to consider.  
1. The first paragraph of the Project Summary states that ‘Prostate and 
bowel cancers were amongst the most common tumour sites and generally 
males and females were equally affected.’ which is rather misleading. Men 
with prostate cancer are likely to be a dominant grouping of the target 
population (lots of them, lots of radiotherapy and common toxicities), with 
slightly more male rectal cancers and more female colon cancers, plus a 
mixed group of gynaecological patients.  
The mix of participants will be interesting, as the likelihood of toxicities will 
vary with site, with one big difference being that, say with prostate cancer, 
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the target is not part of The GI tract, whereas with colon cancer it is. There 
will also be major specific life issues, such as female sterility.  
Looking at the working title made me wonder if the focus of the project was 
(1) the impact of the GI symptoms on life or (2) what is life like for people 
who have GI symptoms. Even within the GI system there is a distinction 
between nauseas and vomiting and lower tract toxicity. Then there are 
multiple distinct symptoms for specific sites e.g. urinary and sexual function 
for prostate that may impinge on QoL. The effects of these may or may not 
be easy to separate out in terms of impact on QoL/distress. Other therapies 
e.g. chemotherapy sensitisation will also be in the mix.  
The chronological point of recruitment is also of interest, given that 
sampling occurs at patient’s first clinic attendance. The term early (acute) 
and late (chronic) have quite clear meanings and distinct pathological 
characteristics. Early effects may be expected to resolve within say 4-5 
months, whereas chronic may be largely irreversible. There are also likely 
to be links between the two states. More pragmatically, someone three 
years post treatment is likely to have quite different life insights to one three 
months post treatment.  
Another relevant phenomena may be that more extensive radiation fields 
– e.g. prostate and regional nodes – is likely to lead to greater small bowel 
damage, but will also signify a more advanced disease state/worse 
prognosis. At the extreme, are palliative patients likely to be included as 
well as curative intent?  
3. Favourable risk benefit ratio; anticipated benefits/risks for research 
participants (present and future) e.g.  
Reviewers comments/issues for discussion:  
This is a low risk study, with no obvious benefits or risks to the individuals taking 
part. The benefits of the research will primarily be to the service and users of the 
service in the future.  
4 Care and protection of research participants; respect for potential 
and enrolled research participants’ welfare & dignity. Does the 
proposal and accompanying participant information sheets & 
consent forms consider:  
*permitting withdrawal from the research * protecting privacy through 
confidentiality *informing participants of newly discovered risks or benefits * 
informing participants of results of research *maintaining welfare of participants 
*what will happen at the end of the study *provision of appropriate indemnity and 
insurance  
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    Has the proposal outlined data protection & research participant’s 
confidentiality?   
    Where and how (anonymised/coded) and for how long will data be 
stored?   
    What purpose will be served by the data?   
    Who will access?   
    Are research participants informed that access to their medical 
notes may be required?   
    Have arrangements been made to deal with incidental disclosure? 
  
    Has the Cardiff University guidance been acknowledged? 
 Reviewers comments/issues for discussion:  The participant 
information is very clear. There seemed to be the possibility of a 
second interview, but the purpose of this was not addressed in the 
application. Whether interview data would be kept in an anonymised 
form was not totally clear, but should be easy to facilitate. The need 
to maintain a separation between the role of researcher and clinician 
is touched upon, and will need considerable thought and care to 
protect all parties. Research interviews are clearly different from   
clinical consultations. One related point is how aware research participants 
would be as to whether their medical information would be used in the 
research context. Measures to ensure rigour of methods and validity of 
findings will also be important.  
5. Informed consent process and the adequacy and completeness of 
research participant information e.g.  
Reviewers comments/issues for discussion:  
The participant information are clear and comprehensive.  
6. Suitability of the applicant and supporting staff e.g.  
Comments/issues for discussion:  
The applicant is very well placed to conduct this research. The support 
team is suitably qualified Risk assessment included, which outlines the 
safeguarding procedure for interviews within the host hospital and within 
the patient’s home.  
7. Suitability of supporting information Comments/issues for 
discussion:  
Interview schedules will need to be developed for IRAS applications. 
Presumably, the narrative approach means that the interviews will be 
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relatively unstructured (?)  
Please do not hesitate to contact me if you have any questions. Yours 
sincerely  
Mrs Liz Harmer – Griebel Research Administration Manager  
cc : Tina Gambling Dikaois Sakellariou  
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Appendix 5: Health and Care Research Wales Permissions   
 
 
 
09 June 2016  
Dr Tina Gambling School of Healthcare Sciences Eastgate 
House Newport Road Cardiff CF24 0AB  
Dear Dr Gambling  
Study title:  
REC reference: Protocol number: IRAS project ID:  
Using a narrative analysis, what is the lived experience of people (and 
their partners where appropriate) who have gastrointestinal 
symptoms following pelvic radiotherapy for pelvic cancer?  
16/W A/0126 SPON 1501-16 201783  
Gwasanaeth Moeseg Ymchwil Research Ethics Service  
Thank you for responding to the Committee’s request for further 
information on the above research and submitting revised documentation.  
The further information has been considered on behalf of the Committee 
by the Chair.  
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We plan to publish your research summary wording for the above study on 
the HRA website, together with your contact details. Publication will be no 
earlier than three months from the date of this opinion letter. Should you 
wish to provide a substitute contact point, require further information, or 
wish to make a request to postpone publication, please contact the Senior 
Ethics Service Manager, Dr. Corinne Scott, corinne.scott@wales.nhs.uk.  
Confirmation of ethical opinion  
On behalf of the Committee, I am pleased to confirm a favourable ethical 
opinion for the above research on the basis described in the application 
form, protocol and supporting documentation as revised, subject to the 
conditions specified below.  
Conditions of the favourable opinion  
The REC favourable opinion is subject to the following conditions being 
met prior to the start of the study.  
Management permission must be obtained from each host organisation 
prior to the start of the study at the site concerned.  
Management permission should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance 
arrangements. Each NHS organisation must confirm through the signing of 
agreements and/or other documents that it has given permission for the 
research to proceed (except where explicitly specified otherwise).  
Wales REC 3  
Health and Care Research Support Centre Castlebridge 4 15-19 Cowbridge 
Road East Cardiff CF11 9AB  
Telephone : 029 2078 5735 E-mail : corinne.scott@wales.nhs.uk Website : 
www.hra.nhs.uk  
 
  
Guidance on applying for NHS permission for research is available in the 
Integrated Research Application System, www.hra.nhs.uk or at 
http://www.rdforum.nhs.uk.  
Where a NHS organisation’s role in the study is limited to identifying and 
referring potential participants to research sites ("participant identification 
centre"), guidance should be sought from the R&D office on the information 
it requires to give permission for this activity.  
258 
 
For non-NHS sites, site management permission should be obtained in 
accordance with the procedures of the relevant host organisation.  
Sponsors are not required to notify the Committee of management 
permissions from host organisations  
Registration of Clinical Trials All clinical trials (defined as the first four 
categories on the IRAS filter page) must be registered on a publically 
accessible database within 6 weeks of recruitment of the first participant 
(for medical device studies, within the timeline determined by the current 
registration and publication trees).  
There is no requirement to separately notify the REC but you should do so 
at the earliest opportunity e.g. when submitting an amendment. We will 
audit the registration details as part of the annual progress reporting 
process.  
To ensure transparency in research, we strongly recommend that all 
research is registered but for non-clinical trials this is not currently 
mandatory.  
If a sponsor wishes to contest the need for registration they should contact 
Catherine Blewett (catherineblewett@nhs.net), the HRA does not, 
however, expect exceptions to be made. Guidance on where to register is 
provided within IRAS.  
It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular site 
(as applicable).  
Ethical review of research sites  
NHS sites The favourable opinion applies to all NHS sites taking part in 
the study, subject to management permission being obtained from the 
NHS/HSC R&D office prior to the start of the study (see "Conditions of the 
favourable opinion" below).  
Approved documents  
The final list of documents reviewed and approved by the Committee is as 
follows:  
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Document  Version  Date  
IRAS Checklist XML [Checklist_02062016]   02 June 2016  
Letter from sponsor   12 March 2016  
Other [Partner Consent]  1  16 May 2016  
Other [Interview Schedule]  1  16 May 2016  
Other [Consent tracked changes]   18 May 2016  
Other [PIS V3 with tracked changes]  3  01 June 2016  
Other [PIS V3 Ready to use]  3  01 June 2016  
Other [PIS Partner V 2 tracked changes]  2  01 June 2016  
Other [PIS Partner V2 Ready to use]  2  01 June 2016  
Participant consent form  2  16 May 2016  
REC Application Form [REC_Form_06042016]   06 April 2016  
Research protocol or project proposal   12 March 2016  
Summary CV for Chief Investigator (CI)   16 May 2016  
Summary CV for student   12 March 2016  
Summary CV for supervisor (student research)  1  11 March 2016  
Statement of compliance  
The Committee is constituted in accordance with the Governance 
Arrangements for Research Ethics Committees and complies fully with the 
Standard Operating Procedures for Research Ethics Committees in the 
UK.  
After ethical review  
Reporting requirements The attached document “After ethical review – 
guidance for researchers” gives detailed guidance on reporting 
requirements for studies with a favourable opinion, including:  
The HRA reporting  
Notifying substantial amendments Adding new sites and investigators 
Notification of serious breaches of the protocol Progress and safety 
reports Notifying the end of the study  
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website also provides guidance on these topics, which is updated in the 
light of changes in requirements or procedures.  
User Feedback  
The Health Research Authority is continually striving to provide a high 
quality service to all applicants and sponsors. You are invited to give your 
view of the service you have received and the application procedure. If you 
wish to make your views known please use the feedback form available on 
the HRA website: http://www.hra.nhs.uk/about-the-
hra/governance/quality-assurance/  
HRA Training  
We are pleased to welcome researchers and R&D staff at our training days 
– see details at  
http://www.hra.nhs.uk/hra-training/  
With the Committee’s best wishes for the success of this project. Yours 
sincerely  
Dr. Corinne Scott  Senior Ethics Service Manager Health and Care 
Research Wales  
pp Dr Pete Wall Chair  
E-mail: corinne.scott@wales.nhs.uk Enclosures: “After ethical review – 
guidance for researchers” Copy to: Dr Tina Gambling  
Mrs Louise Hesp, Cardiff & Vale UHB R&D Department  
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Appendix 6: Participant Information Sheet 
 
   
 
What is the lived experience of people who have gastrointestinal 
symptoms following pelvic radiotherapy for pelvic cancers? 
 
Version:  3 
Date:   01.06.2016 
Sponsor:   Cardiff University 
  
 
I would like to invite you to take part in research interviews to learn more about the 
experiences of living with gastrointestinal effects of pelvic radiation for treatment of 
pelvic cancers. This includes both those who themselves who are experiencing such 
symptoms, and possibly interested partners who have lived through the experience with 
you.  
 
This information sheet is in two parts: 
 
Part One provides a summary of the research study and what will happen if you take 
part 
Part two provides more detailed information about the study 
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If you have any questions about the study please contact using the details at the end of 
the information sheet. 
 
Part One: Information about the research study 
 
• The purpose of the study is to improve understanding of people’s experiences of 
living with gastrointestinal symptoms after receiving pelvic radiotherapy for 
pelvic cancers. This includes both the person themselves and their partners, if 
applicable. 
 
• There is currently a lack of awareness of what it is like for people to have these 
symptoms, although there is growing knowledge about the actual symptoms 
themselves. 
 
• The research study aims to use the information it produces to inform other 
patients, the healthcare professionals treating them and to improve services for 
those affected.  
 
• The research would involve hearing about your experiences using interviews, for 
me to learn more about your experiences of having gastrointestinal symptoms 
following pelvic radiotherapy for a pelvic cancer 
 
Thank you for reading Part One. 
If you may be interested in taking part in the study please read Part two 
before making any decision 
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Part two: additional information about the research study 
 
My contact details are at the end of this information sheet. If you would 
like to take part please contact me to make arrangements 
 
 
1. What is the purpose of this study? 
The University Hospital Llandough is currently the only Hospital in Wales 
providing dedicated assessment and treatment for people who have 
gastrointestinal symptoms after receiving pelvic radiotherapy treatment for 
pelvic cancers. Whereas the assessment and treatment aspects are improving, it 
is apparent that there is a lack of awareness of what it is actually like for people 
with these symptoms following their treatment, as well as for their partners. In 
order to improve the care available it is important that knowledge and 
understanding of people’s experiences is increased. 
 
 
2. Why have I been asked to take part? 
You have been invited to participate in the research study because you have 
been referred to the Pelvic Radiation disease Clinic due to having gastrointestinal 
symptoms following your pelvic radiotherapy treatment. I would like to talk to 
you about your experiences and that of your partner if possible- they are 
welcome to join you at the same interview. It is hoped that learning about your 
experiences will help to improve services in the future and raise awareness of 
the issues faced.  
 
 
3. What will I need to do if I take part? 
I will talk to you about the study and answer any questions that you may have. 
If you agree, I will ask you to take part in one or two interviews at the time and 
place of your choice, either at the clinic or your home. One interview is likely to 
be more than adequate- you will be offered a second interview if you feel that 
you would like to take more time to tell me about your experiences. You will be 
asked to sign a consent form prior to the start of the first interview. After the 
information from the first interview has been analysed, I may need to contact 
you to ask you to be interviewed a second time if any further information is 
required.  
 
4. What will the interviews involve? 
The interviews will each last around 30-60 minutes. I can either talk to you alone 
or you can have your partner there with you also, to help us understand their 
experiences too. The choice is yours if you would prefer to be interviewed alone 
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or together with your partner. Whoever takes part in the interviews will be asked 
to sign a consent form before we begin. I will ask you about your experiences of 
having gastrointestinal symptoms after receiving pelvic radiotherapy for a pelvic 
cancer. Whilst you are talking, I will make some notes and the conversation will 
be recorded on a small digital recorder.  At the end of the interview I will check 
again that you are happy for the conversation to be included in the study. 
 
 
5. What are the possible benefits and disadvantages of taking part? 
The interview will not alter your clinical treatment in any way and it is unlikely 
that the study will help you personally. There is no payment for taking part in the 
study. I hope however, that the results of the study will help to improve the 
future care for people with gastrointestinal symptoms after pelvic radiotherapy 
and those close to them.  
 
 
6. What if I do not wish to take part or change my mind? 
You do not have to take part in the study if you do not want to. If you initially 
decide to take part and then change your mind at any time you are free to do so, 
without giving a reason. Your current or future clinical care will not be affected 
in any way. If you withdraw from the study after starting the interviews I would 
ask for your permission to use any information you had previously provided. If 
you do not agree to this then the recorded information and written notes would 
be destroyed and not included in the study.  
 
7. What if there is a problem? 
If you have a concern about any aspect of this study please speak to myself, 
Helen Ludlow and I will do my best to answer any questions. If you remain 
unhappy and wish to make a formal complaint please contact: 
 
Dr Kate Button 
Director of Research and Governance 
Ty Dewi Sant 
Heath Park Campus 
Cardiff University 
Cardiff University CF14 4XN 
hcareresearch@cardiff.ac.uk 
 
In the very unlikely event that something goes wrong and you are harmed by 
taking part in this study, there are no special compensation arrangements. If you 
have any concerns about your medical treatment that have not been addressed 
by your medical team then you can go through the NHS Complaints process as 
usual.  
 
As previously discussed, the details that you tell me will be treated with the 
strictest confidentiality. However please be aware that if during the interview 
process you disclose any information that might relate to a risk of harm to 
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yourself or to others, or you give details regarding misconduct or bad practice by 
a healthcare professional involved in your care, I am required by the Nursing and 
Midwifery Council Code of Conduct to refer the matter to a higher authority to 
investigate. If this is the case I will tell you. 
 
8. Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the study will be 
kept confidential. With your permission, the interview will be audio recorded 
and transcribed word for word. All personal information that could identify you 
will not  
be used and the transcript will be anonymous. The consent form will ask 
permission to use extracts from the transcripts in both the study report and any 
future publication but will be totally anonymous.  
Any information, including audio recordings and transcripts, will be stored in a 
safe place for up to 15 years and then destroyed, in accordance with the data 
protection Act 1998.  
9. What will happen to the results of the study? 
The results of the study will contribute to a Professional Doctorate programme 
of study and will also be presented at meetings and submitted for health journals 
for publication.  You will not be identified in any way during the results 
dissemination, although some direct quotes may be used unless you specifically 
do not agree to this on that section of the consent form. 
 
10. Who has reviewed this study? 
Cardiff University School of Healthcare Sciences Research and Ethics 
Department, the University Research Governance Department and the Health 
and Care Research Wales Research Ethics Service (Wales REC 3) have reviewed 
this study. 
 
11. Additional support available 
I am aware that some people may become distressed when thinking/talking 
about difficult experiences. If you would like to talk to a professional about your 
feelings you may find the following points of contact helpful: 
 
• Pelvic Radiation Disease Association www.prda.org.uk 
• Tenovus Helpline 0808 808 1010 
• I can also refer you to a Macmillan Psychologist if you prefer 
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If you would like to take part in this study please contact: 
 
Helen Ludlow 
Macmillan/TrueNth Senior Nurse for Late GI Effects of Pelvic Radiotherapy. 
Department of Gastroenterology 
University Hospital Llandough 
Vale of Glamorgan 
CF64 2XX 
029 20715623 
Helen.ludlow@wales.nhs.uk 
 
Or if you have any further concerns please contact: 
Dr John Green Consultant Gastroenterologist 
Department of Gastroenterology 
University Hospital Llandough 
Penarth 
CF64 2XX 
029 20716811 
john.green2@wales.nhs.uk 
 
or  
 
Dr Tina Gambling  
Director of Post Graduate Research 
School of Healthcare Sciences 
Room 12  
Eastgate House 
35-34 Newport Road 
Cardiff  
CF24 0AB 
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Appendix 7: Partner Participant Information Sheet 
 
   
What is the lived experience of people who have gastrointestinal 
symptoms following pelvic radiotherapy for pelvic cancers? 
PARTNER INFOMATION 
Version:  2 
Date:   01.06.2016 
Sponsor:   Cardiff University 
 
I would like to invite you to take part in research interviews to learn more about the 
experiences of living with gastrointestinal effects of pelvic radiation for treatment of 
pelvic cancers. This includes both those who themselves who are experiencing such 
symptoms, and possibly interested partners who have lived through the experience with 
them.  
 
This information sheet is in two parts: 
 
Part One provides a summary of the research study and what will happen if you take 
part 
Part two provides more detailed information about the study 
If you have any questions about the study please contact using the details at the end of 
the information sheet. 
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Part One: Information about the research study 
 
• The purpose of the study is to improve understanding of people’s experiences of 
living with gastrointestinal symptoms after receiving pelvic radiotherapy for 
pelvic cancers. This includes both the person themselves and their partners, if 
applicable. 
 
• There is currently a lack of awareness of what it is like for people to have these 
symptoms, although there is growing knowledge about the actual symptoms 
themselves. 
 
• The research study aims to use the information it produces to inform other 
patients, the healthcare professionals treating them and to improve services for 
those affected.  
 
• The research would involve hearing about your experiences using interviews, for 
me to learn more about your experiences of having gastrointestinal symptoms 
following pelvic radiotherapy for a pelvic cancer 
 
Thank you for reading Part One. 
If you may be interested in taking part in the study please read Part two 
before making any decision 
Part two: additional information about the research study 
My contact details are at the end of this information sheet. If you would 
like to take part please contact me to make arrangements 
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1. What is the purpose of this study? 
The University Hospital Llandough is currently the only Hospital in Wales 
providing dedicated assessment and treatment for people who have 
gastrointestinal symptoms after receiving pelvic radiotherapy treatment for 
pelvic cancers. Whereas the assessment and treatment aspects are improving, it 
is apparent that there is a lack of awareness of what it is actually like for people 
with these symptoms following their treatment, as well as for their partners. In 
order to improve the care available it is important that knowledge and 
understanding of peoples experiences is increased. 
 
 
2. Why have I been asked to take part? 
You have been invited to participate in the research study because you are a 
partner of someone who has been referred to the Pelvic Radiation disease Clinic 
due to having gastrointestinal symptoms following your pelvic radiotherapy 
treatment. I would like to talk to you about your experiences and that of your 
partner if possible. It is hoped that learning about your experiences will help to 
improve services in the future and raise awareness of the issues faced.  
 
 
3. What will I need to do if I take part? 
I will talk to you about the study and answer any questions that you may have. 
If you agree, I will ask you to take part in one or two interviews at the time and 
place of your choice, either at the clinic or your home. One interview is likely to 
be more than adequate- you will be offered a second interview if you feel that 
you would like to take more time to tell me about your experiences. You will be 
asked to sign a consent form prior to the start of the first interview. After the 
information from the first interview has been analysed, I may need to contact 
you to ask you to be interviewed a second time if any further information is 
required.  
 
4. What will the interviews involve? 
The interviews will each last around 30-60 minutes. I can either talk to your 
partner alone, or if they would prefer for you to be present as well it would help 
us understand your experiences also.  Whoever takes part in the interviews will 
be asked to sign a consent form before we begin. I will initially ask your partner 
about their experiences of having gastrointestinal symptoms after receiving 
pelvic radiotherapy for a pelvic cancer and if your partner agrees you are more 
than welcome to join in the conversation so I can hear about your experiences 
also. Whilst you and/or your partner are talking, I will make some notes and the 
conversation will be recorded on a small digital recorder.  At the end of the 
interview I will check again that you are happy for the conversation to be 
included in the study. 
 
5. What are the possible benefits and disadvantages of taking part? 
The interview will not alter your partner’s clinical treatment in any way and it is 
unlikely that the study will help them or you personally. There is no payment for 
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taking part in the study. I hope however, that the results of the study will help to 
improve the future care for people with gastrointestinal symptoms after pelvic 
radiotherapy and those close to them.  
 
6. What if I do not wish to take part or change my mind? 
You do not have to take part in the study if you do not want to. If you initially 
decide to take part and then change your mind at any time you are free to do so, 
without giving a reason. Your partner’s current or future clinical care will not be 
affected in any way. If you withdraw from the study after starting the interviews 
I would ask for your permission to use any information you had previously 
provided. If you do not agree to this then the recorded information and written 
notes would be destroyed and not included in the study.  
 
7. What if there is a problem? 
If you have a concern about any aspect of this study please speak to myself, 
Helen Ludlow and I will do my best to answer any questions. If you remain 
unhappy and wish to make a formal complaint please contact: 
 
Dr Kate Button 
Director of Research Governance 
Ty Dewi Sant 
Heath Park Campus 
Cardiff University 
Cardiff University CF14 4XN 
hcareresearch@cardiff.ac.uk 
 
In the very unlikely event that something goes wrong and you are harmed by 
taking part in this study, there are no special compensation arrangements. If you 
have any concerns about your partners medical treatment that have not been 
addressed by your medical team then you can go through the NHS Complaints 
process as usual.  
 
As previously discussed, the details that you and tell me will be treated with the 
strictest confidentiality. However, please be aware that if during the interview 
process you disclose any details regarding misconduct or bad practice by a 
healthcare professional involved in your partner’s care, I am required by the 
Nursing and Midwifery Council Code of Conduct to refer the matter to a higher 
authority to investigate. If this is the case I will tell you. 
 
8. Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the study will be 
kept confidential. With your permission, the interview will be audio recorded 
and transcribed word for word. All personal information that could identify you 
will not be used and the transcript will be anonymous. The consent form will ask 
permission to use extracts from the transcripts in both the study report and any 
future publication but will be totally anonymous.  
271 
 
Any information, including audio recordings and transcripts, will be stored in a 
safe place for up to 15 years and then destroyed, in accordance with the data 
protection Act 1998.  
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  9. What will happen to the results of the study? 
The results of the study will contribute to a Professional Doctorate programme 
of study and will also be presented at meetings and submitted for health journals 
for publication.  You will not be identified in any way during the results 
dissemination, although some direct quotes may be used unless you specifically 
do not agree to this on that section of the consent form. 
 
10. Who has reviewed this study? 
Cardiff University School of Healthcare Sciences Research Ethics Committee, the 
University Research Governance Department and the Health and Care Research 
Wales Research Ethics Service (Wales REC 3) have reviewed this study. 
 
11. Additional support available 
I am aware that some people may become distressed when thinking/talking 
about difficult experiences. If you would like to talk to a professional about your 
feelings you may find the following points of contact helpful: 
 
• Pelvic Radiation Disease Association www.prda.org.uk 
• Tenovus Helpline 0808 808 1010 
• I can also refer you to a Macmillan Psychologist if you prefer 
 
If you would like to take part in this study please contact: 
Helen Ludlow 
Macmillan/TrueNth Senior Nurse for Late GI Effects of Pelvic Radiotherapy. 
Department of Gastroenterology 
University Hospital Llandough 
Vale of Glamorgan 
CF64 2XX 
029 20715623 
Helen.ludlow@wales.nhs.uk 
 
Or if you have any further concerns please contact: 
Dr John Green Consultant Gastroenterologist 
Department of Gastroenterology 
University Hospital Llandough 
Penarth 
CF64 2XX 
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029 20716811 
john.green2@wales.nhs.uk 
 
or  
 
 
Dr Tina Gambling  
Director of Post Graduate Research 
School of Healthcare Sciences 
Room 12  
Eastgate House 
35-34 Newport Road 
Cardiff  
CF24 0AB 
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Appendix 8: Consent Form  
 
I                                          
 
CONSENT FORM 
What is the lived experience of people who have gastrointestinal 
symptoms following pelvic radiotherapy for pelvic cancers? 
Version:  3 
Date:   13.06.2016 
Sponsor:   Cardiff University 
 
Participant name: 
Participant Study Number: 
 
Please read the following and if you agree with the statement write your initial on the 
line: 
1. I confirm that I have read and understood the Participant Information Sheet 
(Version 1, date….)  I have had the opportunity to consider the information and 
ask questions which have been answered to my satisfaction  __________ 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected       __________ 
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3. I give permission for direct quotes taken from the interviewed to be used in any 
publication of findings or presentations  Yes / No 
I understand that any identifiable personal information (such as my name) will 
only  be written on the consent form   otherwise a number will be used to 
identify the different participants  Yes / No 
I understand that the interview will be audio-recorded and I give my permission 
for this    Yes / No 
 
___________ 
 
4. I consent to the storage of personal information, including electronic, for the 
purposes of this study. I understand that any information that could identify me 
(such as my name on the consent Form) will be kept strictly confidential and that 
no personal information will be included in the study report or other publications 
__________ 
 
_______________   __________  _______________ 
Name of participant   Date   Signature 
 
_______________   __________  _______________ 
Name of person taking consent Date   Signature 
 
1 for participant; 1 for Site File; 1 to be kept with hospital notes 
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Appendix 9: Partner Consent Form  
 
                                     
 
PARTNER CONSENT FORM 
What is the lived experience of people who have gastrointestinal 
symptoms following pelvic radiotherapy for pelvic cancers? 
 
Version:  1 
Date:   18.05.2016 
Sponsor:   Cardiff University 
 
Participant name: 
Participant Study Number: 
 
Please read the following and if you agree with the statement write your initial on the 
line: 
1. I confirm that I have read and understood the Participant Information  Sheet 
(Version 1, date….)  I have had the opportunity to consider the information and 
ask questions which have been answered to my satisfaction  __________ 
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2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected       __________ 
 
3. I give permission for direct quotes taken from the interviewed to be used in any 
publication of findings or presentations      Yes / 
No 
I understand that none of my personal information will be identifiable    Yes / 
No 
I understand that the interview will be audio-recorded and I give my permission 
for this            
 Yes / No        
 ___________    
 
4. I consent to the storage of personal information, including electronic, for the 
purposes of this study. I understand that any information that could identify me 
will be kept strictly confidential and that no personal information will be included 
in the study report or other publications    
 __________ 
 
 
_______________   __________  _______________ 
Name of participant   Date   Signature 
 
 
_______________   __________  _______________ 
Name of person taking consent Date   Signature 
 
1 for participant; 1 for Site File; 1 to be kept with hospital notes 
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Appendix 10: Alert-B Screen Tool Form 
 
 
279 
 
 
